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ABSTRACT
The National Cancer Institute and the American Cancer Society estimate that 1.6 
million new cancer incidences and over half a million cancer related deaths occur 
annually [1][2], Cancer the second most common cause of death in the United States [1], 
[2]. Although the causes of cancer can vary depending on cell type, all or almost all 
instances of cancer arise from a mutation or from an abnormal activation of the cellular 
genes that control cell growth and mitosis [3],
Treatment of a given cancer type depends on the subtype, stage and progression 
of the cancer. Varieties of cancer therapy include surgery, immunotherapy, radiation 
therapy, chemotherapy, hormone therapy, targeted therapy, gene therapy and stem cell 
transplant [4], Some treatments help patients achieve remission, and with additional 
treatment, can cure the illness. Many of the available therapies have drawbacks that can 
negatively affect patients. Some of these drawbacks include systemic, as opposed to 
local, delivery of chemotherapeutic agents, pain, hair loss, reoccurrence and metastasis 
post-surgery.
A major goal of current research in cancer medicine is to develop novel strategies 
and materials to halt the advance of cancer and its potential metastasis. This goal can be 
achieved by employing strategies that can localize treatments to affected areas, sustaining 
drug release to these areas, and destabilizing cellular processes that affect cell-drug 
interaction.
The focus of this dissertation was to design and develop novel injectable and 
implantable applications for gene and chemotherapeutic cancer treatment. The use of 
naturally occurring materials can improve gene and drug delivery characteristics in vivo. 
The research aimed to establish halloysite nanotubes as a novel delivery system for drugs 
and/or genes. The first stage of this goal was to analyze the drug and gene release by 
establish a release profile from halloysite nanotubes. The next stage was in vitro assay to 
determine the transfection efficiency of pIRES2-EGFP loaded Halloysite Nanotubes 
(HNTs), and the and in vitro cell proliferation and cytotoxicity assay of methotrexate- 
loaded HNTs. Results indicate that methotrexate-or pIRES2-EGFP loaded nanotubes, and 
composite films can boost transfection efficiency and reduce cancer cell growth and 
proliferation. Nanotubes showed promise in gene delivery as they enhanced the 
transfection efficiency of commonly used transfection reagents. Nanotubes and nanotube- 
imbedded films show promise as novel chemotherapeutic treatments as the provided a 
platform for sustained and localized drug delivery in vitro.
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CHAPTER 1 
INTRODUCTION AND BACKGROUND
The National Cancer Institute and the American Cancer Society estimate that 1.6 
million new cancer incidences and over half a million cancer related deaths occur 
annually [1][2], Cancer the second most common cause of death in the United States [1] 
[2], Although the causes of cancer can vary depending on cell type, all or almost all 
instances of cancer arise from a mutation or from an abnormal activation of the cellular 
genes that control cell growth and mitosis [3],
Treatment of a given cancer type depends on the subtype, stage and progression 
of the cancer. Varieties of cancer therapy include surgery, immunotherapy, radiation 
therapy, chemotherapy, hormone therapy, targeted therapy, gene therapy and stem cell 
transplant [4], Some treatments help patients achieve remission, and with additional 
treatment, can cure the illness. Many of the available therapies have drawbacks that can 
negatively affect patients. Some of these drawbacks include systemic, as opposed to 
local, delivery of chemotherapeutic agents, pain, hair loss, reoccurrence and metastasis 
post-surgery.
A major goal of current research in cancer medicine is to develop novel strategies 
and materials to halt the advance of cancer and its potential metastasis. This goal can be 
achieved by employing strategies that can localize treatments to affected areas, sustaining
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drug release to these areas, and destabilizing cellular processes that affect cell-drug 
interaction.
1.1 Cancer and Therapies
Cancer, also referred to as malignant tumors or malignant neoplasm, is a generic 
term used to describe a variety of illnesses caused by mutations and/or disruptions in 
cellular machinery that cause cells to multiply uncontrollably and invade other tissues. 
Generally, cell growth, damage repair, and death within the body are highly ordered. 
Malignant neoplasm can disrupt this order by allowing cells to live past their normal cell 
death and multiply incessantly. Cancerous cells multiply to form masses called malignant 
tumors which can invade surrounding tissues and metastasize, a term used to describe the 
circulation and development of malignant tumors distant from the primary site of 
malignant neoplasm. Cancerous tumors can further disrupt the body’s natural order by 
syphoning off nutrients to support their own growth and creating abnormalities in 
surrounding tissues. In this chapter, I will discuss different types of cancer, their causes, 
and the current treatment modalities.
Several cell lines were chosen based on the clinical relevance of the research 
outlined in this dissertation. Osteosarcoma, breast cancer and prostate cancer were chosen 
due to potential applications of halloysite nanotubes for gene delivery, drug delivery and 
blow sprayed chitosan films for adjuvant delivery of chemo therapeutic agents. Drug or 
gene loaded halloysite nanotubes could potentially be injected into tumors to shrink them 
and drug loaded films may be used to coats sites where tumors have been removed.
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1.1.1 Osteosarcoma
Osteosarcoma is the most common primary bone cancer. It is an aggressive 
neoplasm that arises from primitive bone forming mesenchymal cells. Osteosarcoma is 
most prevalent in children and young adults, although it can affect a person of any age. 
Around 1000 new cases occur per year and more than 400 of those new cases are in 
patients under the age of 18 [5], Most osteosarcomas affect people between the ages of 
10-30, with the most affected group being teens. In addition at least 10% of the cases 
affect people over the age of 60 [6],
Osteosarcoma occurs most frequently in the metaphyseal portion of tubular long 
bones with 42% incidence in the femur, 19% in the tibia and 10% in the humerus.
Around 8% of all cases affect the skull and jaw, while another 8% arise in the pelvis 
[7],Subtypes of osteosarcoma are differentiated by grade:
1. High grade is the fastest growing grade of the osteosarcomas. They do not exhibit 
normal morphology of bone and many can be observed in mitosis. High-grade 
osteosarcomas are the most common osteosarcoma affecting youths and there are 
many different types. The most common are osteoblastic, chondroblastic and 
fibroblastic. Other types can include mixed, small cell, telangiectatic and pagetoid 
(a tumor resulting from Paget disease of the bone) and post-radiation (a tumor 
resulting from radiation therapy) [8].
2. Intermediate grade falls between the high grade and low grade. The most common 
type is periosteal (just cortical intermediate grade) [8],
3. Low grade is the slowest growing form, and has morphology closer to that of 
normal bone. Some of the more common low-grade osteosarcomas include
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periosteal (juxta cortical low grade) and intramedullary or intraosseous well 
differentiated (low-grade central) [8], See Table 1-1.





























Osteosarcoma is described as malignant tumors of the connective tissue that can 
give rise to bone. Osteosarcoma retains the ability to produce fibrous tissue and cartilage 
matrix. Histologically, it is more similar to bone fracture or fracture callus than other 
differentiated bone tumors. The traditional method of classification for osteosarcoma has 
led to three subdivisions: osteoblastic, chondroblastic and fibroblastic. However,
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osteosarcomas typically exhibit all three cell types in varying amounts. Classification 
generally means 50% or more of a particular cell type is present.
Osteosarcoma typically affects the medullary cavity of the metaphysis of a 
growing long tubular bone, but it also can arise at the surface, cortex and even extra- 
skeletal sites. Osteosarcomas on the bone surface are 20 times less common then their 
medullary counterparts [9], Patients with bone surface osteosarcoma are on average a 
decade or more, older than those with osteosarcomas of medullary origin. Low and high 
grade can be present throughout the osteosarcoma. However, when they are of medullary 
origin they are most likely high grade.
Symptoms of osteosarcoma are generally nonspecific; the most common 
symptom is pain. At first the pain can be inconsistent but over time it worsens and can 
become constant. Often, if it affects the lower extremities, it can cause a limp. The pain 
can be so excruciating at times it can interrupt sleep and prompt affected persons to seek 
medical attention. Another common symptom is swelling, which results in a firm and 
almost always tender mass in the affected bone region. This swelling can also lead to a 
limp, loss of function and decreased range of motion. These symptoms are common in 
active children and may be thought to arise from some other type of injury complicating 
diagnosis. Although osteosarcomas can cause bones to weaken, fractures are not 
common. Rare forms of osteosarcomas tend to weaken bones and cause fractures.
Diagnosis usually begins with a physical examination of the bone to see if a tumor 
or abnormal mass is near the bone. If an abnormal mass is observed, the next step is 
usually imaging tests followed by a biopsy. Imaging tests help elucidate whether the 
suspicious mass is a tumor, how far it has spread, where it was derived and whether
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treatment is working. The first imaging examination is usually a bone x-ray. An x-ray 
will strongly suggest whether a mass is a tumor versus some type of infection. Magnetic 
resonance imaging gives a more detailed analysis of the affected region and can help to 
identify the progression, as well as, whether there is smaller tumor in close proximity to 
the major tumor mass. CT scans, chest X-rays and bone scans can also be used to 
determine the progression of the cancer, whether it has grown into nearby tissue or bone 
and whether or not it has spread to the lungs. While imaging may strongly suggest that 
the patient may be suffering from osteosarcoma, a biopsy is necessary to confirm that the 
abnormality is osteosarcoma. A blood test may also be administered, as it can provide 
useful information about the progression of osteosarcoma.
Great advances have recently been made in the treatment of osteosarcoma.
Current and cutting edge treatments will be reviewed briefly in this section and more 
thoroughly in the cancer treatments section. In the 1960’s, amputation was the major 
mode of treatment for osteosarcomas, the survival rate post diagnosis was 2 years and 
amputation was associated with a 5 year survival rate of less than 20% [8][5], Current 
treatments include surgery, chemotherapy and radiation therapy. Typically surgeries fall 
into three categories, including limb salvage surgery (depending on the size), tumor 
excision (depending on whether it has invaded surrounding tissues) and amputation. Most 
regular treatments combine chemotherapy and surgery. Several groundbreaking strategies 
improved outcomes drastically by adding adjuvant and neoadjuvant chemotherapies 
increasing long term survival rates to nearly 70% [5], Furthermore, surgical 
advancements in limb salvage surgeries have made amputation a rarity. For localized 
pediatric osteosarcoma, high dose methotrexate, doxorubicin and cisplatin are the
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standard for cooperative group clinical trials [5], For young adults, less is known about 
how the treatment and pathology of the illness affect survival, but age is a prognostic 
factor for osteosarcoma as well as other cancers [5],
Osteosarcoma occurs slightly more in men than in women and in African 
Americans than in whites. People who have been subjected to radiation therapy, as well 
as those who have a noncancerous bone disease are also slightly more likely to develop 
osteosarcoma (e.g. Paget’s disease) [8][9]. Also people with rare inherited bone cancer 
syndromes have an increased risk of developing osteosarcoma, these illnesses can 
include:
1. The Li-Fraumeni syndrome can be attributed to the TP53 tumor suppressor gene. 
This syndrome increases the risk of develop certain types of cancer, including 
breast cancer, brain tumors, osteosarcoma, and other types of sarcoma.
2. Retinoblastoma is a rare juvenile cancer of the eye. Many children have the 
inherited form of retinoblastoma where all the cells of the body have a mutation in 
the RB1 gene. Children affected by retinoblastoma are more likely to develop 
bone or soft tissue sarcomas, including osteosarcoma. When radiation therapy is 
used for retinoblastoma treatment, the risk of osteosarcoma in the bones around 
the eye increases.
3. Rothmund-Thomson syndrome is the result of abnormal changes in the REQL4 
gene. Children with this syndrome tend to have a stunted growth and typically 




Prostate cancer is a carcinoma that that develops in the prostate gland of the male 
reproductive system [10]. Prostate cancer is the second most common cancer affecting 
men in the United States. In 2015 over 220,000 new cases of prostate cancer will be 
reported and over 27,000 men will die from prostate cancer [11], One in seven men will 
have prostate cancer in their lifetime [11], Prostate cancer is a disease that primarily 
affects older men and it is uncommon for a man to develop it before the age of 40. 6 out 
of 10 men who have prostate cancer are over the age of 65 [11], In the U.S., it is more 
common in African American men than in white men and almost 99% of cases occur in 
men over the age of 50.
Prostate cancer develops when the rates of cell death and cell division are not 
equal and can in turn lead to tumor growth [12], After the initial transformation, cells can 
undergo additional mutations that contribute to tumor growth, progression and eventually 
metastasis [12], 95% of all prostate cancers are adenocarcinomas. 4% have transitional 
morphologies and are derived from urethral lining of the prostatic urethra and an even 
smaller number neuroendocrine morphology and are believed to be derived from 
neuroendocrine stem cells normally in the prostate [12],
Adenocarcinoma of the prostate gland can arise in several locations throughout the 
prostate. 70% of the time it arises in the peripheral zone, 15-20% in the transition zone 
and 15-20% in the central zone [12]. As it spreads, it invades the capsule medially and 
spreads by direct extension through vascular and lymphatic channels. More aggressive 
tumors invade the seminal vesicles and bladder and can cause urethra obstructions. As the 
cancer metastasizes it can invade bones of the pelvis, spine (lumbar and thoracic) femur,
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ribs and sternum. As it viscerally metastasizes it commonly invades the lungs, liver and 
adrenal glands.
Prostate cancer has been called the ‘silent killer’ because often times it is 
asymptomatic. Most are slow growers and often go unnoticed because they are 
symptomless or have very mild symptoms. More advanced cases typically have 
symptoms including pain and/or difficulty urinating (20-25%), blood in urine (10-15%), 
fecal incontinence and erectile dysfunction. Pain in the hips, back, chest or bones can 
indicate that the cancer has spread. As the tumor grows, it can begin to press against the 
spine, resulting in weakness in the lower extremities (20-40%) and/or a weakened 
bladder control [13] [12]. Metastatic symptoms can include weight loss from lack of 
appetite, bone with or without fracture due to the cancers affinity for bone and back and 
leg pain due to obstruction of local venous and lymphatic systems resulting in edema 
[12]. Also ureteral obstruction can occur due to local prostate growth, nodal metastasis 
and other factors. The presence of one or more of these symptoms is not a specific 
indicator of prostate cancer, and over half of men affected are symptomless.
Several diagnostic methods are used for prostate cancer, but only biopsy provides 
a definitive diagnosis. In most cases, a patient is symptomless; therefore, the American 
Cancer Society recommends a prostate examination for highest risk men at age 40, high 
risk men at age 45 and average risk men at age 50 annually.
Staging describes the process of determining the amount of cancer present 
throughout the body and where it is located. Staging can be clinical, which is determined 
during the patient’s diagnosis, or pathological, which is determined by examination of 
surgically removed tissue. A detailed report on staging can be reviewed at the American
Cancer Society’s webpage. The physical examination typically involves a prostate 
specific antigen blood test (PSA) and a digital rectal exam. The American Cancer Society 
states “Men with a PSA level between 4 and 10 have about a 1 in 4 chance of having 
prostate cancer. If the PSA is more than 10, the chance of having prostate cancer is over 
50%,” it is then up to the doctor’s discretion at what level to perform a biopsy. In men 
diagnosed with prostate cancer, the results from a PSA can be used along with tumor 
grade and physical examination to determine if other tests are needed. The results can 
also be useful in staging as a high PSA number can indicate the metastasis of prostate 
cancer. Digital rectal examinations (DRE) are administered to check for abnormalities, 
and the number and timing of abnormalities can indicate metastasis. Biopsy is the best 
test option, as it is a confirmatory test. The procedure usually uses a transurethral 
ultrasound to pinpoint the area for biopsy and get a general image of the prostate. Prostate 
MRI provides better resolution when imaging the prostate and is the standard for imaging 
due to the TRUS’s resolution issues.
The Gleason score is the most commonly used system to grade prostate cancer. 
The Gleason score is determined by studying biopsy under low power magnification. 
Score is calculated by adding the grades (1-5) of the two most common tumor growth 
patterns. The range is between 2 and 10 with 2 being the least aggressive and 10 being 
the most aggressive. The grades are based on how similar the cells look to unaffected 
glandular tissue. A grading of 1 indicates a near normal pattern, and 5 indicates a highly 
abnormal pattern with little or no glandular similarity. The scoring system is as follows:
1. A score of 2-4 is considered low grad or well differentiated [12].
2. A score of 5-7 is considered moderate grade or moderately differentiated [12].
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3. A score of 8-10 is considered high grade with little to no differentiation [ 12], 
Glandular architecture evaluation by Gleason score is the most widely used histological 
assessment for grading prostate cancer, although other histological changes such as cell 
and nuclear morphology, neuroendocrine differentiation, and vascularity can have 
prognostic significance [12],
Cancer may be linked to several some precancerous conditions. Prostatic 
intraepithelial neoplasia (PIN) is a possible precancerous end of morphology of cellular 
proliferation that presents itself in prostatic ducts, ductules, and acini [12], Low grade 
PIN cells have almost identical morphology to cells of an unaffected prostate, while high 
grade PIN cells have a morphology that differs strongly from normal cells. The presence 
of PIN cells can begin as early as the late 20’s of an adult male and about half of males 
have this condition by the age of 50. Low grade PIN cells do not necessarily develop into 
prostate cancer, and the importance of low grade PIN in the development of prostate 
cancer has not been determined. Patients with high grade PIN, have a 20% chance of 
developing cancer in another part of their prostate, and these patients are generally 
monitored [13][12]. Proliferative Inflammatory Atrophy (PIA) is another precursor to 
prostate cancer. Cells of the prostate are smaller than normal cells and inflammation can 
be observed. Many researchers believe this condition can result in high grade PIN and 
even prostate cancer [13]. Another condition that may suggest the development of 
prostate cancer is atypical small acinar proliferation (ASAP). In this condition, cells 
appear to be cancerous but are often too few to make that assumption. ASAP indicates a 
high likelihood of cancer.
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TNM staging is the most widely used system for staging, and can be useful in the 
treatment process. The staging system is based on five key elements [13]:
1. The extent of the primary tumor (T category)
2. Whether the cancer has spread to nearby lymph nodes (N category)
3. The absence or presence of distant metastasis (M category)
4. The PSA level at the time of diagnosis
5. The Gleason score, based on the prostate biopsy (or surgery)
The most common treatment modalities are surgery, chemotherapy, radiation 
therapy, cryotherapy, and gene therapy and vaccine treatment. Treatment often involves a 
combination of said treatment and can vary based on patient demographics. Another 
important factor involving demographics and family history is the level of risk factor for 
the patient. Risk factor, along with grading and staging, can determine how aggressive 
the treatment needs to be. Here I will discuss, in general, some treatment modalities 
commonly used to treat prostate adenocarcinoma. The main surgical method for prostate 
cancer is through a radical prostatectomy. This procedure involves the removal of the 
entire prostate gland and some of the surrounding tissues. Prostatectomy may involve full 
or partial removal of the prostate gland and surrounding tissues [12], [13], Laparoscopic 
approaches are noninvasive techniques, which use small incisions and laparoscopic tools 
performed by specialized surgeons to remove the prostate gland. This procedure can 
often involve the surgeon either holding the tools directly, or using a robotic assisted arm 
to hold tools and precisely remove tissues. Cryotherapy involves the freezing of tissues to 
destroy affected cell. This procedure is carried out with cold gas to flash freeze the tissue, 
and transrectal ultrasound (TRUS) is used to target cancerous tissue. A catheter is
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implemented to help drain necrotic tissue over a 3 week period. Common side effects of 
surgical procedures include incontinence, impotence, changes in orgasm, lymphedema, 
change in penis length, and hernia. Many of these side effects are treatable or 
manageable.
Radiation therapy uses high energy radiation to destroy cancer cells. The two 
main types of radiation therapy are external beam radiation (EBRT) and brachytherapy 
(internal radiation). EBRT uses a focused beam of radiation to kill cancer cell and may 
also be used in bone to eliminate bone metastasis. Brachytherapy uses a radioactive seed, 
millimeters in size, implanted into the prostate to destroy cells. It may be used as the first 
treatment for low-grade localized prostate cancer and has cure rates comparable to those 
of radical prostatectomy. Brachytherapy may be paired with hormone treatment as part of 
the first treatment for localized cancer and micro-metastasis into surrounding tissues. For 
recurrent cancer, cancer that is not fully removed, or advanced cancer, brachytherapy 
may reduce tumor size and provide relief from present and possible future symptoms
[12], [13], Side effects are similar to surgery but may also include bladder problems, 
bowel problems and fatigue.
Hormone therapy, referred to as androgen deprivation therapy (ADT) or androgen 
suppression therapy, is used to reduce levels called androgens in the body, or to stop 
them from affecting the growth of prostate cancer cells. Testosterone and 
dihydrotestosterone (DHT) are the main androgens, the majority of which come from the 
testicles and adrenal glands [12], [13], This treatment can slow the growth rate and shrink 
tumors of the prostate but alone does not cure prostate cancer. ADT may be used 
neoadjuvantly to shrink cancer before radiation therapy or in tandem with radiation
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therapy. In addition, this treatment may be used if the cancer has spread, is recurrent, or 
remains following another procedure [13]. Many types of hormone therapy can be used to 
treat prostate cancer. Some therapies lower the levels of testosterone or other androgens, 
while others block the action of those hormones. Side effects are: loss of libido, hot 
flashes, breast tenderness and growth of breast tissue, osteoporosis which can lead to 
broken bones, anemia, decreased mental sharpness, and loss of muscle mass, weight gain, 
fatigue, increased cholesterol and depression.
Chemotherapy is an approach that delivers anti-cancer drugs orally or through 
intravenous injection. These drugs can travel through the bloodstream and throughout the 
body, making them useful for treating cancers that have metastasized. It is typically used 
when prostate cancer has invaded tissues surrounding the prostate gland or that have 
metastasized. Chemo is not a standard treatment for early prostate cancer and may be 
used when hormone therapy is ineffective. Some studies show it could be helpful if  given 
for a short time after surgery [13]. Chemotherapy is generally administered in cycles with 
treatment being followed by a rest period to allow the body time to recover. For prostate 
cancer, chemotherapeutics are administered one at a time. Some common 
chemotherapeutic agents used include docetaxel (Taxotere®), mitoxantrone 
(Novantrone®), doxorubicin (Adriamycin®), etoposide (VP-16), vinblastine (Velban®) 
and paclitaxel (Taxol®) [13]. In most cases, the first chemo drug given is docetaxel, 
combined with the steroid drug prednisone. This combination is also the standard for men 
with castrate resistant prostate cancer [12]. If this drug-steroid combination does not 
work, mitoxantrone had been the standard second line of treatment but research has 
indicated that cabazitaxel has a statistically significant advantage [12].
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Sipuleucel-T (Provenge®) is a cancer vaccine that boosts the immune system to 
target and destroy prostate cancer cells on a systemic level. This gene therapy is typically 
used after subsequent hormone therapy is rendered ineffective. This vaccine is engineered 
specifically for each patient by using white blood cells harvested from the patient. Cells 
are then exposed to prostatic acid phosphatase (PAP). The cells are then reintegrated 
intravenously. This treatment is administered to the patient 3 times over a one month 
period. These modified immune cells induce a response from the host’s immune system 
cells to attack the prostate cancer. The vaccine does not stop cancer growth but increases 
the patient’s life span by several months on average. The side effects of chemo and gene 
therapy will be discussed in the Current Treatment section.
1.1.3 Breast Cancer
Breast cancer is cancer that develops in the breast. In 2016 alone there will be 
over 230,000 new cases of invasive breast cancer diagnosed in women, over 60,000 new 
cases of carcinoma in situ (CIS) diagnosed in women (non-invasive and earliest form) 
and about 40,000 women will die from breast cancer. As breast cancer can be genetically 
linked a woman is more likely to develop breast cancer if other women in her family have 
the disease.
The female breast is primarily made up of lobules, ducts and stroma (comprised 
of connective tissue around ducts and lobules, blood and lymphatic vessels) [14], Breast 
cancer is a malignant neoplasm that begins in the lobules or ducts of the breast and can 
invade surrounding tissue and or metastasize to other parts of the body. Ductal 
carcinoma accounts for 50-80% of reported cases and lobule carcinoma is the second 
most common accounting for 5-15% of the cases. When discussing breast cancers it is
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important to understand lymphatic system of the breast in order to fully comprehend how 
these cancers spread. Most lymphatic vessels of the breast connect via axillary nodes 
located under the arm, while some connect via internal mammary nodes of the chest or 
supraclavicular and inffaclavicular nodes. Most breast cancers are carcinomas of the 
epithelial cells and adenocarcinomas, which affect glandular tissue. Other types of 
cancers that occur in breast are sarcomas, which start in the muscle, fat and connective 
tissue. In most cases, a tumor of the breast can be a combination of these different 
phenotypes and a mixture of invasive and cancer in situ.
Invasive breast carcinoma is characterized as malignant epithelial tumors that 
invade surrounding tissues and tend to metastasize [15]. Most of them are 
adenocarcinoma, which may arise from the mammary parenchymal epithelium, 
specifically the terminal duct lobular unit. They may have a wide range of phenotypes 
and morphologies and particular types have select histopathology and clinical 
characteristic. The main type of breast cancer accounting for 50-80% of all cases is 
invasive ductal carcinoma (IDC) [ 15] [ 16]. The carcinoma begins in the milk duct of the 
breast, pierces through the wall of the duct and invades the fatty tissue of the breast. As 
this occurs, the cancer may be able to metastasize to other parts of the body via the 
lymphatic system. The second most common type of breast cancer occurs in the milk 
producing lobules of the breast and is called invasive lobular carcinoma. Similarly to IDC 
it can metastasize via the lymphatic system of the breast. Additionally it may be more 
difficult to detect by mammogram. See Table 1-2: Frequency and Survival Rates of 
different types of Invasive Breast Cancer [15], [16]
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Table 1-2: Frequency and Survival Rates of different types of Invasive Breast Cancer 
[15], [16],
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Usually the first symptom of breast cancer is a lump or mass with irregular edges 
that feels distinctly different from the rest of the breast tissue. Lumps can also be found in 
the lymph nodes of the armpits. More than 80% of cases are found when a woman 
discovers a lump [14], [17], One breast may have a thickening when compared to the 
other, or one breast may become larger than the other. Other symptoms can include 
change in the position of the nipple, inversion of the nipple, discharge from the nipple, 
constant pain in the breast or armpit, and swelling or rash in the breast or armpit [14], In 
early stages, the lump may move freely and in more advanced stages the lump may 
adhere to the chest wall or skin [17], Inflammatory breast cancer can result in the breast 
becoming warm, red and swollen, the skin may appear to be dimpled and leathery, 
possessing the texture of an orange.
The screening process for breast cancer starts with a physical examination. If 
abnormalities are discovered during the initial screening process additional test will be 
performed. The next screen is usually an imaging test called a mammogram. The breast is 
pressed between two plates and X-ray images are taken from two different angles. Other 
imaging tests a physician may order are breast ultrasound, and an MRI. The MRI is
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typically used in tandem with a mammogram to judge disease progression, to screen if 
the cancer has spread to the other breast, as well as, to help to determine the size of the 
mass. If imaging does not show a mass and the physician can still feel a lump, a biopsy is 
done to confirm whether the mass is cancerous or not. The next step following imaging 
test is a biopsy, a test that confirms the presence of cancerous tissue. Different types of 
biopsies include fine needle aspiration, which is the least invasive and can also be guided 
by ultrasound, core needle biopsy, which provides a larger sample and can be vacuum 
assisted, and open biopsy, which is rarely done. A lymph node biopsy can also be done if 
the lymph nodes of the arm pit are enlarged.
Breast cancer can be further classified. One classification is based on the presence 
of estrogen and progesterone receptors (ER+ and PR+), as estrogen and progesterone can 
fuel the growth of breast cancers. Another classification is based on the status of HER2 
gene, the presence of which can indicate greater than normal amount of HER2 protein, 
which usually is associated with a more aggressive cancer type. The term “triple 
negative” refers to the status when the tumor cell is both hormone receptor negative (PR- 
and ER-) and HER2-. Other classifications are based on ploidy, proliferation, and gene 
type and patterns as well as gene expression.
The staging of breast cancer follows the American Joint Committee on Cancer 
TNM staging. Treatment can depend on the stage of the cancer, as well as, the 
progression of the disease. Treatment can also be split into two groups:
1. Local treatment applies therapy directly to the tumor, surgeries and radiation 
therapy.
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2. Systemic treatment can reach cancerous cell throughout the body and usually 
administered orally or intravenously. Examples include chemotherapy, 
targeted therapy, and hormone and gene therapy.
Surgery is often the first line of treatment for localized breast cancers. Surgical 
tumor removal can be either breast-conserving or mastectomy [14] [17]. The breast can be 
reconstructed at the same time as surgery or later. Surgery is also used to check the 
lymph nodes under the arm for cancer spread [14], [17]. Options for this include a 
sentinel lymph node biopsy and an axillary (armpit) lymph node dissection. With Stage 1, 
invasive cancer mastectomy and breast conservation therapy with radiation are 
comparable in terms of remission rate, but it is important that physicians remove all 
cancerous tissue. Prior to surgery chemotherapy can be used to shrink the tumor and this 
approach may enable the use of breast conserving surgery rather than mastectomy. Post­
mastectomy many women can opt in for breast reconstructive surgery.
Radiation therapy is typically given to kill cancer cells near the site where a tumor 
was removed including nearby lymph nodes. It may also be administered in patients 
where cancer has spread to others areas like the bone or brain. The most common type of 
radiation therapy given to women with breast cancer is external beam radiation. If breast 
conservation therapy is done, the entire breast gets radiation and an extra boost is given to 
the area of the breast where the cancer was removed. It is usually given after the patient 
has healed from surgery, and if given after chemotherapy it usually follows a recovery 
period [14], [17], It is only given for a few minutes at a time 5 days a week for 5 days at a 
time. Side effects include numbness, pain, and nerve damage, fatigue, swelling and 
blistering. Alternatively, internal beam radiation treatment can be given for 5 days, after
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which the pellets are removed. This technique has comparable side effects to those of 
external beam radiation.
Chemotherapy is used to kill rapidly growing cancer cells or to slow replication. It 
is usually given along with surgery or radiotherapy because it cannot kill cancer alone. 
Treatment is usually given for one day followed by 2 weeks of recovery, orally or 
intravenously. Adjuvant chemo is given after surgery as a safeguard to kill any cancer 
cells that have been left behind [14], Neo adjuvant chemo is administered pre surgery to 
shrink the tumor and or to see how the cancer responds to chemotherapy [17], 
Chemotherapeutic drug are most effective when given in combination. Some common 
combinations include doxorubicin, epirubicin or paclitaxel in combination with 
fluorouracil or carboplatin [14], Chemotherapeutics may be used alongside drugs that 
target HER2 to enhance their effects. Trastuzumab or Pertuzumab is given along with a 
taxane [14], [17], Side effects include hair loss, fatigue, nausea, mouth sores and because 
of possible affects to bone marrow increased chance of infections and bruising.
Hormone therapy is another systemic treatment that can be used like chemo 
therapy adjuvant or neoadjuvant to decrease risk of reoccurrence and to shrink the 
tumors. They can be used to block estrogen and progesterone, hormones known to have 
an effect on the aggressiveness and growth of cancer cells. These treatments are used on 
ER+ and PR+ cancers and can either lower production of the enzymes or block receptors 
in ER and PR positive cancers. Such treatment is ineffective on ER- and PR- breast 
cancers. Tamoxifen is a drug commonly used that blacks estrogen receptors. It acts as an 
anti-estrogen in breast cancer cells and has the effect of estrogen in other tissue [17], 
Because of this feature tamoxifen belongs to a class of drug called selective estrogen
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receptor modulators. Its side effects include hot flashes, vaginal dryness, fatigue and 
mood swings [14], In premenopausal women, it can lead to bone thinning, but in post­
menopausal women it can have the opposite effect. Other commonly used hormone drugs 
include toremifene, letrozole and anastrozole [14], [17], Chemotherapies, hormone 
therapies, gene therapies and targeted therapies will be discussed in the current treatments 
for cancers later.
1.2 Multi-Drug Resistant Cancer
Off-target toxicity to adjacent healthy tissues and poor accumulation of 
chemotherapeutics into the tumor site are major drawbacks of firee-drug chemotherapy, 
which will necessitate high drug doses. Consequently, emergence of multidrug resistance 
(MDR) gives rise to cancer progression or recurrence, which requires multiple treatment 
courses. Increased drug efflux mainly via transporting activity of ATP-binding cassette 
(ABC) family and inactivation of apoptosis pathways are major molecular mechanisms 
causing MDR phenotype.
1.2.1 Multi-Drug Resistance Mechanisms
Multi-drug resistance is a system that protects the cell against a various amount of 
compounds like drugs, which may have different chemical structures, and different 
mechanisms of intracellular activity. Complex biochemical networks of the above- 
mentioned pathways play a multi-factorial role in the implication of MDR, which could 
be intrinsic or acquired. Transporters in the body are security gates altering the molecular 
distribution of therapeutic agents. MDR is facilitated by the existence of several different 
mechanisms. It is widely known that membrane transporters account for the resistance to 
many of the commonly used chemotherapeutics by affecting the cellular uptake and
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retention of these drugs into tumor cell. Other factors may have may contribute to MDR, 
such as inactivation of apoptosis pathways, but here I will describe membrane 
transporters and will only refer to apoptosis inactivators as they relate to transport 
mechanisms.
1.2.2 ABC Family of Transporters
Two classes of membrane transporters affect the pharmacokinetics of cellular 
uptake of drugs. Changes to these membrane transporters can be directly and indirectly 
responsible for MDR tumors. One of the classes is the adenosine triphosphate (ATP)- 
binding cassette super family, which is often times correlated with decreased 
accumulation of hydrophobic anti-cancer therapeutic drug. It pumps the drugs outward 
when drugs diffuse down a concentration gradient into the cells. The other superfamily is 
solute carrier transporters which commonly increase sensitivity to chemicals by 
mediating the uptake of hydrophilic anticancer agents [18]. If either one of these systems 
is affected it can result chemotherapeutic drug resistance.
ABC proteins are characterized by having a cytoplasmic ATP-binding domain 
with a specific nucleotide binding domain. They function by harvesting energy from 
hydrolysis so that transporters act as efflux pumps to remove various intracellular 
chemotherapeutic agents. ABC transporters also have a trans membrane domain which 
offers a binding site for substrate or chemotherapeutics which are, in turn, translocated 
from the cytoplasm out to the cell membrane [18].
The human ABC family proteins are divided into seven subfamilies based on 
binding domain organization (the number and configuration of TMDs and NBs). This 
family has a total of 49 members, but three members are noted for their contribution to
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MDR [18], [19], They are P-glycoprotein(p-gp:MDRl/ABCl) MDR-associated Protein 
(MRP1/ABCC1) and the breast cancer resistance protein (BCRP:ABCG2) [18]. All have 
characteristics which include the expulsion of a variety of hydrophobic compounds, 
decreased substrate specificity which allow for the transport of many of the major drugs 
used in chemotherapy and MRP1, as well as ABC2 which can remove xenobiotics and 
intracellular metabolites.
1.2.2.1 P-slvcoprotein fP-sp. MDRL ABCB1)
A member of ATP-binding cassette (ABC) family of transport is called P- 
glycoprotein (P-gp) which is a 70 kDa membrane bound protein and expels 
chemotherapeutics. In other words, reduced drug accumulation inside the cell, due to the 
energy-dependent drug efflux activity of P-gp is the primary cause of MDR. P-gp is a 
membrane bound protein consisting of 1280 amino acids. P-gp is a full transporter 
consisting of 2 homologous half transporters each having a TBD and NBD. [ 18] A linker 
region connects the two half transporters and this region may be important in proper 
communication between the subunits. If the central core is deleted, the p-gp is still 
expressed at levels similar to the wild type but is not functional for transport of ATP 
activity [18].
The P-gp transporter removes neutral and cationic hydrophobic compounds like 
doxorubicin vinblastine actinomycin D, daunorubicin, vincristine, etoposide and 
paclitaxel. The mechanism for drug transport is as follows. ATP is hydrolyzed, forming a 
transition state intermediate of the complex, then the drug is extruded from the P-gp and 
ADP dissociates from the complex. An additional ATP then binds and returns the P-gp to 
its original conformation to prepare for the next round of transport [18], [20].
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In tumors, P-gp expression and overexpression can be caused by mutations to the 
p53 gene and overexpression of the p63 and or p73 gene. Upregulation of P-gp may be 
the result of ABCB1 promotor activation via nuclear protein MDR1 promotor enhancing 
factor or multiprotein complex RNA helicase I [18]. Some factors can also silence 
ABCB1, such as epigenetic methylation; and chromatin modifying enzymes like histone 
acetylates and deacetylases can also regulate ABCB1 genes. Other factors involved may 
include heat shock, chromosomal rearrangement, inflammation, hypoxia, toxic 
metabolites and ultraviolet radiation [18].
1.2.2.2 MDR-associated Protein (MRP1. ABCC1)
The MRP1 gene arises from chromosome 16p 13.1. MDR-associated protein is a 
membrane bound glycoprotein with a 1,531 amino acid residue. The protein has a similar 
structure to that of the P-gp but the MRP1 contains an n-terminus segment, TMDO, which 
connects TMD1 with LO linker region. The LO region is absolutely necessary for 
transport and the TMDO is not.
Although MRP1 behaves similarly to the P-gp (requires 2 ATPs for transport), the 
mechanisms for transport differ. In MRP1, the NBD1 has a higher affinity for o ATPs 
than NBD2 as opposed to the equal affinities between NBDs in P-gp.[18] The transport 
proceeds as follows. First the substrate binds to TMDs of MRP 1 and then a 
conformational change induces ATP binding NBD1. The confirmation is further altered 
and enhances the binding of ATP at NBD2. Once ATP is bound at both NBDs, the 
substrate is transported out of the cell. Shortly after extrusion, ATP bound at NBD2 is 
hydrolyzed and it induces a partial conformation change which allows dissociation of the
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ATP bound at NBD1. The release of ADP and inorganic phosphate brings MRP1 back to 
its original conformation [18].
Unlike P-gp, MRP1 expression can be found in a variety of cell types and organs. 
P-gp located in the apical membranes of epithelial cell, whereas MRP1 is found 
basolaterally and tends to pump drugs into the body rather than being excreted in bile, 
urine and the gut. Overexpression of MRP 1 results in resistance to a wide array of drugs 
including doxorubicin, epirubicin, vinblastine vincristine, and etoposide. Research has 
shown that MRP1 requires glutathione to transport unmodified anticancer drug. MRP1 
may co-transport GSH or GSH may bind to MRP1 to enhance transport of hydrophobic 
anticancer agents across membranes [ 18][21],
1.2.2.3 Breast Cancer Resistance Protein (BCRP. ABCG2)
The chromosome locus 4q21-4q22 is the location of ABCG2 gene and encodes 
for a 655 amino acid plasma membrane glycoprotein. This gene was first cloned from the 
drug resistant breast cancer cell line MCF7/ADVO [18][22], ABCG2 is half the structure 
of P-gp containing one TMD and NBD while showing a reverse domain arrangement, 
i.e., NBD-TMD. Two ABG2 molecules combine to form a functioning homodyne via a 
sulfide bond. This bond allows ABCG2 to have 2 TMDs and NBDs so that it can 
function as a drug transporter [18], ABCG2, like MRP1, is expressed ubiquitously across 
tissues, but most abundantly found in the liver, intestinal epithelium, placenta, and blood 
brain barrier and in various stem cells. Overexpression is typical in drug resistant 
(selective) cell lines from ovary, lung, breast, colon and gastric cancer.
The mechanism of action for the ABCG2 transporter had not been investigated as 
of 2009, but researchers speculate that is does not have any major difference from the
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mechanisms for P-gp and MRP1. As mentioned, substrates may include similar 
chemotherapeutic drugs for P-gp and MRP 1, as well as some molecularly targeted drugs, 
such as mitoxantrone, topotecan, irinotecan, methotrexate, gefitinib and imatinib. As for 
P-gp and MRP1, several factors control expression of ABCG2. Estrogen, progesterone 
and testosterone effect its expression, although data are conflicting. Expression can be 
upregulated by the mammary gland during lactation. Also, hypoxia regulates expression, 
and research has suggested that stem cells and tumor cells may be protected in hypoxic 
conditions from chemotherapeutics due to upregulation of ABCG2 [18][22][23],
1.3 Current T reatments
This section will discuss, in detail, the current treatments for osteosarcoma, 
prostate cancer and breast cancer. It will focus on chemotherapy, gene therapy and 
combination therapies used to shrink tumors that may be paired with surgical methods. 
Surgical methods will only be discussed when they are paired with the treatment 
modalities discussed below.
1.3.1 Chemotherapies
Chemotherapy refers to the use of anticancer drugs to shrink tumors or eliminate 
metastasis throughout the body. Chemotherapy is systemic and usually administered 
intravenously or orally. For cancers like osteosarcoma, chemotherapy is an important part 
of treatment. In breast cancer and prostate cancer it can be used adjuvantly when tumors 
are un-ressectable, to destroy any cancer cells left behind, and neoadjuvantly to shrink 
tumors before surgery. Chemotherapy can be used to treat the majority of cancers once 
they have become metastatic; however, it but does not cure cancer. Chemotherapeutic
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agents are often administered in combination with surgery or other types of treatment but 
are most useful in shrinking tumors and destroying metastasis.
1.3.1.1 Free Pru2s
There are a variety of free drugs that may be evaluated for patients with cancer 
who are seeking chemotherapy to shrink tumors in adjuvant or neoadjuvant therapies. 
Some of the same drugs can be administered to patients with osteosarcoma, prostate 
cancer or breast cancer; these drugs are doxorubicin (Adriamycin) and platinum agents 
(cisplatin, carboplatin) [8][13][14], Etoposide is administered to both osteosarcoma 
patients and prostate cancer patients while gemcitabine may be administered to both 
osteosarcoma and breast cancer patients [8j[ 13]. Docetaxel, paclitaxel, vinorelbine and 
mitoxantrone may be given to both prostate cancer patients and breast cancer patients
[13][14], Some other commonly administered chemotherapeutic drugs for osteosarcoma 
are methotrexate (given in high doses along with leucovorin to help prevent side effects), 
epirubicin, ifosfamide, cyclophosphamide and topotecan. Often, two or more drugs are 
given together. Some common combinations of drugs include high-dose methotrexate, 
doxorubicin, and cisplatin, doxorubicin and cisplatin, ifosfamide and etoposide and 
ifosfamide, cisplatin (or carboplatin) and epirubicin [8][13][14]. Some commonly 
administered chemo drug for prostate cancer are cabazitaxel, estramustine, and 
vinblastine [13]. Other chemotherapeutic drugs for breast cancer include capecitabine, 
liposomal doxorubicin, ixabepilone, albumin-bound paclitaxel and eribulin.
1.3.1.2 Nanomedical Approaches
Nanomedical approaches to cancer therapies involve the use of nanoparticles 
(NPs) or nanoparticulate-based systems or devices used along with drugs, genes or other
28
therapeutic mechanisms to treat cancer. NPs used as drug delivery vehicles are 1-300 nm 
particles made from polymers, lipids, proteins, viruses, or even organometallic 
compounds and combinations of any of these.
Polymeric nanoparticles are NPs less than a half micron in diameter formed from 
naturally occurring polymers (chitosan, chitin, albumin, etc.) and/or synthetic polymer 
(PLGA, PLA and PEG, etc.). These particles may be used to deliver DNA, proteins, 
cancer drugs or oligonucleotides. Gradishar et al. developed a nanoparticle paclitaxel 
formulation, where serum albumin was used as a nanocarrier [24], This complex known 
as abraxane has been used for the treatment of metastatic breast cancer and has entered 
clinical trials for many other cancers, including small cell lung carcinoma and advanced 
nonhematologic malignancies. Some of the most widely used non-biodegradable 
synthetic polymers are /V-(2-Hydroxypropyl) methacrylamide (HPMA) and polyethylene 
glycol (PEG) [25], PK1, a conjugate of HPMA and doxorubicin, was the synthetic 
polymer-drug evaluated in clinical trials as an anticancer agent. Phase I clinical trials 
were completed in patients with a variety of tumors that were refractory or resistant to 
prior therapy such as chemotherapy [26], Liang et al. fabricated paclitaxei-loaded 
nanoparticles with galactosamine conjugates to target liver cancer cells. These NPs were 
efficient in shrinking the size of tumors when injected into hepatoma-tumor-bearing nude 
mice, through the specific interaction between galactosamine and asialoglycoprotein 
receptors [27], Genexol-PM (PEG-poly (D, L-lactide)-paclitaxel) is one of the first 
polymeric micelle formulations of paclitaxel. Phase I clinical trials and pharmacokinetic 
studies have been conducted in patients with advanced refractory malignancies [28].
29
Chitosan nanoparticles, 100 nm in diameter, have been fabricated to encapsulate 
of dextran-doxorubicin conjugates (DDC). In the study, mice were intravenously injected 
with DDC-loaded chitosan nanoparticles. DDC-chitosan nanoparticles showed a decrease 
in the tumor volume after 4 weekly injections. The DDC-chitosan nanoparticles were 
60% as effective on tumors treated with the conjugate alone, while treatment with 
doxorubicin alone did not decrease the tumor volume [29]. Another group conjugated 
doxorubicin with PLGA and formed nanoparticles of 200-250 nm diameter with an in 
vitro release of up to 1 month. In vivo analysis indicated that a single injection of 
doxorubicin-PLGA conjugated nanoparticles inhibits tumor growth for up to 12 days, 
although NPs were not as effective as daily doxorubicin injections at the concentrations 
tested [30], SN-38 analogs of irinotecan in lipid nanoparticles were prepared and yielded 
sizes of 100-375 nm diameter. It was found that the longest tumor regression and 
survival was seen in mice injected with nanoparticles of 375 nm in diameter (65 days 
survival, 1.98 mg SN-38/mouse), followed by those injected daily with Camptosar (51 
days survival, 9 mg irinotecan/mouse) and then by those injected with nanoparticles of 
100 nm diameter (48 days survival, 1.51 mg SN-38/mouse).
1.3.2 Gene Therapies
Gene therapy provides a novel approach to combating cancer at its source. Gene 
therapy can be used to reactivate apoptotic pathways, selectively target tumors cells, to 
destabilize membrane proteins that affect drug resistance and to activate pathways that 
may serve to boost the actions of drugs. Genes can be delivered to cells in a variety of 
ways even though some systems have major drawbacks. Direct injection can be a 
delivery pathway, but nucleic acids delivery may be blocked due degradation of nucleic
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acids DNases and RNases. Viral vectors may be used for highly efficient delivery of 
nucleic acids but some hurdles may be faced due to safety issues, immunogenicity, low 
transgene and high cost. Cationic polymers and lipids show promise in the field of gene 
delivery as they can be adapted for large scale manufacture, have a typically low 
immunogenic response, and can be modified and also allow for the carrying large inserts. 
In addition, they can be co-loaded with drugs to allow for a co-administration of drugs 
and genes for localized cancer therapy.
Some ligands that have shown selective targeting to cancer cells are transferrin 
(Tf) and epidermal growth factor (EGF) [31], The group designed and fabricated 
complexes for gene delivery with polyethylenimine (PEI) linked to PEG which were 
subsequently coated with either Tf or EG PEI-PEG-DNA complexes, this process yielded 
nanoparticulates ranging in diameter from 49 to 1200 nm. Plasmid pCMVLuc, which 
codes for luciferase production, was complexed with these nanoparticles for in vivo 
studies. In vivo studies in mice showed that the gene expression from administration of 
targeted systems was 10-100 higher in tumors than in other organs [32].
Liu et al. [33] fabricated ultra-low size calcium phosphate nanoparticles (23 .5- 
34.5nm) for entrapping DNA molecules. In vitro studies demonstrated that nanoparticles 
efficiently encapsulated the DNA and protected it from DNase degradation. Suicide gene 
therapy assays, assays in which a gene is delivered to transform a pro-drug into an active 
drug, displayed promising results even though these nanoparticles were not tested via 
systemic injection. This therapy activates pathways that induce apoptosis.
Another promising approach to gene delivery is through polyelectrolyte complex 
(PEC) micelle based vector. PEC micelles result from interactions between PEG
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conjugated oligo nucleic acids (PEGylated ODN) and a polycations (e.g. PEI). 
Vonarbourg et al states “The negatively charged antisense c-Raf ODN interacts with 
polycations to form a neutral charged hydrophobic inner core of PEC micelles, while 
PEG segments are localized outside the core to form a hydrophilic shell [34].” When 
compared to ODN alone, micelles show a grander anti-proliferative activity against 
ovarian cancer cells in vitro and in vivo, when injected to the tumor [34],
Kommareddy et al. [35] developed PEGylated modified gelatin nano-vectors for 
delivery of pDNA and encoding for the soluble form of the extracellular domain of 
vascular endothelial growth factor receptor-1 (VEGF-R1 or sFlt-1). Intravenous 
administration in female nude mice, bearing orthotopic MDA-MB-435 breast 
adenocarcinoma xenografts, showed size reduction in tumors and suppression of 
microvasculature to the tumor. This system has proven its effectiveness for systemicaily 
administered gene delivery vehicle in solid tumor models.
Clusterin/apolipoprotein gene is a heterodimeric ubiquitously expressed 
glycoprotein that may be linked to many severe physiological disturbances such as tumor 
formation and cancer progression [36], Zimmermann et al. [37] was the first group to 
report siRNA-mediated silencing of the apolipoprotein (ApoB) in response to systemic 
delivery in non-rodent species. Stable nucleic acid lipid particles (SNALP) were 
composed of lipids 3-N-[(-methoxypoly(ethyleneglycol)2000)carbamoyl]-1,2- 
dimyristyloxy-propylamine(PEG-C-DMA), l,2-dilinoleyloxy-N,N-dimethyl-3- 
aminopropane (DLinDMA), 1,2-distearoyl-sn- glycero-3-phosphocholine (DSPC) and 
cholesterol, in a 2:40:10:48 molar per cent ratio. SNALP containing ApoB-specific 
siRNA were administered by intravenous injection to cynomolgus monkeys at doses of 1
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or 2.5 mg kg'1. They reported a significant reduction in ApoB protein, serum cholesterol 
and low-density lipoprotein levels as early as 24 hours after treatment. Levels were 
sustained at low amounts for 11 days at the highest siRNA dose. Results indicated an 
immediate, potent and lasting biological effect of siRNA treatment. This landmark study 
demonstrated, for the first time, a clinically relevant systemic RNAi-mediated gene 
silencing in non-human primates.
1.3.3 Combination Therapies
Cancer is a complex illness that may result from a variety of factors depending on 
progression, staging type, apoptosis demodulation and angiogenesis. Consequently, 
treatment may involve a combination of remedies to achieve remission. It often involves 
chemotherapeutics, hormone modulation, gene therapy and surgeries paired to treat 
cancers. Hormone therapy used is before surgery to shrink the tumor, after surgery to 
eliminate left over cancer cells, and with advanced stages of cancer. Hormone therapy 
can cut off pathways that feed tumor growth and aggressiveness of cancer, thus leading to 
a reduction in tumor size, which aids in resection. When treating certain types of cancer, 
gene therapy can be paired with chemotherapeutics. Consequently, gene therapy actively 
or passively targets tumor cells for localized drug interaction, restores apoptotic 
functions, destabilize membrane proteins that lead to resistance, and/or silences genes 
that may be active in metastatic and more aggressive cancers. An ideal model may 
involve both gene/drug therapy with surgery or possibly eliminate surgery altogether. 
Recent advances in MDR targeting and drug localization have led to reduced tumor 
proliferation and size.
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1.3.3.1 Hormone Therapies and Sureeries
In prostate cancer, hormone therapy is referred to as androgen deprivation 
therapies. The main goal of therapy is to disrupt hormone pathways in order to inhibit 
their response in prostate cancer cell. It is often administered when the cancer has spread 
too far to be removed by surgery or radiation. It can be used neoadjuvandy to shrink 
tumor prior to resection or to reduce the risk of reoccurrence after surgery. Some 
therapies involve the removal of the testicles, which are major producers of androgens, 
while others rely on drugs, and/or genes that reduce androgen production or block 
androgens. Luteinizing hormone releasing hormone analogs (LHRH or GnRH agonist) 
are injected or implanted subcutaneously [10], Some of the drugs available in the U.S. are 
leuprolide (Lupron®, Eligard®), goserelin (Zoladex®), triptorelin (Trelstar®) and 
histrelin (Vantas®) [13]. The American Cancer Society states “Degarelix is an LHRH 
antagonist. LHRH antagonists work like LHRH agonists, but they reduce testosterone 
levels more quickly and do not cause tumor flare like the LHRH agonists do.” LHRH acts 
in the testicles, inhibiting testosterone production, but does not limit the production in the 
prostate and other tissues. Abirateron blocks the CYP17 enzyme, thus inhibiting other 
tissues from producing androgens. It may be administered to men with advanced staged 
castrate-resistant cancer because it may shrink or slow the growth of tumors and prolong 
life [13],
Another class of drugs that disrupts the action of androgens is anti-androgens. 
Anti-androgens bind androgen receptors, blocking androgen binding. Some anti­
androgens include flutamide (Eulexin®), bicalutamide (Casodex®), and nilutamide 
(Nilandron®) in pill form and are taken daily [13], These drugs are often added to
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treatment if orchiectomy, an LHRH analog, or LHRH antagonist is ineffective alone.
They are typically administered for a few weeks when an LHRH analog is first started to 
prevent a tumor flare. When anti-androgen treatment is combined with orchiectomy or 
with an LHRH analog as the first line hormone therapy, the therapy is called combined 
androgen blockade (CAB) [13], Enzalutamide (Xtandi®) is a newer type of anti­
androgen that blocks growth and division signals sent from the androgen receptor to the 
nucleus. In men with castrate-resistant prostate cancer, enzalutamide can lower PSA 
levels, shrink or slow the growth of tumors, and help men live longer. Other androgen- 
suppressing drugs include ketoconazole (Nizoral®), which was first used for treating 
fungal infections, and estrogens. Both block the production of certain hormones, 
including androgens, similarly to abiraterone. Ketoconazole is most often used to quickly 
lower testosterone levels in men diagnosed with advanced prostate cancer and an 
abundance of metastasis [13].
In breast cancer, hormone therapy is either used as an adjuvant therapy to help 
reduce the risk of the recurrence or used as a neoadjuvant therapy, to shrink tumors prior 
to resection. If cancer is recurrent or metastatic, cancer hormone therapy can be used.
Two thirds of breast cancers are PR+ or ER+ and most types of hormone therapy for 
breast cancer is geared towards lowering estrogen levels, and blocking or limiting 
estrogen activity in breast cancer cells. These treatments are only useful in hormone 
receptor positive cancer types.
A commonly administered drug that blocks estrogen receptors is tamoxifen
[14][38], It can reduce the risk of developing breast cancer in women at high risk. 
Tamoxifen is a SERM and generally acts like an anti-estrogen in breast cells. It can also
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act like an estrogen in other tissues, like the uterus and the bones. For women with 
hormone receptor-positive invasive breast cancer, tamoxifen can be given for 5 to 10 
years after surgery to lower the chances of the cancer recurring and helping patients live 
longer. Tamoxifen can inhibit growth and reduce tumor size in women with metastatic 
breast cancer. It may also reduce the risk of a new breast cancer occurring in the other 
breast. Toremifene is another a SERM approved to treat metastatic breast cancer but it is 
not likely to work if tamoxifen has been used and stopped working. Another drug used is 
Fulvestrant, which blocks the estrogen receptor and also eliminates it temporarily [14], 
[17]. It is typically used to treat advanced metastatic breast cancer, most often after other 
hormone drugs. Aromatase Inhibitors (AIs) are drugs that block estrogen production in 
postmenopausal women. Some AIs include letrozole (Femara), anastrozole (Arimidex), 
and exemestane (Aromasin). They do not inhibit estrogen production in the ovaries and 
are only effective in postmenopausal women or in women with luteinizing hormone- 
releasing hormone analogs. AIs are taken daily as pills. So far, drugs in this group seem 
to work equally well in treating breast cancer. These drugs alone or in combination with 
or after tamoxifen, reduce the risk of the cancer recurring more effectively than just 
tamoxifen for 5 years [14] [17] Ovarian ablation in pre-menopausal women is the 
removal or shutting down of the ovaries (ovarian oblation), which effectively makes the 
woman postmenopausal and may be synergistic with other hormone therapies, and is 
most often used to treat metastatic breast cancer. Often, ovarian ablation is carried out 
using drugs called LHRH analogs, such as goserelin (Zoladex®) or leuprolide 
(Lupron®), which disrupt the estrogen production signal. They may be used alone or in 
tandem with tamoxifen, aromatase inhibitors, or Fulvestrant in pre-menopausal women or
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in women whose cancers do not respond to the other hormone treatments. Its major side 
effect is weight gain, and it is sometimes used in higher doses to reverse weight loss for 
people with advanced cancer. Androgens (male hormones) may rarely be considered after 
other hormone treatments for advanced breast cancer have been tried.
1.3 .3.2 Gene/Drue Hybrid Approaches
Drug resistance and systemic toxicity are major issues in cancer chemotherapy. 
Also off-target activity can affect localized drug dosage. In combination with gene 
therapy, chemo drugs can be directed to and act more effectively on their target cell type 
at a radiometric dose. Gene delivery vectors allow targeting of specific cell types by 
taking advantage of interactions between cell membrane receptors and cell surface 
ligands. Current chemotherapeutic strategies are limited by the development of resistance 
and by their severe side effects.
Ligand targeting can play an essential role in targeting cancers like breast cancer. 
Strategies have been developed to select internalizing antibodies from phage libraries 
[31]. This technique identified F5 and Cl antibodies in the breast tumor cell line SK-BR- 
3 that bind to ErbB2 growth factor, which is overexpressed in 20- 30% of human breast 
carcinomas and other adenocarcinomas [39], This study incubated antibody F5 
conjugated PEG, with Doxil (commercial liposomal doxorubicin formulation from Alza) 
to form a coupled liposome system. The in vivo comparison of Doxil or F5-coupled Doxil 
in mice showed a faster and greater regression in tumor volume for F5-containing Doxil 
over unmodified Doxil [39],
In healthy tissues, the cell surface folic acid receptor is inaccessible; but in cancer 
cell surfaces, the receptor is expressed. The folate receptor has been successfully targeted
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in in vitro and in vivo tumor models. Some studies have shown the effectiveness of 
folate-targeting immune therapy with a vaccine. This approach applied to positive lung 
metastasis in mice, showed cures in up to 56% of tumor bearing mice [40], Cho et al. 
generated a novel folate receptor-targeted nanoparticle formulation of paclitaxel using 
heparin as a carrier [heparin-folate-Taxol (paclitaxel), HFT], and tested it using nude 
mouse animal models. This novel ternary nanoparticle HFT demonstrated more activity 
against the growth of tumor xenografts of human KB and paclitaxel-resistant KB 
derivatives than did binary heparin-Taxol or free drug (paclitaxel) [41].
Aptamers have been applied as ligands to drug delivery systems to enhance 
selectivity. DNA and RNA aptamers are oligonucleic acids that bear unique three- 
dimensional conformations capable of binding to target antigens with high affinity and 
specificity [42]. Animal models were used to investigate the in vivo efficacy of docetaxel- 
encapsulated poly(lactic-co-glycolic acid) nanoparticle conjugated with an aptamer to 
target prostate-specific membrane antigens [43], Results showed single intratumoral 
injection of Docetaxel-NP-Apt bioconjugates, was able to completely reduce tumor size 
in five of seven LNCaP (prostate cancer) xenograft nude mice, whereas with Docetaxel- 
NP, only two of seven mice had complete tumor reduction. Also, Docetaxel-NP-Apt had 
a 100% survival rate, where Docetaxel-NP had a 57% survival rate, Docetaxel alone had 
a survivability of only 14%.
A serum glycoprotein, transferrin, transports iron through the blood and into cells 
by binding to the transferrin receptor then it is internalized via receptor-mediated 
endocytosis [42]. Its receptor is overexpressed in tumor tissues, making it an ideal target 
for tumor-specific drug delivery. Transferrin-conjugated paclitaxel-loaded PLGA
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nanoparticles showed a greater inhibition of cell growth than free paclitaxel in MCF-7 
and MCF-7/Adr cells [44], Another group conjugated transferrin to liposomes to increase 
the transfection efficacy of p53, resulting in the sensitization of the transfected cancer 
cells/xenografts to ionizing radiation [45].
Ediriwickrema et a l synthesized a multi-layered polymer nanoparticle (MLNP), 
comprising of poly (lactic-co-glycolic acid) with surface poly-ethyleneimine and 
functional peptides, for targeted drug and gene delivery. Nanoparticle delivered 
camptothecin (CPT), and plasmid encoding TNF related apoptosis inducing ligand 
(pTRAIL) (CT MLNPs), and synergistically inhibited growth of multiple cancer cells in 
vitro.[46\ They confirmed the results using the Chout-Talalay method and the 
combination index (Cl) values at 50% inhibition ranged between 0.31 and 0.53 for all cell 
lines. Further, co-delivery with MLNPs resulted in a 3.le i5 fold reduction in CPT and 
4.7e8.0 fold reduction in pTRAIL dosing. They observed significant growth inhibition in 
HCT116 in vivo models when compared to a monotherapy. Another group designed and 
fabricated double-layered microsphere consisting of a PLA shell and a PLGA core doped 
with chitosan nanoparticles conjugated with p53 tumors suppressor gene and DOX.
These microspheres demonstrated a smooth and sustained release in vitro and 
encapsulation efficiency was not affected by DOX [47].
Overexpression of the drug efflux transporters like the P-glycoprotein is one of 
the major mechanisms leading to multi drug resistance. New approaches involve 
targeting and inactivating the P-gp via siRNA and or chemotherapeutics. To accomplish 
cell killing in an additive or synergistic fashion, Meng et al [48] fabricate mesoporous 
silica nanoparticles (MSNP) functionalized with phosphonate groups to deliver
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doxorubicin (Dox) and P-gp siRNA efficiently to drug-resistant KB-V1 cancer cells. The
phosphonate surface also allows for the addition of PEI as an exterior coating, which
carries P-gp silencing siRNA. The dual delivery of Dox and P-gp siRNA was capable of
intracellular and intranuclear drug concentration exceeding levels of free DOX alone.
Results indicate that P-gp silencing by siRNA increases sensitivity to the
chemotherapeutic agent DOX. Similarly, Lamrecht et a l [49] fabricated lipid
nanocapsules [(LNC), known for inhibiting P-gp activity] loaded with etoposide. They
conducted drug release studies and evaluated the efficiency of the synergistic
combination in reducing cell growth in vitro. Release of etoposide was sustained over a
period of one week. LNCs were internalized in all glioma cell types and Etoposide LNC
showed a generally higher efficiency than the drug solution, while blank LNC was found
to be less inhibitory than the pure drug at equivalent. This effect was found to be particle
size dependent within a range of an 8- (C6) to 33-fold (F98) increased cytotoxicity for
smallest particles. The mechanism of action for the inhibition of cell growth was
etoposide LNC cell uptake, followed by a sustained drug release from the LNC in
combination with an intracellular P-gp inhibition, ensuring a higher anticancer drug
concentration inside the cancer cells.
1.3.4 Nanomedical Approaches to Multidrug 
Resistant Cancers
Off-target toxicity to adjacent healthy tissues and poor accumulation of 
chemotherapeutics into the tumor site are major drawbacks of free-drug chemotherapy 
that necessitate high drug doses. Consequently, emergence of multidrug resistance 
(MDR) gives rise to cancer progression or recurrence, which requires multiple treatment 
courses. Increased drug efflux, mainly via transporting activity of ATP-binding cassette
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(ABC) family and inactivation of apoptosis pathways, are major molecular mechanisms 
causing MDR phenotype. Detailed surveys on MDR-involved pathways can be found in 
review papers [18][50][51], The promise of nanomedicine in surmounting the MDR 
obstacle to effectively fight against cancer lies in the development of customizable 
nanovehicles equipped with four modules; namely, single/multiple chemotherapeutic 
drugs, chemosensitizer, imaging-aid components and targeting moiety. A multifunctional 
nanocarrier capable of synergizing the effect of four modules is described as 
"Quadrugnostic Nanostructures" by A. Shapira et al. [52] much of research and many 
clinical trials have focused on rational design of personalized and directed therapies with 
maximum efficacy. Controlling the action time of different modules in a "multi-weapon 
integrated system" is obviously important for its maximum damage potential. In similar 
reasoning, precise spatiotemporal control over action period of "Quadrugnostic 
Nanostructures" being studied extensively. Vijayaraghavalu et al. showed the enhanced 
therapeutic index achieved by sequential exposure of two drugs to drug resistant breast 
cancer cells [53], The IC50 is a measure of how effective a drug is and indicates the 
amount of drug necessary to inhibit biological process by half. They reported: "The 
sequential treatment of resistant cells, first with an epigenetic drug, decitabine (DAC), 
and then with doxorubicin, induces a highly synergistic effect, thus reducing the IC50 of 
doxorubicin by several thousand fold." Basically, the initial drug restores sensitivity of 
breast cancer cells by reactivating the tumor suppressor genes, which are silenced in 
epigenetic alterations. Then, exposure of doxorubicin could act more effectively because 
the susceptibility of cancer cells is enhanced. Similarly, M. J. Lee proved that sequential 
inhibition of epidermal growth factor (EGFR) in a time-staggered manner, but not
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simultaneous co-administration, immensely sensitizes breast cancer cells to genotoxic 
drugs [54]. In fact, time and order-dependent drug combinations were more effective. 
These two reports introduce the time scheduling of dose exposures as a new design 
paradigm to synthesize superior combinatorial therapeutics.
Controlling the release kinetic of payloads and their possible interactions, as well 
as formulating a synergistic combination of bioactive agents has been proposed to 
reshape the future of nanomedicine. Synthesis of sequentially releasing nanoparticles via 
tuning the release kinetic of each drug in a time-staggered fashion seems to be drastically 
promising. Kinetically discrete sequential release of multiple agents provides localized 
delivery of multiple drugs in a desirable time period. Inspiringly, novel multifunctional 
nanoparticles possessing a well-defined release pattern could efficiently rewire the cancer 
regulation pathways and transform drug-insensitive cells into drug-sensitive cells. Proper 
selection of synergistic drug ratios and precise calculation of combination doses, released 
with time-staggered rate, will truly impact the personalized design of combinatorial 
systems with maximal efficacy and minimal adverse effect. Orderly releasing 
quadrugnostic aimed to selectively target biochemical pathways will realize the 
promising era of "network nanomedicine"; Network nanomedicine needs intimate 
knowledge of systems biology and advanced screening technologies to monitor complex 
pool of signaling networks. In this section, my group is proposing the envisioned “orderly 
releasing multifunctional quadrugnostic” platform capable of MDR reversal and able to 
selectively target the biochemical networks with minimum adverse effects. As an 
example, some sequentially releasing nanostructures loaded with synergistic combination 
of multiple components will be suggested as starting points for the future advancements.
42
1.3.4.1 Combinatorial Nanoparticles for P-sp Downregulation
Most of the therapeutic modalities for cancer treatment have become ineffective, 
mainly due to multidrug resistance (MDR) phenotype caused by various intracellular 
biochemical mechanisms. The adaptive response of cancer cells to present MDR is 
caused by an inter-connected network of numerous pathways including cellular 
pharmacokinetic and metabolic sequestration of drugs, drug-target interactions, and DNA 
repair pathways. Complex biochemical networks of the above-mentioned pathways play 
a multi-factorial role in implication of MDR, which could be intrinsic or acquired. 
Transporters in the body are security gates altering the molecular distribution of 
therapeutic agents. A member of ATP-binding cassette (ABC) family of transport is 
called P-glycoprotein (P-gp) which is a 70 kDa membrane bound protein and expels 
chemotherapeutics. In other words, reduced drug accumulation inside the cell due to the 
energy-dependent drug efflux activity of P-gp is the primary cause of MDR. The most 
distinctive approach used to bypass the MDR seems to be blockage of P-gp pump using 
P-gp inhibitor molecules. Multiple mechanisms are governing the inhibition activity of P- 
gp pump. In-depth investigation of driving mechanisms involved in P-gp pump activity, 
and its substrates/inhibitors, and structural information to design potential P-gp inhibitors 
can be found in literature reviews [18][20][23][55], Co-administration of potent and long 
lasting P-gp inhibitor molecules with genotoxic drugs delivered by polymeric and 
liposomal nanocarrier have shown promising results compared to single-dose regimens.
C. Sarisozen et al. synthesized and characterized a PEG-PE-based long-circulating 
micelle-based delivery systems co-loaded with a P-gp inhibitor molecule called elacridar 
and paclitaxel [56], Based on their claims, elacridar/paclitaxel-co-loaded micelles showed
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maximal cytotoxicity compared to both free and micellar paclitaxel. Patel et al. 
investigated co-delivery of the P-gp inhibitor, tariquidar, and cytotoxic drug, paclitaxel, 
into tumor cells to reverse the MDR using long-circulating liposomes [57], Results 
indicate SKOV-3TR taxol resistant ovarian cancer cells treated with Tariquidar- and 
paclitaxel-loaded long-circulating liposomes, resensitized significantly, due to the 
bypassing effect of Tariquidar in blockage of P-gp pump. Simultaneous delivery of 
doxorubicin and Elacridar with encapsulation efficiency of 89% was reported in 2006 by 
Wong et al [58], They prepared a polymer-lipid hybrid nanoparticle (PLN) formulation 
capable of simultaneous delivery of a cytotoxic drug, doxorubicin (Dox), and a 
chemosensitizer, Elacridar. Their Dox and GG918 co-encapsulated PLN formulation 
((DG) n) demonstrated the greatest Dox uptake and anticancer activity to 
MDA435/LCC6/MDR1, a human breast carcinoma cell line. Based on their 
developments, drugs and structures are classified in three generations. First, second and 
third generation.
Third generation P-gp inhibitors developed rationally based on structure-activity 
relationships and have shown the most potent efficacy. Elacridar, Tariquidar and 
Zosuquidar trihydrochloride (LY335979) are third generation P-gp inhibitors, which have 
shown synergistic efficiency in combination with genotoxic drugs. In fact, co-loading of 
P-gp inhibitors with antineoplastic agents circumvent the transport activity of P-gp and 
reduces the MDR leading to enhanced cancer cell vulnerability and consequently, 
improved therapeutic efficacy. Based on the above-mentioned research, the sequential 
release of a P-gp inhibitor and a chemotherapeutic agent seem to be more effective, based 
on network systemic point of view. Evaluation of sequential vs. concurrent exposure of
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free therapeutic molecules in oncology labs, stimulates the nanomedicine platforms to 
design sequentially releasing nanoparticles capable of dynamic rewiring of drug- 
insensitive cancer cells into more susceptible state. Evasion of P-gp mediated cellular 
efflux by initial release of P-gp inhibitor followed by second release of 
chemotherapeutics, seems to have drastically improved outcomes. Moreover, results of 
Vijayaraghavalu et al. trigger the fabrication of orderly releasing nanoparticles delivering 
epigenetic drugs and chemotherapeutics in a time-staggered manner [53], Initial drug 
accumulation will resensitized the MDR cancer cells and second delivery of genotoxic 
drug will knock down the sensitive cells.
1.3.4.2 Pharmaceutical Excipients for P-ep Downrezulation
Some pharmaceutical surfactants mediating the membrane lipids' integrity can 
cause interruption in P-gp structure. Tween 80 and Cremophor EL hindered the P-gp 
pump using a fluidization, while TPGS 1000 demonstrated rigidization in lipid bilayers. 
[59][60] Hydrophilic surface decoration using PEG 400 and PEG 1000, co-administered 
with fexofenadine, caused twofold increase in plasma concentration of fexofenadine. Co­
administration of labra sol (P-gp inhibitor) and fen fibrate in the form of a reverse micelle 
has been investigated by Shire Laboratories, Inc. [60][61], Labrasol was found as one of 
the best among all examined P-gp inhibitors for the delivery of digoxin and enhanced its 
permeability across the cell [62][63][60], Polysorbate 80, Gelucire 44/14, Labrasol and 
Vitamin E TPGS have also been evaluated by SRI International for the delivery of 
vancomycin hydrochloride [64][65], Synthetic subcategory of PEGs, poloxamers, 
dendrimers and thiomers have been extensively reviewed for their P-gp inhibitory 
activity [60], When these polymers were administered with drugs, drug accumulation and
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efficacy were enhanced. Branched chain fatty acids and their derivatives have been 
investigated by D-Pharm Ltd in term of P-gp mediated drug transport. Permeability of 
drugs co-administered with branched chain fatty acids on monolayer of endothelial cells 
of the blood brain barrier has been studied before [66][67], Utilizing these potent 
excipients along with chemotherapeutics reflected less nonspecific pharmaceutical 
adverse effects. Prodrug derivatization of P-gp substrates appears to be another viable 
approach in bypassing the P-gp. Overall, improved bioavailability, enhanced sensitivity, 
and accurate dose formulation are beneficial when potent agents are co-administered with 
P-gp inhibitors. These benefits lead to a decrease the IC50 value of drugs, consequently 
lowering cytotoxicity to the adjacent normal tissues. Discrete release of P-glycoprotein 
inhibitors and chemical molecules from sequentially released from nanoparticles masked 
with PEG chains. These PEG masked NPs, when modified with potent surfactants or 
tailored with branched chain fatty acids, could yield superior multi arrow nanostructures, 
thwarting P-gp pump and turning the MDR cells into a defenseless state which is more 
easily targeted for subsequent release of drugs.
1.3.4.3 Combinatorial RNAi-based Nanotherapies for P-2p Downreeulation
RNA interference (RNAi) is a regulatory pathway in which an allele-specific gene 
regulation is inhibited by small RNA molecules, typically cleavage specific mRNA 
molecules. SiRNA-based therapeutics can target "non-drug gable" sites leading to 
blockage of gene expression. Biological pathways involved in regulatory mechanisms of 
siRNA have been widely investigated [68]. Vector-enabled delivery and transfection of 
synthetic analogs of RNAi (siRNA), miRNA mimics, or hairpin RNAs introduced RNAi- 
based therapeutics as an alternative nanomedicine. Stable nucleic acid lipid particle
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(SNALP)-based and cyclodextrin-based nanoparticulate siRNA formulation developed 
by Tekmira, Alnylam, Calando, and Silence Inc. have entered Phase I trials. Several 
interrelated parameters are crucial in approaching the synthesis and safety evaluation of 
siRNA-based formulations for cell and tumor tissue targeting: 1) Toxic kinetics and 
distribution of formulation governed by fenestrated endothelium found in liver and 
spleen, 2) Size and surface characteristics affecting the formulation interaction with 
plasma proteins and vascular endothelium and immune system cells, 3) dosage design 
and administration route for different species and 4) biochemical reactions with complex 
hemostatic cascade and receptors are key safety checkpoints needed to be considered for 
optimum and desirable pharmacokinetic and pharmacodynamics. Ever-increasing 
“omics” technology coupled with RNAi-based screening technologies and bioinformatics 
advancements, opened-up new avenues in the development of individualized siRNA 
formulations.
1.3.4.4 Nanoparticles with Multipronged Functionalities for MDR Reversal
Core-shell lipid-polymer hybrid nanoparticles (CSLPHNPs) are composed of a 
polymeric core as mechanical back-bone, a hydrophobic lipid shell, and a hydrophilic 
PEGylating mask. Polymer choices could be PLGA, PCL, albumin or dextran as their 
biocompatibility and biodegradability have been approved. DPPC, DPTAP, DOTAP, 
DOPE are the most common lipid candidates which serve as a molecular fence to prevent 
drug leakage from polymeric core. The hydrophilic PEG chains provide chemical and 
serum stability, prolong the bioavailability in circulation system and can be conjugated 
with targeting moieties and ligands for active site specific targeting.
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1.3.5 Electrospun Scaffolds
Electrospinning is a process used to produce fibers in a submicron to nanometer 
range with a controlled surface morphology [69] [70], Ultrafine fibers are generated by 
applying a strong electric field to a polymer solution or melt [70], Electrospinning 
emerged as a novel technique over 100 years ago and has since evolved and demonstrated 
itself as a simple and versatile approach with a variety of potential applications. Some of 
the more noteworthy applications include filtration, wound dressing, protective military 
clothing, drug and gene delivery and tissue engineering scaffolds [70][71],
Electrospinning has a variety of applications, but drug delivery is emerging as one 
of its most promising uses. Electrospun fibers have high loading capacity and efficiency 
and may be used to deliver a variety of therapies. Simultaneously, electrospinning is a 
simple cost effective process, which makes it appealing for the field of drug delivery 
[70][71], Electrospun fibers can be drug carriers and may be promising in localizing 
chemotherapeutic post op therapies [70][72] Kenawy et al. demonstrated an application 
of poly(lactic acid) and poly(ethylene-co- vinyl acetate), and a blend of these polymers, 
as matrices and provided a sustained release of the model drug tetracycline hydrochloride 
[70], Researchers have shown that electrospun nanofibers can be successfully used to 
control drug release profiles, such as immediate, smooth, pulsatile, delayed, and biphasic 
releases [73] [70] [74]. In addition, other drugs ranging from antibiotics, 
chemotherapeutics, nucleic acids, aptamers and proteins have been doped into 
electrospun fibers.
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1.3.5.1 Polymers with Potential for Drug Delivery
Synthetic and natural polymers and hybrids have been used to synthesize 
electrospun fibers. Natural fibers show good cytocompatibility and cell adhesion, and 
also some intrinsic antibacterial and clinical properties. Synthetic polymers have 
flexibility in modification and synthesis, but lack some of the properties natural polymers 
have in cell affinity. Hybrid polymers can harness properties of both synthetic and 
natural polymers while limiting the drawbacks. Many natural polymers, such as 
polysaccharides (cellulose, chitin, chitosan and dextrose), proteins (silk, collagen and 
gelatin, DNA, and biopolymer derivatives and composites are reportedly being used in 
electrospinning [70], [75], [76], Lipofectamine is a commercially available transfection 
reagent produced by Invitrogen [77]. It is a cationic liposome formulation that forms 
complexes with nucleic acids allowing them to pass the cell membrane. Cationic lipids 
are fused with a neutral co-lipid and when complexed with DNA the cationic liposomes 
fuse with the plasma membrane transporting the DNA to the cytoplasm for replication 
and expression. Lipofectamine may additionally carry the DNA to the nucleus. This 
system was invented by Yonglian Chu et al. [78] Electrospinning of polysaccharides 
such alginate chitosan, chitin cellulose, starch, dextran and heparin for tissue engineering, 
wound healing and drug delivery was investigated by Lee et al. [70][79], Research has 
shown that electrospun chitosan and quartnemized derivatives have anti-cancer properties 
and show promise in the field of drug delivery. These properties were demonstrated in 
vitro against HeLa, Hep3b and SW480 cells [70], Biodegradable synthetic polymers also 
warrant attention as they do not have to be removed by a second surgery following 
implantation. Polymers like PLA, PCL, PLGA, PEI and PCLA have been extensively
49
studied in fiber fabrications because they have desirable properties for drug delivery and 
tissue engineering [70] [71], Altering composition and polymer blends of biodegradable 
synthetic polymers can limit degradation and offer a tailored release of drugs. Hybrid 
fibers made of natural and synthetic polymers may show the most favorable properties. 
The synthetic polymers can be used to add mechanical properties. Park et al. designed a 
novel fiber by electrospinning a hybrid blend consisting of polyfglycolic acid) (PGA) and 
chitin.[80] Results indicated that PGA in PGA/Chitin blend degrades faster than PGA 
alone, which may be attributed to the hydrodrophilicity of chitin. PGA/chitin blend also 
show a promising amount of cell attachment for human fibroblast when compared to 
PGA alone. Additionally, natural, synthetic and hybrid polymer fibers can be 
functionalized with bioactive molecules to facilitate the desired cellular response.
1.3.5.2 Scaffolds Doped with Chemotherapeutics Drues and Antibiotics
Antibacterial and antimicrobial agents are the most ideal biocides for loading into 
in nanofibers for wound healing. Ignatova et al. explored a variety of biocides, such as 
tetracycline hydrochloride, ciprofloxacin, levofloxacin, and moxifloxacin, and anti­
bacterial agents (e.g., 8-hydroxyquinoline derivatives, itraconazole, 
benzalkoniumchloride (BC), fusidic acid or silver nanoparticles) doped nanofibers for 
wounds [21] [81]. PLGA, and PLA were commonly used as carriers, along with natural 
polymer blends to regulate biodegradability and the hydrophilic nature of the fibers, 
resulting in the modulation of drug release. Kenawy et al. conducted pilot research on 
drug eluting nanofibers using tetracycline hydrochloride as a model drug and poly 
(ethylene-co-vinyl acetate), poly (lactic acid) and their blends as polymeric carriers.
These experiments demonstrated that drug release profiles were influenced by the nature
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of the polymer and drug content. The results demonstrated that drug release behavior was 
influenced by the nature of polymeric carrier and drug content. The drug release profile 
for a 50/50 electrospinning blend with a relatively low drug concentration (5 wt. %) was 
smooth and regulated, whereas a higher drug concentration (25 wt. %) resulted in a rapid 
release. The more rapid release may be caused by surface-segregation of the drug.
Electrospun mesh has shown promise in the area of localized administration of 
chemotherapeutic drugs. Doxorubicin (Dox), paclitaxel (PTX), platinum complexes [67], 
and dichloroacetate have been electrospun into fibers and used for postoperative local 
chemotherapy [21]. A water-in-oil emulsion was used to electrospin ultrafine Dox- 
containing PEG-PLLA fibers where the aqueous phase contained the water-soluble drugs 
while the oily phase was a chloroform solution of PEG-PLLA. The resulting fiber 
completely encapsulated Dox and results indicated that the Dox was entirely 
encapsulated inside the electrospun fibers [82], In later research, the group succeeded in 
the co-encapsulation of both hydrophobic PTX and hydrophilic Dox, simultaneously, into 
PEG-PLA nanofiber mats by the emulsion-electrospinning method, and realized drug co­
administration [70], Xie et al. synthesized cisplatin-loaded PLA/PLGA (30/70) fibers for 
long-term sustained delivery of cisplatin to treat C6 glioma in vitro [83]. They achieved a 
drug encapsulation efficiency of more than 90% and the cisplatin-loaded fibers sustained 
release for over 75 days without initial burst release.
1.3.5.3 Sustained and Localized Drue Delivery
Most of the past research in biomedical applications of electrospinning has been 
geared towards the parameters and electrospinning technique, loading method and their 
application in tissue-engineering scaffold and wound healing. The application of novel
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electrospun fiber mats for localized chemotherapy became popular only recently. When 
compared to systemic dosage forms like liposomes, micelles, and nanoparticles, 
electrospun mats can reduce systemic toxicity by localizing drug concentrations. Local 
drug administration is a favorable choice of treatment for post-surgical cancer 
reoccurrence prevention and may prove useful in treating unresolvable tumors. Lui et al. 
tested DOX encapsulated PLLA nanofibers against secondary hepatic carcinoma and 
results indicated the majority of the drug diffused into the tumor site beneath the fibers 
[72]. This application greatly reduced tumor growth with little effect on other organs. 
Ranganath et al. did a similar study replacing DOX with paclitaxel to test the post­
surgery chemotherapeutic effects [70] against malignant glioma. Other groups such as 
Liu et al. incorporated dichloroacetate (DCA) into the polylactide (PLA) non-woven 
fabrics by electrospinning [84]. Liu et al. implanted DCA-loaded electrospun mats to 
cover the solid tumor. A total tumor suppression degree of 96% was achieved in fewer 
than 19 days and solid subcutaneous tumors completely disappeared from 50% of the 
tumor-bearing mice and fewer side effects were observed [84],
1.3.5.4 Extending Delivery with Embedded Nanoparticles
As discussed above electrospun fibers and mats have shown great promise in the 
fields of drug delivery and cancer therapy. They provide a platform for localized delivery 
of drugs for antibacterial and anticancer treatments. The polymer concentrations and the 
blend of drug release, can be varied to modulate biodegradability. When implanted and 
after the mats have degraded, embedded nanoparticles containing drugs can provide 
sustained a drug release. The mats also may help to localize chemotherapeutic bearing 
nanoparticles in the tumor site or tumor resection site. Various nanoparticles and
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naturally occurring clays can be incorporated into electrospun fibers to modulate release. 
PLGA nanoparticles, iron oxide NPs, halloysite nanotubes, chitosan nanoparticles and 
more have been incorporated to add mechanical properties and to modulate drug release. 
Amna et al. fabricated camptothecin/iron(III) oxide (CPT/Fe203)-loaded poly(D,L- 
lactide-co-glycolide) (PLGA) composite mats to modulate the CPT release and to 
improve the structural integrity and antitumor activity of the released drug [85], Pristine 
PLGA did not exhibit noteworthy cytotoxicity; conversely, the CPT/Fe20 3 composite 
fibers inhibited C2C12 cells significantly. Yu et al. encapsulated DOX using inorganic 
rod-like nano-hydroxyapatite (n-HA) as a carrier and mixed with poly(lactic-co-glycolic 
acid) (PLGA) solution to fabricate electrospun hybrid nanofibers [86], The loaded DOX 
n-HA PLGA nanofiber hybrids demonstrated a sustained release profile, and non­
compromised antitumor activity towards the growth inhibition of KB cells. Tada et al. 
developed a dual drug delivery system where chitosan films were embedded with 
fluorescent paclitaxel doped PLGA nanoparticles and carboxyflourescin (a hydrophilic 
drug model) [87], Chitosan films containing CF and FPTX-loaded PLGA NPs showed a 
biphasic release profile. In the first phase, 78% of CF and 34% of NPs were released 
within few days. In the second phase, the release was slower, showing an additional 
release of 22% of CF and 18% of NPs after 3 weeks. FPTX-loaded PLGA NPs showed 
the release of 19.8% of total drug in 2 days, and no additional release was detected in the 
next 26 days. Qi et al. used tetracycline hydrochloride (TCH)-loaded halloysite 
nanotubes/poly(lactic-co-glycolic acid) composite nanofibers (TCH/HNTs/PLGA), and 
investigated drug release and antibacterial activity of this delivery system [88], The 
nanofibers were cytocompatible, and the TCH/HNTs/PLGA composite nanofibers
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sustained a release of the antibacterial drug TCH for 42 days while displaying 
antimicrobial activity solely associated with the encapsulated TCH drug. Research has 
demonstrated that embedding nanoparticles in films, fibers, and mats can add beneficial 
mechanical properties, localize drug dosage, and sustain long term release for drug 
delivery in antibiotic and chemotherapeutic applications.
CHAPTER 2 
ENHANCED NANOPARTICULATE 
STRATEGIES FOR NOVEL 
CANCER THERAPIES
Cancer is referred to as a malignant neoplasm, resulting from abnormalities in 
morphology and cell growth and death cycles. Depending on the stage, progression and 
amount of metastasis, a variety of treatments can be employed. These treatments can 
include, but are not limited to chemotherapy, hormone therapy, gene therapy, and 
radiation therapy, although therapy most commonly involves the surgical removal of 
tumors. Clinically available treatments are used to shrink, slow growth, remove, or 
destroy tumors and have many drawbacks.
The term cancer therapy describes the use of surgery, chemotherapy, gene 
therapies, or other bioactive molecules to remove, shrink or destroy cancerous tissue 
(malignant neoplasms). Once the type of cancer is identified and staged, one or more of 
the aforementioned treatment strategies may be employed. Chemotherapeutics, genes, 
and bioactive molecules may be employed to selectively target, shrink, or stop and 
destroy tumors and metastasis. Depending on the cell type, size, degree of metastasis, and 
biomarkers expressed, a therapy can be developed to localize and enhance treatment at a 
safe and effective dosage.
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Most of the clinically available treatment modalities do not target cancer cell 
types and require high doses which lead to systemic cytotoxicity that affect adjacent 
tissues. These treatments may also require multiple injections over a prolonged time 
period. In order to sustain localized drug release, I propose the combination of 
nanoparticles and films to compensate for drawbacks. In addition nanoparticles can be 
complexed with bioactive molecules that target drug resistant cancer cell types. These 
particles would selectively target and kill drug resistant cancer cells. Drug releasing NPs 
and NP-embedded films, with modified surface properties, hold promise in fulfilling 
criteria for effective and targeted cancer therapies.
Nanomedicine is an emerging field that combines the use of nanoparticles and/or 
nanoscale architecture with drugs, genes and bioactive molecules to initiate a cellular 
response based on the infirmity. Cancer, its progression, and the development of drug 
resistance result from a variety of factors. Cancer therapy requires a tailored approach, 
based on tissue type and progression, to localize and sustain cell death in affected tissues. 
Nanomedicine may be used to attack cancer at its core, delivering targeted therapies to 
destroy tumors and metastasis.
Recent advances in the field of nanomedicine for cancer therapy have yielded 
polymeric nanoparticle-based treatment modalities capable of selectively targeting 
multidrug resistance and localizing drugs in cancerous tissues. Natural, synthetic and 
hybrids can be used to synthesize nanoparticle and microfilms/fibers. By applying 
engineering principles and the properties of polymers, we can design a system where 
cancer targeting drug-NPs, combined with bioactive films and meshes, can be provide a 
localized and sustained drug delivery to tumors and metastasis. This approach can be
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used for in situ drug delivery to significantly reduce and/or eliminate systemic 
cytotoxicity therefore eliminating many severe side effects.
Targeted nanoparticles or nanoparticulate-embedded films can be employed as a 
means of delivery for chemotherapeutics and genes to target apoptotic pathways and 
selectively, rather than systemically, induce cell death in cancer cells. Films and NPs may 
also be used post surgically to reduce or eliminate the risk of recurrence. Materials should 
be biocompatible to reduce the risk of side effects and should also possess certain 
mechanical properties. Said properties may be manipulated to modulate biodegradability 
and facilitate a sustained release of drugs or genes.
2.1 Rationale behind the Three Integrated Projects
This chapter describes the three integrated and interrelated projects that focus on 
localized, sustained and targeted chemotherapy for the treatment of cancer by applying 
principles of nanomedicine, gene therapy and chemotherapy. All three projects use drug- 
doped nanoparticles, plasmid-doped nanoparticles, and enhanced bioactive films to 
present a localized treatment for cancer, especially drug resistant forms.
The first project attempted to establish Halloysite Nanotubes (HNTs) as a gene 
delivery platform. The project attempted to deliver plasmids to cancer cells as a means to 
induce a cellular response. HNTs contained the gene of choice. The HNTs’ efficacy for 
gene delivery would be analyzed first in vitro.
The second project attempted to delivery drugs to cancer cells as a means to 
inhibit growth and induce apoptosis. HNTs contained the drug choice. The HNTs’ 
efficacy for drug delivery would be analyzed first in vitro.
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In the third project, films were made from chitosan, through a novel method 
termed solvent evaporation air-brushing. These films, enhanced with nanoparticles, were 
used as an in situ delivery of chemotherapeutic agents. In the following studies, chitosan 
films would hold HNTs in their network and the release would be sustained and extended 
when compared to chitosan films alone. With this design, changing the chemotherapeutic 
agent loaded into HNTs and adding a P-gp blocker to the polymer itself can modify films.
Certain types of cancers require different types of targeting modalities. If 
osteosarcoma cells are the targets, methotrexate can be used to inhibit proliferation and 
stop cell growth. HNTs, loaded with methotrexate, could then be directly injected into the 
tumor, or applied to the tumor surface using a HNT-chitosan film.
In conclusion, chitosan films would aid in localizing the delivery of drugs to 
cancerous tissues. If the objective is to reduce side effects resulting from systemic drug 
and gene treatments and extending drug/gene release, HNT-chitosan films can be used. 
Figure 2-1 illustrates the rationale behind the three related projects. The following 
sections describe the projects in detail.
58
Rationale o f the Three Interrelated Projects
M TX-HNT
OSTEOSARCOMA
p D N A -H N T
M DR BREAST CANCER
CHT-HNT-MTX
Figure 2-1: Graphical representation of the rationale behind the three interrelated 
projects[50],
2.2 HNTs: A New Platform for Delivery of Genes for 
Cancer Therapy
HNTs are ideal for gene delivery because they can provide a protective container 
and provide a sustained release of agents over time [89] [90], Halloysite particles are 
double-layered aluminosilicates which have a hollow tubular structure with an inner 
diameter of 15 nm and an external diameter of 50-70 nm [90], Their lengths can be up to 
1 micron. HNTs naturally occur and hold several properties that may make them useful 
in a variety of applications. They have a high loading capacity, can be loaded with a
1
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variety of chemicals and can sustain an extended and controlled release over time. 
Polymers can be enhanced with HNTs, resulting in a prolonged delivery of chemical 
agents and enhanced strength, while providing thermal stability and adding surface 
roughness. HNTs are cytocompatible and are already being used in many health-related 
fields [90].
HNTs show promise as they can provide a sustained release when localized in the 
affected tissues. They can act as a nanocarrier for proteins, enzymes, nucleic acids and 
other bioactive materials. They provide protection from RNases and DNases, other 
degradation proteins, and heat, and they can house a number of small molecule 
biocatalysts.
In the first project, HNTs were loaded with plasmid IRES2-EGFP to evaluate 
gene release and transfection efficiency in vitro. Studies were aimed at showing whether 
HNTs were capable of sustaining release and acting effectively in vitro. After suitable 7- 
day release profiles were obtained, HNTs doped with plasmids were assessed in vitro to 
discover if they performed suitably.
In our preliminary studies, HNTs were loaded with antibiotics or methotrexate, 
and showed promising results. Studies indicated a biphasic release profile, which was 
sustained for more than 7 days. Subsequently, HNTs were tested in vitro. In bacterial 
culture, HNTs doped with antibacterial agents inhibited bacterial growth of Escherichia 
Coli and Staphylococcus aureus. In mammalian in vitro studies, HNTs loaded with 
pIRES2-EGFP enhanced lipofectamine transfection in CRL-2836 murine osteosarcoma. 
Lipofectamine is commonly used alone for transfection and the concentration used is 
typically based on the concentration of DNA and cell density. The results indicate that
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gene-doped HNTs may be either applied directly or embedded in films for localized 




Figure 2-2: Graphical representation of the use of HNTs for gene delivery.
2.3 HNTs: A New Platform for Delivery of Drugs for 
Cancer Therapy
HNTs are ideal for drug delivery because they can provide a protective container 
and a sustained release of agents over time [89] [90], HNTs’ geometrical structure and 
surface charges make them an ideal nanocontainer for drugs, bioactive macromolecules, 
and polymers, for sustained and extended releases [91 ][89]] [12-14]. Recent studies 
showed HNTs biocompatibility with several cell types such as mesenchymal stem cells, 
fibrochondrocytes, osteoblasts, and human dermal fibroblasts (up to concentrations of 0.1 




of chemical agents and enhanced strength while providing thermal stability and adding 
surface roughness.
In the second project, HNTs were loaded methotrexate to evaluate release profile 
for drug and proliferation inhibition in vitro. Studies were aimed at showing whether 
HNTs could sustain release and act effectively in vitro. After obtaining suitable 7-day 
release profiles, HNTs doped with drugs were assessed in vitro to discover if they 
performed suitably.
In our preliminary studies, HNTs were loaded with antibiotics or methotrexate, 
and showed promising results. HNTs loaded with resveratrol with subsequent surface 
modifications was able to deliver the drug to cancer cells [93], The results indicate that 
drug-doped HNTs may either be applied directly or be embedded in films for localized 







Figure 2-3: Graphical representation of the use of HNTs for drug delivery.
2.4 Air-Brushed HNT-Doped Chitosan Films for Sustained 
and Localized Delivery of Methotrexate
The objective of this study was to investigate the potential of methotrexate loaded 
HNT doped chitosan films and fiber synthesized via a novel air brushed solvent 
evaporation method for cancer therapy. The main goal was of this research was to 
develop a novel system for localized delivery of chemotherapeutics for a sustained 
release that inhibited tumor growth.
During this study, HNTs were loaded with methotrexate, mixed with chitosan and 
air brushed into a film with nanoscale architecture. Various imaging techniques (SEM) 
and material tests were used to determine material properties. Drug-loaded chitosan films 
and HNT-chitosan were then assessed to determine loading capacity and release profile.
HNT-chitosan films were sprayed onto the wells of 12-well tissue culture dishes. 
Chitosan films and HNT-chitosan composite films were first assessed to determine
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whether they had an anti-proliferative effect on CRL-2836 murine osteosarcoma. Drug 
loaded chitosan films and drug-loaded HNT-chitosan composites were used in vitro to 
comparatively assess their inhibition of cell growth in ATCC cell line CRL-2836 murine 
osteosarcoma. Figure 2-4 is the experimental design and concept for air-brushed HNT- 
doped chitosan films for sustained and localized delivery of methotrexate.







Figure 2-4: Experimental design and concept for Air-Brushed HNT doped chitosan 
films for sustained and localized delivery of methotrexate.
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2.5 Objective of the Projects
The objectives of all three projects are to design two cytocompatible systems 
capable of sustaining gene and drug release, to localize drug administration, and to target 
cancerous tissue and metastasis. The detailed objectives of the individual projects are as 
follows:
1. To obtain an extended and controlled release of genes and chemotherapeutic 
drugs from HNTs.
2. To obtain an extended and controlled release of chemotherapeutic drugs from 
HNTs.
3. To obtain a sustained and extended release of chemo drugs and genes from 
nanoparticles and films enhanced with nanoparticles.
4. To evaluate whether HNTs can be used for plasmid transfection.
5. To evaluate whether HNTs, loaded with drugs can be used to elicit a inhibit 
cell growth and induce cell death.
6. To design HNT-chitosan films with chemotherapeutic drugs loaded in them to 
inhibit cell growth and induce cell death
7. To investigate material properties and characterize nanoparticles, drug- and 
gene-loaded nanoparticles, and films.
CHAPTER 3
INSTRUMENTATION AND METHODS
The current chapter details the instrumentation and methods used for HNT and 
nanoparticle loading, nanoparticle and film preparation, material characterization of films 
and nanoparticles, and cellular response to drug or gene loaded nanoparticles and films.
3.1 Instruments
Instruments are integral in investigating nanoparticle and film properties. The
following subsections describe the instruments used in this dissertation. The instruments
and types of data they produce are listed below.
3.1.1 HITACHI S 4800 Field Emission Scanning 
Electron Microscope
HITACHI S 4800 Field Scanning Electron Microscope (FE-SEM) (Figure 3-1) 
was used to image HNTs, chitosan films and double-layered PLGA-Lipid nanoparticles. 
The high magnification attained allowed for a close comparison of the surface 
morphologies of chitosan films and chitosan-HNT films. The comparison helped to 
assess the surface properties and to predict the behavior of the films in in vitro conditions.
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Figure 3-1: HITACHI S 4800 FE-SEM at Institute of Micromanufacturing, Louisiana 
Tech University [94],
3 1 2  Tecnai G2 F30 TWIN 300 kV/FEG 
Transmission Electron 
Microscope
Tecnai G2 F30 TWIN 300 kV / FEG Transmission Electron Microscope (TEM) 
(Figure 3-2) was used to image HNTS. The high magnification attained via TEM 
allowed for a comparison of morphologies of halloysite nanotubes.
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Figure 3-2: Tecnai G2 F30 TWIN 300 kV / FEG Transmission Electron Microscope at 
CIF Microscopy lab, Tulane University [95],
3.1.3 Brookhaven Instruments ZetaPlus
Potential and Particle Size Analyzer
Brookhaven Instruments ZetaPlus Potential and Particle Size Analyzer (Figure
3-3) were used to characterize HNTs. The instrument operates on dynamic light 
scattering principles; subsequently, it provides the average particle size and average zeta 
potential. This instrument was used to determine the zeta potential and particle size of 
HNTs, methotrexate-loaded HNTs and plasmid-loaded HNTs.
68
Figure 3-3: Brookhaven Instruments ZetaPlus Potential and Particle Size Analyzer 
IFM, Louisiana Tech University [96].
3.1.4 NANODROP 2000 Spectrophotometer
The NANODROP 2000 spectrophotometer (Figure 3-4), from Thermo Scientific, 
is a UV-VIS spectrophotometer, which uses a pi volume samples for DNA, RNA, 
protein, and various fluorescently active drugs or chemicals. This instrument analyzes 
samples over a short period of time. Cuvettes can be used for dilute samples, or the 
pedestal can be used to analyze samples, while the data are reported in the form of graphs 
and absorbance values through the software [97].
The NANODROP 2000 spectrophotometer (Figure 3-4) was used to measure 
samples for the drug release studies. The NANODROP 2000 used for this research was 
located in the common second floor lab in the Biomedical Engineering building, 
Louisiana Tech University.
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Figure 3-4: Thermo Scientific NANODROP 2000 spectrophotometer.
3.1.5 Qubit® 2.0 Fluorometer
The Qubit® 2.0 fluorometer (Figure 3-5) is a benchtop fluorometer used to 
quantify DNA, RNA, and protein, using the highly sensitive and accurate fluorescence- 
based Qubit™ quantitation assays.The Qubit® 2.0 fluorometer uses the latest 
illumination and detection technologies to attain the highest sensitivity and allows the use 
of as little as 1 pL of sample to still achieve high levels of accuracy, even with very 
dilute samples [98],
The Qubit® 2.0 fluorometer (Figure 3-5) was used to analyze samples from DNA 
release studies. The Qubit® 2.0 Fluorometer used is located in the second floor Mills 






Figure 3-5: Qubit® 2.0 Fluorometer.[98]
3 .1.6 Multiscan Spectrum Absorbance 
Microplate Reader
The absorbance microplate reader acts similarly to a spectrophotometer, but the 
stage on which the samples are mounted for analysis differs. This stage can read 12-well 
plates or similar plates that are used for cell culture.
For the quantification of cell proliferation via XTT assay, a Thermo Scientific 
Multiskan spectrum absorbance microplate reader was used (Figure 3-6). The assays 
were done in a 12-well plate specifically treated with XTT cell Proliferation assay.
Figure 3-6: Thermo scientific Multiskan spectrum absorbance microplate reader 
Decoster laboratory, Louisiana Tech University.
3.1.7 Olvmnus BX51 Epifluorescence 
Microscope
The Olympus BX51 epifluorescence microscope (Figure 3-7) images cells 
live/dead or in the fixed state. The microscope has a filter for different fluorescent dyes 
such as DAPI, Alexa Fluor Red, FITC, and TRITC. This microscope can also image the 
cells in phase contrast mode when the UV lamp is turned off. The images are captured in 
high definition and can be taken at 10X, 20X or 40X magnifications. To visualize the 
cells stained with live/dead fluorescent dyes and green fluorescence protein expression
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we used 10X and 20X magnifications. The composite films and the seeded cells were 
also imaged on the phase contrast mode.
Figure 3-7: Olympus BX51 epifluorescence microscope in BME microscopy lab, 
Louisiana Tech University.
3.1.8 TCP Global Master Airbrush Model G22 
Airbrush Set and Compressor
TCP Global Master Airbrush Model G22 Airbrush Set and Compressor (Figure
3-8) were used to spray chitosan films and composite HNT-chitosan films. This device is 
commonly used in airbrush paintings. The air-brush system settings were altered and 
used with polymer solutions to prepare different films.
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Figure 3-8: Master Performance G222 Airbrush Kit with Master Compressor TC-20 & 
Air Hose [99],
3.2 Methods
The methods used to load HNTs, prepare films, characterize samples, and perform 
the biochemical assays used to determine cellular responses from each system are 
detailed in the Section 3.2.1.
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3.2.1 Vacuum Loading of Halloysite
HNTs were loaded with plasmid IRES2-EGFP and the chemotherapeutic drug 
methotrexate. The basic protocol for vacuum loading remained the same, with 
concentrations differing based on what was being loaded. For sterilization purposes,
HNTs were autoclaved for 45 minutes. Aseptic conditions were maintained throughout 
the loading process.
3 .2.1.1 Loadine HNTs with Plasmids
Plasmid IRES2-EGFP was obtained from Clontech, Mountainview, California. 
Stock solution was obtained through bacterial replication and purified using Gene JET 
plasmid miniprep kit available at ThermoFisher Scientific, Grand Island, New York. Kits 
yielded plasmid solution with a final concentration of 1 pg/pl. This plasmid solution was 
prepared under sterile conditions and diluted with sterile elution buffer.
After autoclave sterilization, HNTs were vortexed for 15 minutes with prepared 
concentrations of pIRES2-EGFP. Separate 1 mg aliquots of HNTs were loaded with 1 pg 
of plasmid, 5 pg of plasmid, and 10 pg of plasmid. A 100 pL volume of elution buffer 
was added to each sample and the resultant solution was kept in a vacuum chamber under 
sterile conditions for 48 hours with intermittent vacuum applied to it at 30 inHG. After 48 
hours, the HNTs loaded with IRES2-EGFP were vacuum-dried for 3 hours and stored at
4 *C.
3.2.1.2 Loadine HNTs with Methotrexate
Methotrexate was obtained from Sigma Aldrich, St. Louis, Missouri. A stock 
solution was prepared according to the manufacturer’s instructions. A solution was
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prepared at 4 mg/ml concentration in a 20% acetone. All solutions were prepared with 
sterile diluents and under aseptic conditions.
After autoclave sterilization, HNTs were vortexed for 15 minutes with prepared 
concentrations of methotrexate. One gram of HNTs was loaded with 100 mg of 
methotrexate. The resultant solution was kept in a vacuum chamber under sterile 
conditions for 48 hours with intermittent vacuum applied to it at 30 inHg. After 48 hours, 
the HNTs loaded with methotrexate were dried in a vacuum oven at 20 inHg of pressure 
and 100 °C for 1 hour until completely dry.
3.2.2 Preparation of Chitosan Films
To blow-spray chitosan microfilms, a 3% chitosan solution was prepared.
Chitosan was diluted in a 3% acetic acid solution with magnetic stirring. The 
chitosan/acetic acid solution was subsequently diluted in acetone and the resultant 
solution was diluted in DMSO. The resultant solution of 3% chitosan, 1% acetic acid, 
33.3% acetone, and 33% DMSO was homogenized for 5 minutes at 500 rpm and for 5 
minutes at 800 rpm. The resultant solution’s pH was adjusted to 3 for 30 minutes with 
magnetic stirring, as chitosan crosslinks at an acidic pH, and then returned to pH 7. The 
addition of acetone allowed for solvents to evaporate during the spraying and drying 
process and yielded a clean smooth film, while DMSO acted as a curing agent. In the 
next step, the unloaded HNTs or MTX-loaded HNTs were added to the chitosan solution 
and the resultant HNT-chitosan mixture was sonicated for 5 minutes to disperse HNTs. A 
separate solution of chitosan was prepared with a MTX concentration of 1 mg/ml.
The solutions were loaded in the reservoir of the Master Airbrush G22 equipped 
with a 0.5 mm needle and sprayed at 30 psi of pressure. A 100 pi aliquot of each solution
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was sprayed into the wells of a 12 well plate. The films were allowed to dry for 15 
minutes before UV sterilization.
3.2.3 Zeta Potential and Particle Size
Plain halloysite, IRES2-EGFP-loaded halloysite, or methotrexate-loaded 
halloysite surface potentials were analyzed by microelectrophoresis (ZetaPlus Potential 
Analyzer, Brookhaven Instruments). Diluted aqueous dispersions of IRES2-EGFP -  
loaded halloysite, or methotrexate-loaded halloysite (ca. 1 pg/mL), were transferred into 
the special cuvette, and electric field was applied across the suspension, causing the 
movement of negatively charged halloysite toward the cathode. Surface electrical 
potential of the particles was determined by Smoluchowski formula using particle speed 
measured with dynamic light scattering (all included in the instrument software). The 
instrument also allowed for average particle size measurement based on dynamic light 
scattering (all included in the instrument software).
3.2.4 SEM/TEM Preparation
The following subsections describe preparation of HNTs and chitosan films for 
SEM and TEM. The basic protocol remained the same for both types of nanoparticle but 
differed for chitosan films. The SEM in IFM was used for imaging and the TEM ate 
Tulane University was used for imaging nanoparticles and features.
3.2.4.1 Sample Preparation for FE-SEM
HNT samples were added to carbon tape and imaged with a Hitachi Field 
Emission Scanning Electron Microscope. Surface features and morphology were 
observed. Chitosan films were sprayed onto lx l mm square silicon wafers and allowed to 
dry for 15 minutes at room temperature
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3.2.4.2 Sample Preparation for TEM
Transmission Electron Microscopy (TEM) images were recorded with a Tecnai 
G2 F30 TWIN 300 kV / FEG Transmission Electron Microscope at CIF Microscopy lab, 
Tulane University. The microscope operated at an accelerating voltage of 100-200 kV.
We prepared samples for analysis by dropping a dilute HNT dispersion in water onto 
carbon-coated copper grids and allowing water to evaporate.
3.2.5 Release Profile Studies
The release profiles for methotrexate and plasmids were done under simulated 
physiological conditions. Release profiles for plasmid DNA were obtained from loaded 
HNTs. Plasmid-loaded HNTs were suspended in nuclease-free water with uniform 
agitation on a vortex. At set time points, HNTs were centrifuged at 13k rpm for 5 minutes 
and 200 pi of nuclease free water was completely removed and collected from HNT 
suspension and replaced with 200 pi fresh nuclease free water.
For plasmid release profile (pIRES2-EGFP), the samples were collected for 24 
hours over 7 days. Qubit® dsDNA HS and BR Assay Kits were used to determine the 
concentrations of the stored samples. The Qubit® dsDNA HS (high sensitivity) and BR 
(broad range) assay kits were custom made for double stranded DNA and were obtained 
from Invitrogen (Carlsbad, CA). The kits bind a fluorescent dye to DNA and allow the 
concentration to be read on Qubit® 2.0 fluorometer. The concentration of DNA is given 
based on the fluorescence measurements and exported directly into an Excel file.
Release profiles for methotrexate were obtained from HNTs, chitosan films, and 
chitosan-HNT composite films. MTX loaded HNTs were suspended in 2 ml Hank’s 
Balanced Salt Solution (HBSS) and put on a rocker for uniform agitation. At set time
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points, HNTs were centrifuged at 3k rpm for 5 minutes, and 2 ml of HBSS was 
completely removed, collected from HNT suspension and replaced with 2 ml of fresh 
HBSS. Samples were taken and stored at 4 °C for further analysis.
Drug-loaded chitosan and chitosan-HNT films were sprayed onto the well of a 12- 
well tissue culture dish. Then 2 ml of HBSS were added, and the plate was put on a 
rocker for uniform agitation. At set time points, 2 ml of HBSS were completely removed, 
collected and replaced with 2 ml of fresh HBSS. Samples were taken and stored at 4 °C 
for further analysis. All release profile experiments were performed at room temperature.
Samples were read using UV/VIS NANODROP spectrophotometer at 300 nm. 
Since, methotrexate is photometrically active, concentrations were estimated by 
comparing UV/VIS spectra to UV/VIS spectra standards for methotrexate.
3.2.6 Cell Assays
Biochemical assays were used to quantify cellular responses to HNTs, DBL-NPs 
and chitosan films. Lab plastics and 96-well plates were purchased from MidSci, St. 
Louis, MO. Dulbecco’s Phosphate Buffered Saline (DPBS), Dulbecco’s Modified 
Eagle’s Medium (DMEM), fetal bovine serum (FBS), Live/Dead Viability/Cytotoxicity 
kit and penicillin-streptomycin-amphotericin (PSA) antibiotics were obtained from Life 
Technologies, Carlsbad, CA
3.2.6.1 Transfection
Transfection was used to determine the loading and delivery capacity for HNTs 
and was compared to common transfection agent Lipofectamine.
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3.2.6.1.1 HNT-Plasmid Complexes
In vitro transfection efficiency studies of Plasmid IRES2-EGFP-loaded HNTs 
were carried out to determine whether HNTs are able to deliver plasmid to the cell. 
Murine osteosarcoma were seeded in 96 well tissue culture dishes (MidSci, St. Louis, 
MO) with serum free Dulbecco’s Modified Eagle Medium. Plasmid IRES2-EGFP-loaded 
HNTs were added with cells at the time of seeding and incubated 24 hours.
Lipofectamine was diluted in serum free DMEM and Plasmid IRES2-EGFP-loaded 
HNTs were diluted in serum free DMEM. These solutions were combined, mixed and 
incubated for 5 minutes. These Lipofectamine Plasmid IRES2-EGFP-loaded HNTs 
complexes were then added with cells at the time of seeding. The media was changed to 
media with serum and cells were evaluated for EGFP expression after 24,48, 96 and 144 
hours. At 72 hours, transfected cells were split from the 96-well and seeded into a 24- 
well plate for further analysis. The negative controls was free plasmid DNA and the 
positive control was Lipofectamine.
3.2.6.1.2 Lipofectamine
To prepare for transfection, cells were seeded and allowed to adhere for 4 hours 
prior to Lipofectamine treatment. Lipofectamine was used as a positive control for 
plasmid transfection because it is known to have a high transfection efficiency. The 
manufacturer’s protocol was followed for transfection. Lipofectamine was diluted in 
serum free DMEM and pDNA was diluted in serum free DMEM. These solutions were 
combined, mixed and incubated for 5 minutes. DNA-lipid complexes were then add to 
cells and incubated for 24 hours. The media was changed at 24 hours and EGFP
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expression was evaluated after 24, 48, 96, and 144 hours. At 72 hours, transfected cells 
were split from the 96-well into a 24-well plate for further analysis.
3.2.6.2 XTT Cell Proliferation Assay
This assay is based on the ability of viable cells to reduce tetrazolium dye. In 
these experiments, osteosarcoma cells were used. For methotrexate-loaded HNTs, cells 
were seeded in 96-well plates and allowed to adhere, and the MTX-HNTs were added to 
well containing cells. There were two sets of controls, untreated cells and cell exposed to 
drug-free HNTs. For chitosan films, cells were seeded in 12-well plates containing drug 
free chitosan composite films and MTX loaded chitosan composite films. Cells were 
tested at 24, 72, 120 and 168 hours. The XTT assay protocol supplied by the 
manufacturer (Sigma-Aldrich) was followed. After aspiration of medium, 100 pL of 
buffer were added to each well along with 20 pL of XTT solution. Photometric 
absorption of each well was measured at 450 nm and 690 nm after 4 hours of incubation. 
After completing the XTT assay, a live/dead cytotoxicity assay was conducted on 
additional wells of each category on the same plate.
3.2.6.3 Live/Dead
A live/dead cytotoxicity kit cat. No. L3224, obtained from Thermo Fischer, 
Waltham, MA, was used for testing. The protocol supplied by the manufacturer was used 
for the assay. The dyes were diluted to 2 pM solutions and were added to the test wells. 
Fluorescence microscopy was used to image live and dead cells after they were incubated 
for 30 minutes in the dye solutions.
CHAPTER 4
USE OF HNTS FOR GENE DELIVERY IN 
CANCER THERAPY
4.1 Introduction
HNTs are ideal for gene delivery because they can provide a protective container 
and a sustained release of agents over time [89][90], Halloysite particles are double­
layered aluminosilicates which have a hollow tubular structure with an inner diameter of 
15 nm and an external diameter of 50-70nm [90], Their lengths can be up to 1 micron. 
HNTs naturally occur and hold several properties that may make them useful in a variety 
of applications. They have a high loading capacity, can be loaded with a variety of 
chemicals and can sustain an extended and controlled release over time. Research has yet 
to establish HNTs efficacy for delivery plasmid DNA to cells.
For osteosarcoma patients who have received chemotherapy alone have a 100% 
recurrence rate without surgical resection [100], [101], Even though recent advances have 
led to increased rates of limb sparing therapy, patients are still at risk of recurrence.
While surgical abscission can physically remove clinically detectable tumor masses, 
systemic chemotherapy or gene therapy can inhibit micrometastasis before and/or after 
surgery. For the treatment of osteosarcoma, many of the research efforts are directed at 
reducing the risk of recurrence following surgical resection. One of the major challenges 
faced by chemotherapy and gene therapy is the inability to sustain and/or localize drug 
release in targeted cell types.
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To address this challenge, HNTs loaded a plasmid pIRES2-EGFP expressing the 
green fluorescence protein is the method being proposed. HNTs have a cylindrical 
structure with concentric aluminosilicate layers and negatively charged surface and 
positively charged lumen [102]. HNTs’ unique structure makes them ideal for loading a 
variety of charge molecules [103], Past research has shown HNTs can be used to deliver 
chemotherapeutic agents, as well as, bioactive molecules like anti-infective agents, 
proteins, etc. in a sustained manner [103][93],
The hypothesis of this project was that HNTs would act as an efficient delivery 
vector for genes, such as pIRES2-EGFP, for a sustained release. If effective for plasmid 
delivery, the model vector pIRES2-EGFP would be replaced with a plasmid that induces 
apoptosis.
4.2 Methods and Materials
All the plastic wares, such as, syringes, centrifuge tubes, microcentrifuge tubes, 
tissue culture plates, and pipettes, were purchased from Mid Scientific, St. Louis, MO. 
Cell culture media, buffers, and serum Life Technologies, Grand Island, NY. HNTs were 
obtained from Sigma-Aldrich, St. Louis, MO, and pIRES2-EGFP was obtained from 
Clontech, Mountainview, CA. Plasmid purification kits, elution buffer and nuclease-free 
water were obtained from Thermo Fisher Scientific, Waltham, MA. Murine osteosarcoma 
cells CRL-2836 were obtained from ATCC, Manassas, VA. The Qubit® dsDNA HS and 




A release study was carried out to understand the elution of plasmid DNA from 
HNTs. These studies provided an analysis of the release of gene from HNTs.
4.2.1.1 Plasmid DNA
The release profile study for pIRES2-EGFP was done to understand the release of 
plasmid DNA from HNTs. As the amount of plasmid eluted fell in the range of 
nanograms and micrograms, the custom made Qubit® dsDNA HS (high sensitivity) kit 
was used. The Qubit® dsDNA HS kit with the Qubit® 2.0 from Invitrogen can estimate 
the amount of DNA as low as 10 pg/pl. The details of sample collection and the overall 
procedure are provided in section 3.2.6.
4.2.2 Cell Culture and Seeding
An osteosarcoma cell line was the model used to study transfection efficiency of 
plasmid loaded HNTs. Osteosarcoma cells were plated in 25 cm2 tissue culture flasks, 
and incubated at 37 °C under humidified 5% CO2 and 95% air in complete DMEM 
containing 10% FBS and 1% PSA. Subconfluent cells were passaged with 0.25% trypsin, 
collected by centrifugation, suspended in complete DMEM and cultured at a 3:1 split into 
25 cm2 tissue culture flasks. These cultures were in vitro transfection efficiency tests.
4.2.2.1 Green Fluorescence Imagine for Transfection Efficiency
A transfection efficiency study was carried out to determine if HNTs were able to 
act as a vector for the delivery of plasmid DNA. Cells were seeded into a 96-well tissue 
culture dish and allowed to adhere and reach 80% confluency. HNT-plasmid complexes 
were added to the cells as described in Section 3.2.7.1 . 1 . Controls did not receive plasmid 
complexes. Negative controls received free plasmids and positive controls receive
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plasmid-lipofectamine complexes as detailed in Section 3.2.7.1.2 (see Table 4-1). The 
wells were evaluated after 24, 48, 96, and 144 hours, using the Olympus BX51 
fluorescent microscope with FITC filter. Image fluorescence was quantified using Image 
J software.
Table 4-1: Platemap for Transfecion Assay.
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4.2.3 Zeta Potential/Particle Size Analysis
To characterize the HNTs, average size and charge measurements, were taken.
4.2.3.1 Zeta Potential and Particle size
The halloysite surface potential was analyzed under microelectrophoresis 
(ZetaPlus potential analyzer, Brookhaven Instruments). A diluted aqueous dispersion of 
halloysite was prepared and analyzed as described in Chapter 3, Subsection 3.2.4. The 
instrument also provided average particle size measurements, based on dynamic light 
scattering.
4.3 Results and Discussion
4.3.1 Release Profile Study of oIRES2-EGFP from HNTs
The release profile study of pIRES2-EGFP from HNTs was done to estimate the 
amount of plasmid eluted from the HNTs for a period of 24 hours and over seven days. 
This study was carried out to determine if HNTs could be loaded with plasmids and elute 
enough plasmid DNA to efficiently transfect cells in vitro. The graph showing the release 
profile study for pIRES2-EGFP for 24 hours is given in Figure 4-1.
Figure 4-1 shows the trend of the pIRES2-EGFP release over 24-hours at the 
three different loading concentrations. This release was achieved for the vacuum-loaded 
HNTs in nuclease free water at room temperature. The amount of pIRES2-EGFP release 
was estimated by the Qubit® dsDNA HS kit and reading the sample on the Qubit® 2.0 
fluorometer. The experiment was repeated three times to reduce error and to check for 
reproducibility of results. The values are the mean of reading of pIRES2-EGFP release 
from HNTS at the respective time points from the 3 repetitions of the experiment. The 
error bars reflect the standard deviation.
The graph shows the cumulative release profile of the plasmid for 24 hours in the 
nanogram to microgram range which is comparable to the amount used in vitro with 
Lipofectamine.
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Figure 4-1: Mean Cumulative Release profile of pIRES2-EGFP from HNTs for 24 
hours mean of n = 9 for each concentration +/- standard deviation.
The graph of the release profile study for pIRES2-EGFP from HNTs for seven 
days is given in Figure 4-2. The release profile study of pIRES2-EGFP from HNTs was 
extended to seven days. The experiment was repeated three times to reduce error and to 
check for reproducibility of the results. The values are the means of the readings of 
pIRES2-EGFP from HNTs at the respective time points recorded from the repetitions of 
the experiments. The error bars reflect the standard deviation.
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Figure 4-2: Mean Cumulative Release profile of varying concentrations of pIRES2- 
EGFP from HNTs for seven days mean of n = 9 for each concentration +/- standard
The release of pIRES2-EGFP from HNTs was extended and sustained for seven 
days. In the first 24 hours, from the three different samples, a mean of 78.7% ±  7.1% of 
loaded plasmid was released and after seven days, an average 93 .7% ±  8.2% of loaded 
plasmid was released. The release for 24 hours and seven days were in the nanogram and 
microgram range for all samples and well within the range of DNA concentrations 
required for commonly used transfection reagents like Lipofectamine.
The release profile of pIRES2-EGFP from HNTs suggests that the majority of the 
plasmid was localized or wrapped around the surface of HNTs. The initial burst release 
was mainly from the surface localization of the plasmid. Even with the majority of the 
plasmids being localized on the surface of the HNTs, the release is in nano and 
micrograms, which is well within the range of DNA concentrations required for 
commonly used transfection reagents like Lipofectamine. Results obtained from the 
seven-day release profile are promising. The majority of plasmid DNA is released in the
deviation.
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first 24 hours, but HNTs release plasmid DNA continuously over a seven-day period, as 
opposed to Lipofectamine which is typically only stable for transfection for 24-48 hours. 
A sustained release of plasmid DNA is beneficial because loaded HNTs can be injected 
once and sustain a release in the cancerous tissues for more than seven-days therefore 
reducing the need for multiple injections. This approach may have a further advantage in 
that HNTs with DNA localized on the surface could be coated with lipids or 
polyelectrolytes to increase cellular uptake and modulate release.
The release of pIRES2-EGFP was not extended beyond seven days as in vitro 
experiments would only focus on the first seven days and primarily on the first 48 hours. 
The comparison of the three loaded volumes, 1, 5, and 10 pg, demonstrated HNTs could 
sustain a release of low and high concentration for more than seven day; however, HNTs 
released the plasmids slightly faster when loaded with a higher volume. Results indicated 
that 10 pg plasmid DNA would be loaded into 1 mg HNTs for in vitro experiments as the 
sample would be split into aliquots that corresponded to concentrations needed to 
transfect cells cultured in a 96-well tissue culture dish. Further analysis of surface 
adsorption was done using particle size measurements in Section 0.
4.3.2 Transfection Assay
Transfection assay result for 4 groups were compared for:
1. Free pIRES2-EGFP




This comparison was done to investigate the potential of HNTs as a transfection agent 
and also to determine if they enhanced the transfection efficiency of Lipofectamine. 
Following transfection, the plates were analyzed after 24 and 48 hours, as green 
fluorescence protein (GFP) is fully expressed at 48 hours. The cells were split from the 
96-well to a 24-well at 72 hours to allow for growth and further analysis of the 
transfection efficiency. The cells were then analyzed after 96 and 144 hours.
Transfection efficiency was determined by the mean fluorescence area in a plate. 
Eight images were randomly selected from each well, four from the edge and four from 
the center, for processing. Image j was used to measure the amount of fluorescent area 
and calculate the fluorescence percentage in each group. IBM SPSS software and a paired 
t-test were used for statistical analysis. Results of paired t-test are seen in Table A-51 of 
the appendix. Figure 4-3, Figure 4-6, Figure 4-9 and Figure 4-12 show the average 
fluorescent percentage of each group after 24,48,96, and 144 hours, respectively. Images 
that represent the amount of average fluorescence among the group are shown in Figure
4-4 and Figure 4-5 for 24 hours, Figure 4-7 and Figure 4-8 for 48 hours, Figure 4-10 
and Figure 4-11 for 96 hours, and Figure 4-10 and Figure 4-11 for 144 hours.
Figure 4-3 shows the mean fluorescence area percentage after 24 hours ± 
standard deviation. As expected, control groups for untreated and free DNA show no 
fluorescence. Fluorescence percentage for Lipofectamine transfection with 100 ng and 1 
pg of pIRES2-EGFP are 44.9% ± 19% and 55% ± 4.5% respectively. All groups with 
HNT-pIRES2-EGFP show little to no fluorescence. HNT-pIRES2-EGFP-Lipofectamine 
groups for 100 ng and 2 pg pIRES2-EGFP have minimal fluorescence by comparison to 
controls. The 1 pg and 500 ng HNT-pIRES2-EGFP-Lipofectamine groups were less
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effective when compared to controls but showed a transfection efficiency of 8.5% ±  1.8% 
and 27% ±3.7%, respectively.
At 24 hours Lipofectamine transfection with 100 ng and 1 pg of pIRES2-EGFP, 
and 1 pg and 500 ng HNT-pIRES2-EGFP-Lipofectamine groups showed a significant 
difference from the untreated control at a  = .05 (Appendix Table A-5). Lipofectamine 
transfection with 100 ng differed significantly from Lipofectamine transfection with 1 pg 
of pIRES2-EGFP. 1 pg differed significantly from 500 ng HNT-pIRES2-EGFP- 











Figure 4-3: Mean Fluorescence Area Percentage of n = 8 images ±  at standard 
deviation 24 hours. Statistical analysis was applied with IBM SPSS 22.0 at a  = .05, and 
the red stars indicate no significant difference exists two groups encircled are compared 
and the black stars indicate significant difference exists when encircled groups are 
compared.
In Figure 4-4 the images for 24 hours are shown. A and B are controls that are 
untreated and treated with Free DNA respectively; C and D are positive controls for 
Lipofectamine with 100 ng and lpg of pIRES2-EGFP respectively. Figure 4-4 E, F, G 
and H show HNTs with 100 ng, 500 ng, 1 pg and 2 pg pf pIRES2-EGFP respectively.
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The image for lOOng pIRES2-EGFP-HNT agrees with the graph and shows that E has no 
fluorescent cells (compare Figure 4-3 with Figure 4-4 E). 500ng pIRES2-EGFP-HNT 
and 1 pg pIRES2-EGFP-HNT have few fluorescents cells (less than 5%) when compared 
to the Lipofectamine controls (-50%) while 2pg pIRES2-EGFP-HNT has no living 
fluorescent cells as the one cell that is fluorescent does not have the morphology of a 
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Figure 4-4: 24 Hours Fluorescent Images for HNT-pIRES2-EGFP. Scale bar indicates 
200pm A and B are Negative controls. C and D are positive controls A) Control 1 
untreated; B) Control 2 free DNA; C) Control 3 100 ng pIRES2-EGFP with 
Lipofectamine.; D) Control 4 lpg pIRES2-EGFP with Lipofectamine; E) Experimental 
1 100 ng pIRES2-EGFP with HNT; F) Experimental 2 500ng pIRES2-EGFP with 
HNT; G) Experimental 3 lpg pIRES2-EGFP with HNT; H) Experimental 4 2pg 
pIRES2-EGFP with HNT.
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In Figure 4-5 the images for 24 hours are shown. A-D are the same controls 
shown in Figure 4-4 A-D. Figure 4-5 E, F, G and H show Lipo-HNTs with 100 ng, 500 
ng, 1 pg and 2 pg pIRES2-EGFP, respectively. The images agree with the graph and 
show that lOOng pIRES2-EGFP-Lipo-HNT and 2pg pIRES2-EGFP-Lipo-HNT have few 
fluorescent cells (less than 5 %) (Compare Figure 4-3 with Figure 4-5 E and H). 500ng 
pIRES2-EGFP-Lipo-HNT and Ipg pIRES2-EGFP-Lipo-HNT have fewer fluorescents 
cells (-25% and -10  % respectively) when compared to the Lipofectamine controls 
(-50%) while 2pg pIRES2-EGFP-Lipo-HNT has no living fluorescent cells as the one 
cell that is fluorescent does not have the morphology of a healthy cell (Compare Figure
















Figure 4-5: 24 Hours Fluorescence Images for HNT-Lipo-pIRES2-EGFP. Scale bar 
indicates 200pm. A and B are Negative controls (also shown in figure 4-4). C and D are 
positive controls (also shown in figure 4-4). A) Control 1 untreated; B) Control 2 free 
DNA; C) Control 3 100 ng pIRES2-EGFP with Lipofectamine; D) Control 4 lpg 
pIRES2-EGFP with Lipofectamine; E) Experimental 5 100 ng pIRES2-EGFP with HNT 
and Lipofectamine; F) Experimental 6 500ng pIRES2-EGFP with HNT and 
Lipofectamine; G) Experimental 7 lpg pIRES2-EGFP with HNT and Lipofectamine; H) 
Experimental 8 2pg pIRES2-EGFP with HNT and Lipofectamine.
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Figure 4-6 show the mean fluorescence area percentage at 48 hours ± standard 
deviation. As expected, control groups for untreated and free DNA show no fluorescence. 
Fluorescence percentages for Lipofectamine transfection with 100 ng and lpg of 
pIRES2-EGFP are 65.8% ±  11.7% and 66.2% ±  8.7% respectively. All groups with 
HNT-pIrES2-EGFP show little to no fluorescence at all. HNT-pIrES2-EGFP- 
Lipofectamine groups for 100 ng and 2 pg pIRES2-EGFP have minimal fluorescence by 
comparison to controls. 1 pg and 500 ng HNT-pIrES2-EGFP-Lipofectamine group were 
less effective when compared to controls but showed a transfection efficiency of 6.2% 
±2% and 60.8 % ± 19.9 % respectively.
At 48 hours Lipofectamine transfection with 100 ng or 1 pg of pIRES2-EGFP, 
and 500 ng HNT-pIRES2-EGFP-Lipofectamine groups showed a significant difference 
from the untreated control at a = .05 (Appendix Table A-5). Lipofectamine transfection 
with 100 ng or 1 pg of pIRES2-EGFP, and 500 ng HNT-pIRES2-EGFP-Lipofectamine 
groups did not differ significantly difference from each other. Lipofectamine transfection 
with 100 ng differed significantly from Lipofectamine transfection with 1 pg of pIRES2- 
EGFP. 1 pg differed significantly from 500 ng HNT-pIRES2-EGFP-Lipofectamine at a  = 








Figure 4-6: Mean Fluorescence Area Percentage of n = 8 images ±  at standard 
deviation at 48 hours. Statistical analysis was applied with IBM SPSS 22.0 at a = .05, 
The red stars indicate no significant difference exists between groups compared lipo 
0.1 pg, lipo lpg and 0.5pg HNT-Lipo.
In Figure 4-7 the images for 48 hours are shown. A and B are controls that are 
untreated and treated with Free DNA; C and D are positive controls for Lipofectamine 
with 100 ng and 1 pg of pIRES2-EGFP, respectively. Figure 4-7 E, F, G and H show 
HNTs with 100 ng, 500 ng, 1 pg and 2 pg pIRES2-EGFP respectively. 500ng pIRES2- 
EGFP-HNT and lpg pIRES2-EGFP-HNT have fewer fluorescents cells (less than 10 %) 
when compared to the Lipofectamine controls (-80%) while lOOng pIRES2-EGFP-HNT 
and 2pg pIRES2-EGFP-HNT have no living fluorescent cells as cells that are 
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Figure 4-7: Fluorescence Images at 48 Hours for HNT-pIRES2-EGFP. Scale bar 
indicates 200pm. A and B are Negative controls C and D are positive. A) Control 1 
untreated; B) Control 2 free DNA; C) Control 3 100 ng pIRES2-EGFP with 
Lipofectamine; D) Control 4 lpg pIRES2-EGFP with Lipofectamine; E) Experimental 
1 100 ng pIRES2-EGFP with HNT; F) Experimental 2 500ng pIRES2-EGFP with 
HNT; G) Experimental 3 lpg pIRES2-EGFP with HNT; H) Experimental 4 2p 
pIRES2-EGFP with HNT.
Figure 4-8 shows the images for 48 hours A-D are the same controls shown in 
Figue 4-7 A-D. Figure 4-8 E, F, G and H show Lipo-HNTs with 100 ng, 500 ng, 1 pg 
and 2 pg pIRES2-EGFP, respectively. The images agree with the graph and show that 
lOOng pIRES2-EGFP-Lipo-HNT and 2pg pIRES2-EGFP-Lipo-HNT have few 
fluorescent cells (less than 5 %) (Compare Figure 4-6 with Figure 4-8 E and H). 500ng 
pIRES2-EGFP-Lipo-HNT has a comparable amount of fluorescent cells (-70%) to 
lipofectamine control (-80%) and lpg pIRES2-EGFP-Lipo-HNT has fewer fluorescents 
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Figure 4-8: Fluorescence Images at 48 hours for HNT-Lipo-pIRES2-EGFP. Scale bar 
indicates 200pm. A and B are Negative controls (also shown in figure 4-7). C and D 
are positive controls (also shown in figure 4-7). A) Control 1 untreated; B) Control 2 
free DNA; C) Control 3 100 ng pIRES2-EGFP with Lipofectamine; D) Control 4 lpg 
pIRES2-EGFP with Lipofectamine; E) Experimental 5 100 ng pIRES2-EGFP with 
HNT and Lipofectamine; F) Experimental 6 500ng pIRES2-EGFP with HNT and 
Lipofectamine; G) Experimental 7 1 pg pIRES2-EGFP with HNT and Lipofectamine; 
H) Experimental 8 2pg pIRES2-EGFP with HNT and lipofectamine.
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Figure 4-9 shows the mean fluorescence area percentage at 96 hours ±  standard 
deviation. As expected, control groups for untreated and free DNA show no fluorescence. 
Fluorescence percentage for Lipofectamine transfection with 100 ng and 1 pg of pIRES2- 
EGFP are 18.5%±14.6% and 53.2%±29.7%, respectively. All groups with HNT- 
pIRES2-EGFP show little to no fluorescence. HNT-pIrES2-EGFP-Lipofectamine groups 
for 100 ng and 2 pg pIRES2-EGFP- have minimal fluorescence compared to controls.
The 1 pg and 500 ng HNT-pIRES2-EGFP-Lipofectamine groups were less effective than 
controls but showed a transfection efficiency of 12%±5.3% and 49.7%±14.1%, 
respectively.
At 96 hours Lipofectamine transfection with 100 ng or 1 pg of pIRES2-EGFP, 
and 500 ng or 1 pg HNT-pIRES2-EGFP-Lipofectamine groups showed a significant 
difference from the untreated control at a  = .05 (Appendix Table A-5). Lipofectamine 
transfection with 1 pg of pIRES2-EGFP, and 500 ng HNT-pIRES2-EGFP-Lipofectamine 
groups did not differ significantly difference from each other. Lipofectamine transfection 
with 0.1 pg of pIRES2-EGFP, and 1 pg HNT-pIRES2-EGFP-Lipofectamine groups did 
not differ significantly difference from each other. Lipofectamine transfection with 100 
ng differed significantly from Lipofectamine transfection with 1 pg of pIRES2-EGFP. 1 
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Figure 4-9: Mean Fluorescence Area Percentage of n = 8 images ±  at standard 
deviation at 96 Hours. Statistical analysis was applied with IBM SPSS 22.0 at a = .05, 
and the red stars indicate no significant difference exists between enclosed groups.
Figure 4-10 shows the images for 96 hours. Figure 4-10 A and B are controls 
that are untreated and treated with Free DNA, respectively. C and D are positive 
controls for Lipofectamine with 100 ng and 1 pg of pIRES2-EGFP, respectively. Figure 
4-10 E, F, G and H show HNTs with 100 ng, 500 ng, 1 pg and 2 pg pIRES2-EGFP, 
respectively. HNTs with 100 ng, 500 ng, andl pg have minimal fluorescence when 
compared to the Lipofectamine controls (-80% for 1 pg and 50% for 100 ng) while 
HNTs with 2 pg pIRES2-EGFP has no living fluorescent cells as cells that are 
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Figure 4-10: Fluorescence Images at 96 Hours for HNT-pIRES2-EGFP. Scale bar 
indicates 200pm. A and B are Negative controls. C and D are positive controls . A) 
control 1 untreated; B) control 2 free DNA; C) Control 3 100 ng pIRES2-EGFP with 
Lipofectamine; D) Control 4 lpg pIRES2-EGFP with Lipofectamine; E) Experimental 
1 100 ng pIRES2-EGFP with HNT; F) Experimental 2 500ng pIRES2-EGFP with 
HNT; G) Experimental 3 lpg pIRES2-EGFP with HNT; H) Experimental 4 2p 
pIRES2-EGFP with HNT.
Figure 4-11 shows the images for 96 hours. A and B are controls that are 
untreated and treated, respectively, with free DNA; C and D are positive controls for
Lipofectamine with 100 ng and 1 pg of pIRES2-EGFP, respectively. Figure 4-11 E, F, G
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and H show Lipofectamine-HNTs with 100 ng, 500 ng, and 1 pg and 2 pg of pIRES2- 
EGFP respectively. The images agree with the graph and show that Lipofectamine-HNTs 
with 100 ng and 2 pg pf pIRES2-EGFP have few fluorescent cells (less than 5 %) 
(Compare Figure 4-9 with Figure 4-11 E and H). Lipofectamine-HNTs with 500 ng of 
pIRES2-EGFP has a comparable amount of fluorescent cells (-70%) compared to the 
Lipofectamine controls (-80% for 1 pg and 50% for 100 ng) and Lipofectamine-HNTs 
with 1 pg of pIRES2-EGFP has fewer fluorescents cells (-10 % respectively) when 
compared to the Lipofectamine controls. Lipofectamine-HNTs with 1 pg of pIRES2- 
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Figure 4-11: Fluorescence images 96 Hours for HNT-Lipo-pIRES2-EGFP. Scale bar 
indicates 200pm. A and B are Negative controls (also shown in figure 4-10). C and D 
are positive controls (also shown in figure 4-10). A) control 1 untreated; B) control 2 
free DNA; C) Control 3 100 ng pIRES2-EGFP with Lipofectamine; D) Control 4 lpg 
pIRES2-EGFP with Lipofectamine; E) Experimental 5 100 ng pIRES2-EGFP with 
HNT and Lipofectamine; F) Experimental 6 500ng pIRES2-EGFP with HNT and 
Lipofectamine; G) Experimental 7 1 pg pIRES2-EGFP with HNT and Lipofectamine; 
H) Experimental 8 2pg pIRES2-EGFP with HNT and Lipofectamine.
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Figure 4-12 shows the mean fluorescence area percentage at 144 hours ± 
standard deviation. As expected, control groups for untreated and free DNA show no 
fluorescence. Fluorescence percentages for Lipofectamine transfection with 100 ng and 1 
pg of pIRES2-EGFP are 22% ±  13.3% and 38.8% ± 19.1% respectively. All groups with 
HNT-pIRES2-EGFP show little to no fluorescence. HNT-pIRES2-EGFP-Lipofectamine 
group for 2 pg pIRES2-EGFP have minimal fluorescence by comparison to controls. 1 
pg, 500 ng and 100 ng HNT-pIRES2-EGFP-Lipofectamine groups were less effective 
when compared to controls but showed a transfection efficiency of 4 .1%± 2.6%, 28.2 
% ±11.9 % and 2.5%±1.6%, respectively.
At 144 hours Lipofectamine transfection with 100 ng or 1 pg of pIRES2-EGFP, 
and 500 ng HNT-pIRES2-EGFP-Lipofectamine groups showed a significant difference 
from the untreated control at a  = .05 (Appendix Table A-5). Lipofectamine transfection 
with 1 pg of pIRES2-EGFP, and 500 ng HNT-pIRES2-EGFP-Lipofectamine groups did 
not differ significantly difference from each other. Lipofectamine transfection with 0.1 pg 
of pIRES2-EGFP, and 500 ng HNT-pIRES2-EGFP-Lipofectamine groups did not differ 
significantly difference from each other. Lipofectamine transfection with 0.1 pg of 
pIRES2-EGFP, and 1 pg HNT-pIRES2-EGFP-Lipofectamine groups differed 
significantly from each other. Lipofectamine transfection with 100 ng differed 
significantly from Lipofectamine transfection with 1 pg of pIRES2-EGFP. 1 pg differed 
significantly from 500 ng HNT-pIRES2-EGFP-Lipofectamine at a = .05 (Appendix 
Table A-5)
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Figure 4-12: Mean Fluorescence Area Percentage of n = 8 images ±  standard 
deviation at at 144 Hours. Statistical analysis was applied with IBM SPSS 22.0 at a  = 
.05, and the red stars indicate no significant difference exists between lipo 0.1 pg and 
lipo lpg with 0.5pg HNT-lipo group.
Figure 4-13 shows the images for 144 hours. A and B are controls that are 
untreated and treated with free DNA respectively; C and D are positive controls for 
Lipofectamine with 100 ng and lpg of pIRES2-EGFP respectively. Figure 4-13 E, F, G 
and H show HNTs with 100 ng, 500 ng, 1 pg and 2 pg pf pIRES2-EGFP respectively. 
HNTs with 100 ng, 500 ng, 1 pg and 2 pg pf pIRES2-EGFP have minimal fluorescent 
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Figure 4-13: Fluorescence Images at 144 Hours for HNT-pIRES2-EGFP. Scale bar 
indicates 200pm. A and B are Negative controls. C and D are positive controls A) 
control 1 untreated; B) control 2 free DNA; C) Control 3 100 ng pIRES2-EGFP with 
Lipofectamine; D) Control 4 lpg pIRES2-EGFP with Lipofectamine; E) Experimental 1 
100 ng pIRES2-EGFP with HNT; F) Experimental 2 500ng pIRES2-EGFP with HNT; 
G) Experimental 3 lpg pIRES2-EGFP with HNT; H) Experimental 4 2p pIRES2-EGFP 
with HNT.
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Figure 4-14 shows the images for 144 hours. A and B are controls that are 
untreated and treated with Free DNA respectively; C and D are positive controls for 
Lipofectamine with 100 ng and 1 pg of pIRES2-EGFP respectively. Figure 4-14 E, F, G 
and H show Lipofectamine-HNTs with 100 ng, 500 ng, 1 pg and 2 pg pf pIRES2-EGFP 
respectively. The images agree with the graph and show that Lipofectamine-HNTs with 
100 ng has around 10% fluorescent cells and Lipofectamine-HNTs with 2 pg has no 
fluorescent cells (Compare Figure 4-12 with Figure 4-14 E and H. Lipofectamine-HNTs 
with 500 ng has a comparable amount of fluorescent cells (-70%) to the Lipofectamine 
controls (-70% for 1 pg and 40% for lOOng) and Lipofectamine-HNTs with 1 pg has 
fewer fluorescents cells (-10 % respectively) when compared to the Lipofectamine 
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Figure 4-14: Fluorescence Images at 144 Hours for HNT-Lipo-pIRES2-EGFP. Scale 
bar indicates 200pm. A and B are Negative controls (also shown in figure 4-13). C and 
D are positive controls (also shown in figure 4-13) A) control 1 untreated; B) control 2 
free DNA; C) Control 3 100 ng pIRES2-EGFP with Lipofectamine; D) Control 4 lpg 
pIRES2-EGFP with Lipofectamine; E) Experimental 5 100 ng pIRES2-EGFP with HNT 
and Lipofectamine; F) Experimental 6 500 ng pIRES2-EGFP with HNT and 
Lipofectamine; G) Experimental 7 1 pg pIRES2-EGFP with HNT and Lipofectamine; 
H) Experimental 8 2pg pIRES2-EGFP with HNT and lipofectamine.
4.3.3 Fluorescence Comparison
Figure 4-15 shows the progression of fluorescence in all groups that exhibited 
EGFP expression over the 144 hour study. HNT-pIRES2-EGFP groups are not shown 
here because imaging and fluorescence percentage data show that HNTs alone did not 
effectively transfect cells. The average fluorescence in HNT-pIRES2-EGFP groups was 
less than 1.5 % for 24, 48, 96 and 144 hours. Image results showed that HNT-pIRES2- 
EGFP groups were more effective than free DNA but did not result in many cells being 
transfected. This low amount of transfection may be due to accumulation of plasmids on 
the surface of the HNTs. The majority of the plasmids were released into the media as 
opposed to being taken up by the cells with the HNTs. Also, in the 2 pg and 1 pg HNT- 
pIRES2-EGFP group, it seems that the concentration of Lipofectamine and HNTs too 
high, resulting in a massive cell death at time points after 24 hours. Results indicated that 
at up to 500 ng of pIRES2-EGFP, HNTs may be effective at raising the efficiency of 
Lipofectamine.
At 24 hours the 500 ng HNT-pIRES2-EGFP groups were seemingly less effective 
than both 1 pg and 100 ng pIRES2-EGFP Lipofectamine control groups but, at 48 hours 
the transfection efficiency was comparable to both Lipofectamine control groups. For 96 
and 144 hours, the 500 ng HNT-pIRES2-EGFP groups yielded nearly twice the 
fluorescence as 100 ng group, but this higher fluorescence may be caused by the five-fold 
increase in the amount of pIRES2-EGFP. For 48, 96, and 144 hours 500 ng HNT- 
pIRES2-EGFP groups were 86% ±11% fluorescent as the 1 pg pIRES2-EGFP 
Lipofectamine controls, which contained twice the amount of plasmid DNA.
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Other groups that showed at least some effectiveness (up to 12% transection 
percentage) were 100 ng and 1 pg HNT-pIRES2-EGFP groups. In the 1 pg HNT- 
pIRES2-EGFP groups, the combination of Lipofectamine and HNTs yielded cytotoxic 
effects causing the majority of the cells to die. However, at 96 hours and 144 hours the 
majority of the cells that remained (>90%) were fluorescent.
Results of the transfection assay demonstrated, at the 500 ng pIRES2-EGFP 
concentration, that HNTs boosted the efficiency of transfection of Lipofectamine and 
were nearly as effective as Lipofectamine alone at twice the concentration of pIRES2- 
EGFP. Furthermore, HNTs-plasmid composite show promise as a delivery system for 
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Figure 4-15: Mean Green Fluorescence (pIRES2-EGFP) Area Percentage comparison 
of n = 8 images ± standard deviation. Lipo O.lpg, Lipo lpg, 0.5 pg HNT-lipo and 1 pg 
HNT-lipo were significantly different from untreated cells at all time points.
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4.3.4 Zeta Potential and Particle Size
The average particle size of plain HNTs and pIRES2-EGFP-loaded HNTs was 
measured to compare and determine if loading had an effect on particle size (Figure 
4-16). For pIRES2-EGFP-loaded HNTs particle size was measured to determine if 
surface adsorption or wrapping increase particle size. Plain HNTs had an average particle 
size of 1522 nm ±  97.3 nm. When comparing plasmid loaded HNTs to plain HNTs there 
is a significant difference in size at a = 0.05 (Appendix A Table A-2). On average 
pIRES2-EGFP-loaded HNTs were 4320 nm±609 nm in diameter. PIRES2-EGFP-loaded 
HNTs were almost 3 times the size of plain HNTs and this may be attributed to the 
plasmid DNA adhering to the surface or wrapping around HNTs. The large error may be 
due to the formation of aggregates during the drying process. The graph of the average 
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Figure 4-16: Mean Particle Size of n = 4 samples ±  standard deviation. Black stars 
indicate significant difference exists between groups at a  = 0.05.
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The zeta potential of plain HNTs and pIRES2-EGFP-loaded HNTs was measured 
to compare and determine if  loading had an effect on zeta potential. For pIRES2-EGFP- 
loaded HNTs, zeta potential was measured to determine if surface adsorption or wrapping 
changed the surface zeta potential of HNTs. Results indicated that surface adsorption and 
/or loading of plasmid DNA caused the zeta potential to decrease slightly. The zeta 
potential of plain HNTs was -41.6±3mV and pIRES2-EGFP-HNT was -51.4±2.1 mV. 
The graph of the zeta potential for plain HNTs and pIRES2-EGFP loaded HNTs is given 
in Figure 4-17.
HNT pDNA-HNT
Figure 4-17: Mean Zeta Potential of HNTs and pDNA-loaded HNTs of n = 4 samples 
±  standard deviations. Black stars indicate significant difference exists between groups 
at a  = 0.05.
CHAPTER 5
USE OF HNTS FOR DRUG DELIVERY IN 
CANCER THERAPY
5.1 Introduction
Osteosarcoma patients who have received chemotherapy alone have a 100% 
recurrence rate without surgical resection [100], [101], Even though recent advances have 
increased the rates of limb sparing therapy, patients are still at risk of recurrence. Tumor 
recurrence can be greater than 90% in patients who have not been clinically diagnosed 
with metastasis and have received surgical resection of the primary malignancy with no 
adjuvant chemotherapy [7][101] [104], While surgical abscission can physically remove 
clinically detectable tumor masses, systemic chemotherapy or gene therapy can inhibit 
micrometastasis before and/or after surgery. For the treatment of osteosarcoma, many of 
the research efforts are directed at reducing the risk of recurrence following surgical 
resection. One of the major challenges faced by chemotherapy and gene therapy is the 
inability to sustain and/or localize drug release.
To address this challenge, HNTs loaded with chemotherapeutic agent 
methotrexate or a plasmid pIRES2-EGFP expressing the green fluorescence protein is the 
method being proposed. HNTs have a cylindrical structure with concentric 
aluminosilicate layers and negatively charged surface and positively charged lumen
[102], HNTs unique structure makes them ideal for loading a variety of charge molecules
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[103], Past research has shown HNTs can be used to deliver chemotherapeutic agents and 
bioactive molecules like anti-infective agents and proteins in a sustained manner
[103][93],
The hypothesis of this project was that HNTs would provide a sustained release of 
methotrexate to inhibit the growth of osteosarcoma.
5.2 Methods and Materials
All the plastic wares, such as, syringes, centrifuge tubes, microcentrifiige tubes,
12 well plates, and pipettes, were purchased from Mid Scientific, St. Louis, MO. Cell 
culture media, buffers, serum and LIVE/DEAD® Viability/Cytotoxicity Kit were 
purchased from Life Technologies, Grand Island, NY. Methotrexate, HNTs and XTT in 
vitro toxicology assay kit were obtained from Sigma-Aldrich, St. Louis, MO. Murine 
osteosarcoma cells CRL-2836 were obtained from ATCC, Manassas, VA.
5.2.1 Release Study
A release study was carried out to understand the elution of methotrexate from 
HNTs. These studies provided an analysis of the release of chemotherapeutic agents from 
HNTs.
5.2.1.1 MTX
The release profile study for methotrexate (MTX) was done to understand the 
release of chemotherapeutic agents from HNTs. A calibration curve was created for MTX 
to compare with the drug elution profiles of the MTX loaded HNT. Three sample sets, 1 
mg HNT 10% MTX, 5 mg HNT 10 %MTX and 10 mg HNT 10% MTX, were immersed 
in HBSS, mixed and collected for varying time period for 24 hours and seven days. For 
collection, samples were centrifuged and the supernatants were collected for UV-vis.
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analysis (Nanodrop 2000c, ABS wavelength 300 nm.). Samples were replenished with 
fresh HBSS. The details of sample collection and the overall procedure are provided in 
Section 3.2.6.
5.2.2 Cell Culture and Seeding
An osteosarcoma cell line was the model used to study in vitro cellular response 
to methotrexate-loaded HNTs. Osteosarcoma cells were plated in 25 cm2 tissue culture 
flasks, and incubated at 37 °C under humidified 5% CO2 and 95% air in complete 
DMEM containing 10% FBS and 1% PSA. Subconfluent cells were passaged with 0.25% 
trypsin, collected by centrifugation, suspended in complete DMEM and cultured at a 3:1 
split into 25 cm2 tissue culture flasks. These cultures were used for the viability and 
proliferation tests.
5.2.2.1 Cell Proliferation and Viability Studies
In these experiments, osteosarcoma cells were used. Osteosarcoma cells were 
seeded in 12-well plates and allowed to adhere for four hours. After osteosarcoma cells 
became adherent, free HNTs were added according to Table 5-1 while negative controls 
were left untreated and free methotrexate and MTX-HNTs were added to a 12 plate 
according to Table 5-2. Two of each plate were prepared for each time period, 1 for XTT 
cell proliferation assay and 1 for live/dead cell viability assay.
Table 5-1: Plate Map for controls and unloaded HNTs.
untreated 1 mg HNT 5 mg HNT 10 mg HNT
untreated 1 mg HNT 5 mg HNT 10 mg HNT
untreated 1 mg HNT 5 mg HNT 10 mg HNT
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Table 5-2: Plate Map for Free MTX and MTX-HNTs.
100 ng MTX 1 mg MTX-HNT 5 mg MTX-HNT 10 mg MTX-HNT
100 ne MTX 1 mg MTX-HNT 5 mg MTX-HNT 10 mg MTX-HNT
100 ngMTX 1 mg MTX-HNT 5 mg MTX-HNT 10 mg MTX-HNT
5.2.2.1.1 XTT Cell Proliferation
This assay is based on the ability of viable cells to reduce XTT dye. These wells 
were analyzed after 24, 72, 120 and 168 hours to evaluate if MTX-HNTs reduced the cell 
proliferation. Cells seeded in 12-well plates were treated as mentioned above (see Section 
5.2.2.1). XTT assay was added as detailed in Section 3.2.7.2 and analyzed with the 
absorbance microplate reader at 450 nm and 690 nm wavelengths.
5.2.2.1.2 Live/Dead Cell Viability Assay
This assay was used to determine if HNT-MTX complexes resulted in cell death. 
Cells seeded in 12-well plates were treated as mentioned above (see Section 5.2.2.1). 
Live/dead assay was added as detailed in Section 3.2.7.3 and cells were imaged after 24, 
72, 120 and 168 hours. Imaging was carried out using the Olympus BX51 fluorescent 
microscope with FITC and TRITC filters and images were processed and quantified 
using Image J software.
5.2.3 FE-SEM. TEM and Zeta Potential /
Particle Size Analysis
For characterization of the HNTs, average size and charge measurements, and FE- 
SEM images were taken.
5.2.3.1 Zeta Potential and Particle Size
Halloysite surface potential was analyzed by using microelectrophoresis (ZetaPlus 
Potential Analyzer, Brookhaven Instruments). Diluted aqueous dispersion of halloysite
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was prepared and analyzed as mentioned in Section 3.2.4. The instrument also allowed 
for average particle size measurement based on dynamic light scattering
52.3.2 FE-SEM/TEM
To visualize the morphology and surface properties of HNTs, FE-SEM and TEM 
images were obtained from HNT samples. The sample preparation and imaging protocols 
are detailed in Sections 3.2.5.1 and 3.2.5.2
5.3 Results and Discussion
5 .3 .1 Release Profile Study of MTX from HNTs
The release profile study of MTX from HNTs was done to estimate the amount of 
drug eluted from the HNTs over a period of 24 hours for seven days. This study was 
carried out to determine if HNTs could be loaded with MTX and elute enough to inhibit 
proliferation in vitro. The graph showing the release profile study for MTX-HNTs for 24 
hours is given in Figure 5-1.
Figure 5-1 shows the MTX release over 24-hours for 1 mg HNT/10%MTX, 5 mg 
HNT/10%MTX and 10 mg HNT/10%MTX. This release was achieved for the vacuum- 
loaded HNTs in nuclease free water at room temperature. The amount of MTX release 
calculated using an equation (Eq. 5-1) derived from the standard curve for MTX 
concentrations absorbance values obtained at 300 nm wavelength via a NANODROP 
2000 Spectrophotometer.
y =  0.047* + 0.015, Eq. 5-1
where y  is the absorbance value and * is the MTX concentration in pg.
1 2 0
The experiment was repeated three times to reduce error and to check for 
reproducibility of results. The values are the means of the readings of MTX release from 
HNTs at the respective time points from the 3 repetitions of the experiment. The error 
bars reflect the standard deviation.
Figure 5-1 shows the cumulative sustained release of the MTX for 24 hours in the 




















Figure 5-1: Mean Cumulative Release profile of MTX from HNTs for 24 hours mean 
of n = 9 for each concentration +/- standard deviation.
The graph of the release profile study for MTX from HNTs for 7 days is given in 
Figure 5-2. The release profile study of MTX from HNTs was extended to seven days. 
The experiment was repeated three times to reduce error and to check for reproducibility 
of the results. The values are the means of the readings of MTX from HNTs at the
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respective time points recorded from the repetitions of the experiments. The error bars 

















Figure 5-2: Release profile of MTX from HNTs for 7 days mean of n = 9 for each 
concentration +/- standard deviation.
The release of MTX from HNTs was extended and sustained for seven days. In 
the first 24 hours, from the three different samples, an average of 91.3%±6.2% of loaded 
MTX was released and after seven days an average 94.7% ±3.6% of loaded MTX was 
released. The release for 24 hours and over seven days was in the microgram and 
nanogram range for all samples and well within the range of MTX concentrations 
required for common in vitro assays.
The release profile of MTX from HNTs suggests that the majority of drug 
localized on the surface of HNTs. The initial burst release was mainly due to the suface 
localization of the MTX. Even with -80% of the drug being localized on the surface of
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the HNTs the release is in nano and micrograms, which is well within the range of MTX 
concentrations required for a cellular response in in vitro assays. Results obtained from 
the seven-day release profile are promising, as HNTs release MTX continuously, even 
with the majority released in the first 24 hours, as opposed to free drug which may be 
metabolized by the cells within the first 2-3 days. A sustained release of MTX is 
beneficial because loaded HNTs can be injected once and sustain a release in the 
cancerous tissues for more than seven days, reducing the need for more injections.
The release studies of MTX was not extended beyond seven days as in vitro 
experiments would only focus on the first seven days and primarily on the first 3-5 days. 
The comparison of the three loaded volumes, 1, 5, and 10 mg HNTS with 10% MTX, 
demonstrated HNTs could sustain a release of low and high concentration for more than 
seven days, and the release profile did not differ significantly when using different 
amounts of HNT. Surface potential and surface adsorption were further analyzed using 
zeta potential and particle size measurements in Section 5.2.3.1.
5.3.2 Cell Culture and Seeding
5.3.2.1 Cell Proliferation
A cell proliferation assay was performed to ascertain whether HNT loaded with 
MTX were capable of inhibiting the proliferation of osteosarcoma cells. The negative 
control for this experiment was untreated cells. The cell proliferation of osteosarcoma 
cells incubated with MTX loaded HNTs was compared to with proliferation of 
osteosarcoma cells treated with drug free HNTs and free MTX. Following seeding and 
incubation, the plates were analyzed after 24, 72, 120 and 168 hours via XTT cell 
proliferation assay. The media was changed in all plates at 72 and 120 hours, as cells in
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the control well were becoming confluent and the cells had used the majority of nutrients 
in the media.
After absorbance was measured, the data were exported to Excel files. The data 
were subsequently processed and normalized based on the absorbance at each time point 
of the untreated. IBM SPSS software and a two-tailed paired t-test were used for 
statistical analysis (Appendix A Table A-4). Figure 5-3 to Figure 5-6 show graphs of 
the cell proliferation from 24-168 hours.
Figure 5-3 shows the proliferation after 24 hours. After 24 hours, the drug had yet 
to affect cellular proliferation in the groups treated with free drug, 1 mg HNT, 5 mg 
HNT-MTX and 10 mg HNT. The 1 mg HNT group showed a higher level of proliferation 
than any other group, and this level may indicate that osteosarcoma cells proliferate more 
in the presence of low concentrations of HNT. As the concentration of drugs was higher 
in 5 mg HNT-MTX (500 pg) and 10 mg HNT-MTX (1 mg) proliferation had begun to be 
inhibited. Also, cells exposed to 10 mg of HNT were not growing as well as other plain 
HNT groups, which may suggest that HNTs at this concentration have a negative effect 
on growth.
Figure 5-3: Mean Cell Proliferation at 24 hours of n = 9 ±  standard deviation. 
Statistical analysis was applied with IBM SPSS 22.0 at a  = .05, and the red stars 
indicate no significant difference exists two groups encircled are compared and the 
black stars indicate significant difference exists when encircled groups are compared.
Figure 5-4 shows the proliferation after 72 hours. After 72 hours the drug began 
to affect cellular proliferation in all MTX-treated groups. The 1 mg HNT group showed a 
higher level of proliferation than any other group except the untreated control. The 1 mg 
HNT-MTX group showed the most proliferation reduction when compared to 1 mg of 
plain HNT, reducing proliferation by nearly half. The 1 mg HNT-MTX was as effective 
as the 100 pg of MTX at inhibiting proliferation.
The 5 mg HNT-MTX reduced proliferation by nearly 60%; however 5 mg plain 
HNT was shown to reduce proliferation by -50%, therefore it became difficult to 
determine if the effect was brought on by MTX or the HNTs. The 10 mg HNT-MTX and 
lOmg plain HNT sets behaved similarly. The 10 mg HNT-MTX group showed the 
highest reduction in proliferation. Results indicate that the presence of MTX in this group 
had little effect by comparison of the 10 mg groups. After 72 hours we continue to see
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that 5 and 10 mg of HNTs negatively affect the proliferation of osteosarcoma. At 72 
hours, the media was changed as it had begun to change colors indicating cells had 
absorbed the majority of the nutrients. Also, in the 100 pg MTX set the media was 
replaced with media containing 100 pg MTX to maintain the proliferative ability.
Figure 5-4: Mean Cell Proliferation at 72 hours of n = 9 ± standard deviation. 
Statistical analysis was applied with IBM SPSS 22.0 at a  = .05, and the black stars 
indicate significant difference exists when encircled groups are compared.
Figure 5-5 shows the proliferation after 120 hours. After 120 hours, the drug 
continued to affect cellular proliferation in the groups in all treated groups. Also, the 
media change at 72 hours caused proliferation to increase slightly in all groups, except 10 
mg HNT and 10 mg HNT-MTX. The 1 mg HNT group showed the highest level of 
proliferation. The case with 1 mg HNT-MTX showed greater proliferation reduction than 
the case of 1 mg of plain HNT, reducing proliferation by nearly half. The 1 mg HNT- 
MTX inhibited proliferation more effectively than the lOOpg of MTX, and at this point, 
the majority of the drug had been released from MTX-loaded HNTs.
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The 5 mg HNT-MTX reduced proliferation by nearly 60% and 5 mg plain HNT 
reduced prolife by -30%, and we began to see a significant difference between these two 
groups. The 10 mg HNT-MTX and 10 mg plain HNT sets behaved similarly, and even 
though the 10 mg HNT-MTX showed the highest reduction in proliferation, the presence 
of MTX in this group had little effect in comparison to the 10 mg groups, only making a 
difference of -10% in cell proliferation. After 120 hours, 10 mg of HNTS continued to 
negatively affect the proliferation of osteosarcoma. At 120 hours, the media was changed 
as it had begun to change colors indicating cells had absorbed the majority of the 
nutrients. Also, in the 100 pg MTX set, the media was replaced with media containing 
100 pg MTX to maintain the proliferative ability.
Figure 5-5: Mean Cell Proliferation at 120 hours of n = 9 ±  standard deviation. 
Statistical analysis was applied with IBM SPSS 22.0 at a = .05, and the black stars 
indicate significant difference exists when encircled groups are compared.
Figure 5-6 shows the proliferation after 168 hours, the final time point. After 168 
hours the drug continued to affect cellular proliferation in all treated groups. The 1 mg 
HNT group (73% proliferation) showed a higher level of proliferation than any other
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group, except the control. The 1 mg HNT-MTX group showed more proliferation 
reduction than 1 mg of plain HNT and untreated controls. The 1 mg HNT-MTX group 
reduced proliferation by more than half when compared to 1 mg HNT and by nearly 60% 
when compared to untreated control. The 1 mg HNT-MTX group continued to be more 
effective at proliferation inhibition than the 100 pg of MTX, and at this point the majority 
(80%) of the drug had been released from MTX-loaded HNTs. The 5 mg HNT-MTX 
case reduced proliferation by nearly 80%, and 5 mg plain HNT was reduced proliferation 
by -60%, and these two groups continue to differ significantly, but the 5 mg still 
negatively affects cell proliferation. The 10 mg HNT-MTX case had highest reduction in 
proliferation (82%). When the 10 mg HNT-MTX and 10 mg plain HNT cases were 
compared the presence of MTX in this group had little effect by comparison of the 10 mg 
groups only making a difference of -9%  in cell proliferation. After 168 hours, 5 mg and 
10 mg of HNTS negatively affected the proliferation of osteosarcoma.
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Figure 5-6: Mean Cell Proliferation at 168 hours of n = 9 ± standard deviation. And 
the red stars indicate no significant difference exists two groups encircled are compared 
and the black stars indicate significant difference exists when encircled groups are 
compared.
Figure 5-7 compares cell proliferation over the seven-day period (168 Hours). 
Even though 5 mg HNT-MTX and 10 mg HNT-MTX showed the largest reductions in 
proliferation over the seven-day period, 5 and 10 mg of plain HNT significantly reduced 
the cellular proliferation and limited the response shown in the drug released in the HNT- 
MTX groups. All groups were more effective than free MTX at every time point which 
may indicate that HNTs can better localize the drug at the cell than drug diluted in the 
media. The 1 mg HNT-MTX showed a higher reduction in proliferation when compared 
to 1 mg HNTs, by reducing proliferation by more than 60% by Day 7. Cell growth 
seemed to be stimulated by 1 mg of HNTs until cells became confluent, and at 
confluency 1 mg HNTs show the lowest reduction in proliferation of all HNT groups.
Cell proliferation was affected by 1 mg HNTs least when it was administered alone and
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yielded the most anti-proliferative effect when loaded with methotrexate. The most 
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Figure 5-7: Seven Day Mean Proliferation Comparison normalized by untreated cells 
proliferation.
5.3.2.2 Live/Dead
A live/dead cell viability assay was performed to determine whether HNT loaded 
with MTX were inducing cell death in osteosarcoma cells. The live/dead assay images of 
osteosarcoma cells incubated with MTX-loaded HNTs were compared to with live/dead 
images of osteosarcoma cells treated with HNTs and free MTX. The negative control for 
this experiment was untreated cells. Following seeding and incubation, the plates were 
treated with the live/dead cell viability assay kit and imaged after 24, 72, 120 and 168 
hours via the Olympus BX51 fluorescent microscope with FITC and TRITC filters. The
Time (Hours)
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media was changed in all plates after 72 and 120 hours because cells in the control wells 
were becoming confluent and the cells had used the majority of nutrients in the media.
The images were saved and processed with ImageJ software. Figure 5-8 to 
Figure 5-15 show live/dead images results from 24-168 Hours.
Osteosarcoma cells in monolayer culture proliferated and became nearly 
confluent within the first 24 hours with little cell death observed (see Figure 5-8 A-C). 
Osteosarcoma cells were also unaffected by the addition of HNTs (Figure 5-8 D-L).
Cells proliferated and achieved confluence comparable to normal, untreated cells 
(Compare B and C with Figure 5-8 E, H, K and F, I, L).
131
PHASE LIVE DEAD
Figure 5-8: Cytotoxic response to HNTS at 24 Hours Scale bars represent 500pm. (A- 
C) Group 1: Osteosarcoma cell cultures with no HNT addition. (D-F) Group 2: 
Osteosarcoma cells exposed to 1 mg HNTs. (G-I) Group 3: Osteosarcoma cells 
exposed to 5 mg HNTs. (J-L) Group 4: Osteosarcoma cells exposed to lOmg HNTs. A, 
D, G and J = Phase contrast; B, E, H and K = Live Dead assay showing live cells 
(green); C, F, I and L = Dead assay showing dead cells (red). The brown coloration in 
D, G and J is caused by the high concentration of HNTs. Haze shown in some of the 
images is also due to high concentrations of HNTs.
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HNTs are seen clearly as particulate material (Figure 5-9 D, G and J). At 24 
hours, in MTX-treated groups, the cellular response was very different from untreated 
cells and cell growth was reduced (Figure 5-9A-C). At 24 hours, in Group 2, 
osteosarcoma cells exposed to 1 mg MTX-HNTs showed a similar reduction in cell 
growth, as compared to free MTX-treated cells (Figure 5-9 D-F). At 24 hours, in Group 
3, osteosarcoma cells exposed to 5 mg MTX-HNTs showed a greatest reduction in cell 
growth as compared to the MTX group and the 1 mg MTX-HNT group (Figure 5-9 G-I). 
After 24 hours, in Group 4, osteosarcoma cells exposed to 10 mg MTX-HNTs showed 
the greatest reduction in cell growth as compared to the MTX group, the 5 mg MTX- 
HNT group, and the 1 mg MTX-HNT group (Figure 5-9 J-l). However, only a few dead 
cells were observed in all groups (Figure 5-9 C, F, I and L).
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Figure 5-9: Cellular response to MTX and MTX-loaded HNTs at 24 Hours Scale bars 
represent 500pm. (A-C) Group 1: Osteosarcoma cell cultures with MTX (100 pg) 
addition. (D-F) Group 2: Osteosarcoma cells exposed to lmg MTX-HNTs. (G-I) Group 
3: Osteosarcoma cells exposed to 5 mg MTX-HNTs. (J-L) Group 4: Osteosarcoma 
cells exposed to lOmg MTX-HNTs. A, D, G and J = Phase contrast; B, E, H and K = 
Live Dead assay showing live cells (green); C, F, I and L = Dead assay showing dead 
cells (red). The brown coloration in D, G and J is caused by the high concentration of 
HNTs. Haze shown in some of the images is also due to high concentrations of HNTs.
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Osteosarcoma cells in monolayer culture proliferated and became confluent 
within 2-3 days with little cell death observed (see Figure 5-10, A-C). Osteosarcoma 
cells were also unaffected by the addition of HNTs (Figure 5-10, D-L). Cells proliferated 
and achieved confluence comparable to normal, untreated cells (Compare Figure 5-10 B 
and C with Figure 5-10 E, H, K and F, I, L).
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Figure 5-10: Cytotoxic response to HNTS at 72 Hours Scale bars represent 500pm. 
(A-C) Group 1: Osteosarcoma cell cultures with no HNT addition. (D-F) Group 2: 
Osteosarcoma cells exposed to 1 mg HNTs. (G-I) Group 3: Osteosarcoma cells 
exposed to 5 mg HNTs. (J-L) Group 4: Osteosarcoma cells exposed to 10 mg HNTs. A, 
D, G and J = Phase contrast; B, E, H and K = Live Dead assay showing live cells 
(green); C, F, I and L = Dead assay showing dead cells (red). The brown coloration in 
D, G and J is caused by the high concentration of HNTs. Haze shown in some of the 
images is also due to high concentrations of HNTs.
After 72 hours, in MTX-treated groups the reduction in cell growth was much 
greater than at 24 hours (Figure 5-11 A-C). After 72 hours, in Group 2, osteosarcoma
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cells exposed to 1 mg MTX-HNTs showed a marked reduction in cell growth as 
compared to untreated controls cells and cells treated with free MTX (Figure 5-11 D-F), 
this reduction was even greater than the reduction seen at 24 hours. At 72 hours, in Group 
3, osteosarcoma cells exposed to 5 mg MTX-HNTs showed a greater reduction in cell 
growth as compared to the MTX group and the 1 mg MTX-HNT group and was greater 
than the reduction seen at 24 hours (Figure 5-11 G-I). At 72 hours, in Group 4, 
osteosarcoma cells exposed to 10 mg MTX-HNTs showed the greatest reduction in cell 
growth as compared to the MTX group, the 5 mg MTX-HNT and the 1 mg MTX-HNT 
group but was similar to the cell growth at 24 hours (Figure 5-11 J-L). However, only a 
few dead cells were observed in all groups (Figure 5-11 C, F, I and L).
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Figure 5-11: Cellular response to MTX and MTX-loaded HNTs at 72 Hours Scale bars 
represent 500pm. (A-C) Group 1: Osteosarcoma cell cultures with MTX (100 pg) 
addition. (D-F) Group 2: Osteosarcoma cells exposed to lmg MTX-HNTs. (G-I) Group 
3: Osteosarcoma cells exposed to 5 mg MTX-HNTs. (J-L) Group 4: Osteosarcoma 
cells exposed to 10 mg MTX-HNTs. A, D, G and J = Phase contrast; B, E, H and K = 
Live Dead assay showing live cells (green); C, F, I and L = Dead assay showing dead 
cells (red). The brown coloration in D, G and J is caused by the high concentration of 
HNTs. Haze shown in some of the images is also due to high concentrations of HNTs.
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Osteosarcoma cells in monolayer culture continued to proliferate and maintained 
confluency after 120 hours with little cell death observed (see Figure 5-12 A-C). 
Osteosarcoma cells also began to show the effects of the addition of HNTs (Figure 5-12 
D-L). Cells proliferated and achieved confluence comparable to normal, untreated cells 
(Compare Figure 5-12 B and C with Figure 5-12 E, H, K and F, I, L), but the HNT 
groups may have many more dead cells.
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Figure 5-12: Cytotoxic response to HNTS at 120 Hours Scale bars represent 500pm 
(A-C) Group 1: Osteosarcoma cell cultures with no HNT addition. (D-F) Group 2: 
Osteosarcoma cells exposed to 1 mg HNTs. (G-I) Group 3: Osteosarcoma cells 
exposed to 5 mg HNTs. (J-L) Group 4: Osteosarcoma cells exposed to lOmg HNTs. A, 
D, G and J = Phase contrast; B, E, H and K = Live Dead assay showing live cells 
(green); C, F, I and L = Dead assay showing dead cells (red). The brown coloration in 
D, G and J is caused by the high concentration of HNTs. Haze shown in some of the 
images is also due to high concentrations of HNTs.
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After 120 hours, in MTX-treated groups, the reduction in cell growth was even 
greater than at 72 hours (Figure 5-13 A-C). After 120 hours, in Group 2, osteosarcoma 
cells exposed to 1 mg MTX-HNTs showed a marked reduction in cell growth as 
compared to untreated controls cells and cells treated with free MTX (Figure 5-13 D-F). 
This reduction was even greater than the reduction seen after 72 hours. At 120 hours, in 
Group 3, osteosarcoma cells exposed to 5 mg MTX-HNTs showed a greater reduction in 
cell growth as compared to MTX group and 1 mg MTX-HNT group (Figure 5-13 G-H). 
After 120 hours, in Group 4, osteosarcoma cells exposed to 10 mg MTX-HNTs showed 
the greatest reduction in cell growth as compared to the MTX group, the 5 mg MTX- 
HNT and the 1 mg MTX-HNT group (Figure 5-13 J-L). However, only a few dead cells 
were observed in all groups (Figure 5-13 C, F, I and L).
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Figure 5-13: Cellular response to MTX and MTX loaded HNTs at 120 Hours Scale 
bars represent 500pm. (A-C) Group 1: Osteosarcoma cell cultures with MTX (100 pg) 
addition. (D-F) Group 2: Osteosarcoma cells exposed to 1 mg MTX-HNTs. (G-I) 
Group 3: Osteosarcoma cells exposed to 5 mg MTX-HNTs. (J-L) Group 4: 
Osteosarcoma cells exposed to 10 mg MTX-HNTs. A, D, G and J = Phase contrast; B, 
E, H and K = Live Dead assay showing live cells (green); C, F, I and L = Dead assay 
showing dead cells (red). The brown coloration in D, G and J is caused by the high 
concentration of HNTs. Haze shown in some of the images is also due to high 
concentrations of HNTs.
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Osteosarcoma cells in monolayer culture continued to proliferate and maintained 
confluency after 168 hours (7 days) with little cell death observed (see Figure 5-14 A-C). 
Osteosarcoma cells also began to show the effects of unloaded HNTs (Figure 5-14 D-L). 
Cell proliferation and confluence are comparable to normal, untreated cells (compare 
Figure 5-14 B and C with Figure 5-14 E, H, K and F, I, L) but the HNT groups had 
many more dead cells. Also, the 5 mg and especially the 10 mg groups, are less confluent 
than the normal, untreated cells, which indicates a more cytotoxic response at 7 days.
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Figure 5-14: Cytotoxic response to HNTs at 168 Hours Scale bars represent 500pm 
(A-C) Group 1: Osteosarcoma cell cultures with no HNT addition. (D-F) Group 2: 
Osteosarcoma cells exposed to 1 mg HNTs. (G-I) Group 3: Osteosarcoma cells 
exposed to 5 mg HNTs. (J-L) Group 4: Osteosarcoma cells exposed to 10 mg HNTs. A, 
D, G and J = Phase contrast; B, E, H and K = Live Dead assay showing live cells 
(green); C, F, I and L = Dead assay showing dead cells (red). The brown coloration in 
D, G and J is caused by the high concentration of HNTs. Haze shown in some of the 
images is also due to high concentrations of HNTs.
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After 168 hours, in MTX-treated groups, the reduction in cell growth was even 
greater than after 120 hours and the cellular response was very different from untreated 
cells (Figure 5-15 A-C). After 168 hours, Group 2 osteosarcoma cells exposed to 1 mg 
MTX-HNTs showed a marked reduction in cell growth as compared to untreated control 
cells and cells treated with free MTX (Figure 5-15 D-F). At 168 hours, in group 3, 
osteosarcoma cells exposed to 5mg MTX-HNTs showed a greater reduction in cell 
growth as compared to the MTX group and the lmg MTX-HNT group (Figure 5-15 G- 
H). After 168 hours, Group 4 osteosarcoma cells exposed to 10 mg MTX-HNTs showed 
the greatest reduction in cell growth as compared to the MTX group, the 5 mg MTX- 
HNT and thel mg MTX-HNT group (Figure 5-15 J-L). However, only a few dead cells 
were observed in all groups, and cells were more confluent than at the 120 hour time 
point, which may be attributed to the changing of the media which removed the majority 
of the drug that had been released (Figure 5-15 C, F, I and L).
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Figure 5-15: Cellular response to MTX and MTX loaded HNTs at 168 Hours Scale 
bars represent 500pm. (A-C) Group 1: Osteosarcoma cell cultures with MTX (100 pg) 
addition. (D-F) Group 2: Osteosarcoma cells exposed to 1 mg MTX-HNTs. (G-I) 
Group 3: Osteosarcoma cells exposed to 5 mg MTX-HNTs. (J-L) Group 4: 
Osteosarcoma cells exposed to 10 mg MTX-HNTs. A, D, G and J = Phase contrast; B, 
E, H and K = Live Dead assay showing live cells (green); C, F, I and L = Dead assay 
showing dead cells (red). The brown coloration in D, G and J is caused by the high 
concentration of HNTs. Haze shown in some of the images is also due to high 
concentrations of HNTs.
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5.3.3 FE-SEM. TEM and Zeta
Potential/Particle Size Analysis
FE-SEM and TEM images, as well as, zeta potential and particle size 
measurements were taken to characterize HNTs.
5.3.3.1 SEM TEM imaeins
Figure 5-16 shows the SEM and TEM images of plain HNTs. Images show 
relative diameters, lengths and lumen size described in earlier chapters.
Magnification
Low Higher Highest
Figure 5-16: SEM and TEM Images of HNTs at different magnifications Scale bars for 
TEM are 500nm for low magnification 200 nm for Higher Magnification and 50nm for 
Highest Magnification. Scale Bars for SEM are 5pm for low magnification, 1pm for 
Higher Magnification and 500nm for Highest Magnification.
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5.3.3.2 Zeta Potential and Particle Size
The average particle size of plain HNTs, methotrexate-loaded HNTs and pIRES2- 
EGFP-loaded HNTs was measured to compare and determine if loading had affected 
particle size. Results are plotted in Figure 5-17. For pIRES2-EGFP-loaded HNTs’ 
particle size was measured to determine if surface adsorption or wrapping increased 
particle size. Plain HNTs and HNTs loaded with methotrexate shared similar particle 
sizes of 1522 nm ±  97.3 nm and 1513.4±562.8 nm respectively with no significant 
difference (Appendix A Table A-2: Results of IBM SPSS two-tailed Paired T-Test for 
Particle Size n = 4 samples.). The major difference in error between plain HNTs and 
methotrexate-loaded HNTs may be attributed to the formation of aggregates during the 
drying process. HNTs loaded with methotrexate may have some methotrexate on the 
surface causing them to stick together. Plasmid-loaded HNTs are noticeably larger than 
plain HNTs and methotrexate-loaded HNTs. On average pIRES2-EGFP-loaded HNTs 
were 4320.3 nm±609 nm in diameter. PIRES2-EGFP-loaded HNTs were almost 3 times 
the size of plain HNTs and methotrexate-loaded HNTs and this increased size may be 
attributed to the plasmid DNA adhering to the surface or wrapping around HNTs. The 












Figure 5-17: Mean Particle Size +/- standard deviation n = 4 samples. Statistical 
analysis was applied with IBM SPSS 22.0 at a  = .05, and the red stars indicate no 
significant difference exists the group and HNTs. The black stars indicate significant 
difference exists when group and HNTs are compared.
The zeta potential of plain HNTs, methotrexate-loaded HNTs and pIRES2-EGFP- 
loaded HNTs was measured to compare and determine if loading affected zeta potential. 
Results are plotted in Figure 5-18. For pIRES2-EGFP-loaded HNTs zeta potential was 
measured to determine if surface adsorption or wrapping changed the surface zeta 
potential of HNTs. With the loading of MTX and surface adsorption and/or loading of 
plasmid DNA, the zeta potential decreased slightly. The zeta potential was -41 6±3 mV 
for plain HNTs, -45±2.3 mV for MTX-HNT, and -51,4±2.1 mV for pIRES2-EGFP- 
HNT.
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Figure 5-18: Mean Zeta Potential +/- standard deviation n = 4 samples. Statistical 
analysis was applied with IBM SPSS 22.0 at a  = .05,and the red stars indicate no 
significant difference exists the group and HNTs.
CHAPTER 6 
AIR-BRUSHED HNT DOPED CHITOSAN 
FILMS FOR SUSTAINED AND LOCALIZED 
DELIVERY OF METHOTREXATE
6.1 Introduction
The previous chapter introduced HNTs as a drug delivery vector for methotrexate. 
Results suggest that MTX-loaded HNTs can release MTX and inhibit proliferation for up 
to seven days. Though capable of releasing drugs for seven days the release MTX from 
HNTs should be tailored to allow for a more controlled release. Here I discuss another 
potential application by pairing drug loaded HNTs with a novel air-brush sprayed film as 
a pre and post-surgical implant for patients with different types of cancer.
In Chapter 5, HNTs were used to deliver MTX to osteosarcoma cells to inhibit 
cellular growth. In the current chapter, HNTs are combined with novel air-brush sprayed 
chitosan films to improve their material and biological properties. The objective of 
adding MTX-HNTs to chitosan films was to tailor drug release, immobilize HNTs, and 
localize drug dosage. These MTX-HNT-doped chitosan films may be useful as post- 
surgical implants that reduce the recurrence of cancer in patients who have had cancerous 




Chitosan, individually and in combination with other polymers, has material and 
biological properties that make it suitable for drug delivery [87], Chitosan is 
biodegradable, biocompatible, and capable of forming films through several methods 
[87]. Aside from the mentioned properties, chitosan can encapsulate free drugs, and it 
may be able to control the release based on film degradation.
The hypothesis of this project was that the combination of air-brush sprayed 
chitosan films and methotrexate-loaded HNTs could inhibit growth and proliferation of 
cells while modulating drug release in vitro.
6.2 Methods and Materials
All the plasticware, which include, syringes, centrifuge tubes, microcentrifuge 
tubes, 12 well plates, and pipettes were purchased from Mid Scientific, St. Louis, MO. 
Cell culture media, buffers, serum and LIVE/DEAD® Viability/Cytotoxicity Kit were 
purchased from Life Technologies, Grand Island, NY. Acetone, DMSO, Methotrexate, 
HNTs and XTT in vitro toxicology assay kits were obtained from Sigma-Aldrich, St. 
Louis, MO. ChitoClear® HQG10 chitosan was obtained from Primex, Siglufjordur, 




To macroscopically view chitosan films, HNT chitosan films and MTX-HNT 
chitosan film images were taken with a 16-megapixel camera.
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6.2.1.2 Phase Contrast Imaeine
The Olympus BX51 fluorescent microscope was used in phase contrast mode to 
image chitosan films, MTX chitosan films, HNT chitosan films and MTX-HNT chitosan. 
The images allowed for the visualization of millimeter and micrometer scale features of 
the different film composites films.
6.2.1.3 FE-SEM Imagine
The HITACHI S 4800 Field Scanning Electron Microscope (FE-SEM) was used 
to image chitosan films, HNT chitosan films, and MTX-HNT chitosan films. The SEM 
microscope’s high magnification allowed for a close comparison of the surface 
morphologies of chitosan films, HNT chitosan films, and MTX-HNT chitosan films. The 
comparison helped to assess the surface properties and to predict the behavior of the films 
in vitro conditions.
6.2.2 Release Study
The release profile study for methotrexate was done to understand the release of 
chemotherapeutic agents from HNT-embedded chitosan films. First, a calibration curve 
was created for MTX to compare with the drug elution profiles of the MTX-HNT 
chitosan films. Four sample sets of films were prepared using methods mentioned in 
3.2.2, 1% HNT-MTX w/v chitosan, 5% HNT-MTX w/v and 10% HNT-MTX w/v 
chitosan and 1 mg/ml concentration of methotrexate in chitosan. After being spayed into 
a 12 will tissue culture dish in triplicates (see plate map Table 6-1), films were immersed 
in HBSS and mixed for 24-hour and 7-day time periods. Samples were centrifuged and 
the supernatants were collected for UV-vis. analysis (Nanodrop 2000c, ABS wavelength
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300 nm). Samples were replenished with fresh HBSS. The details of sample collection 
and the overall procedure are provided in Section 3.2.6.
Table 6-1: 12-Well Plate Map for Chitosan Films Drug Release Study.
























6.2.3 Cell Culture and Seeding
An osteosarcoma cell line was the model used to study in vitro cellular response 
to methotrexate-loaded chitosan composite. Osteosarcoma cells were plated in 25 cm2 
tissue culture flasks, and incubated at 37 °C under humidified 5% CO2 and 95% air in 
complete DMEM containing 10% FBS and 1% PSA. Subconfluent cells were passaged 
with 0.25% trypsin, collected by centrifugation, suspended in complete DMEM and 
cultured at a 3:1 split into 25 cm2 tissue culture flasks. These cultures were used for the 
viability and proliferation tests.
6.2.3.1 Cell Proliferation and Viability Studies
In these experiments, osteosarcoma cells were used. Chitosan films were sprayed 
onto 12 well plates according to Table 6-2 and Table 6-3. Osteosarcoma cells were 
seeded in 12-well plates containing films. Two of each plate were prepared for each time 
period, one for XTT cell proliferation assay and one for live/dead cell viability assay.
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Table 6-2: Drug Free Film Plate Map for Cell Proliferation and Cytotoxcity studies.
Chitosan 1% HNT Chitosan 5% HNT Chitosan
10% HNT 
Chitosan
Chitosan 1% HNT Chitosan 5% HNT Chitosan
10% HNT 
Chitosan
Chitosan 1% HNT Chitosan 5% HNT Chitosan
10% HNT 
Chitosan
Table 6-3: MTX loaded Film Plate Map for Cell Proliferation and Cytotoxcity studies.



























6.2.3.2 XTT Cell Proliferation Assay
This assay is based on the ability of viable cells to reduce XTT dye. These wells 
were analyzed at 24, 72, 120 and 168 hours to evaluate if chitosan films and doped 
chitosan film composites reduced the cell proliferation. Cells seeded in 12 well plates 
were treated as mentioned in Section 6.2.3.1. The XTT assay was added, as detailed in 
Section 3 .2.7.2, and analyzed with the absorbance microplate reader at 450 nm and 690 
nm wavelengths.
6.2.3.3 Live/Dead Assay
This assay was used to determine if chitosan films and doped chitosan film 
composites resulted in cell death. Cells seeded in 12 well plates were treated as 
mentioned in Section 6.2.3.1. A live/dead assay was added as detailed in Section 3.2.7.3,
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and cells were imaged at 24, 72, 120 and 168 hours under the Olympus BX51 fluorescent 
microscope with FITC and TRITC filters. Images were processed and quantified using 
Image J software.
6.3 Results and Discussion
6.3.1 Imagine
Various types of imaging were carried out to visualize chitosan films and identify 
features and/or properties that make them unique and ideal in vitro.
6.3.1.1 Camera Imaeinz
Images were taken to visualize chitosan films embedded with HNTs, MTX and 
MTX-HNTs. Figure 6-1 shows the images taken using a 16 MP camera. Films with 0% 
HNTs, without MTX have a clear and smooth appearance while films with 0% HNT and 
1 mg/ml MTX concentration have a light yellow tint and a slightly more rough 
appearance. Films with 1, 5 and 10% HNTs have an increased roughness as the 
percentage of HNT in the films. The same trend is notice in MTX loaded HNT groups 
however, these groups have a yellow tint due to the loading of MTX.
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Figure 6-1: Camera Images for Chitosan Films.
6.3.1.2 Phase Contrast Imaeinz
Phase contrast imaging was done to identify mm scale and nm scale feature of 
chitosan films. Imaging was carried out at 4x magnification (Figure 6-2) and lOx 
magnification (Figure 6-3)
Figure 6-2 shows images of chitosan films at 4x magnification. Chitosan films 
with no drug or HNTs have sparsely located micron-scale chitosan particles throughout 
the film (Figure 6-2A). Chitosan films with a 1 mg/ml concentration of MTX have many 
-50 pm bubbles, which may signify drug encapsulation within the films (Figure 6-2B).
In chitosan films with no drug and 1% HNTs, there are sparsely located micron 
scale chitosan particles throughout the film (Figure 6-2C) as well as a greater evenly 
distributed HNT particles. In chitosan films with a 1% MTX-HNTs, aggregates of MTX- 
HNT can be seen throughout the image and many of them seem to be encapsulated within 
bubbles which may signify MTX-HNT encapsulation within the films (Figure 6-2D). 
Additionally, it seems that HNTs loaded with MTX are much more pronounce than 
unloaded HNTs and MTX seems to also coat the surface.
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Chitosan films with no drug and 5% HNTs had sparsely located micron scale 
chitosan particles throughout the film (Figure 6-2E) as well as a greater amount of 
evenly distributed HNT particles when compared to 1 %HNT chitosan films (Figure 
6-2C). In chitosan films with a 5% MTX-HNTs, aggregates of MTX-HNT can be seen 
throughout the image and many of them seem to be encapsulated within bubbles, which 
may signify MTX-HNT encapsulation within the films (Figure 6-2F). Additionally, the 
5%MTX-HNT films (Figure 6-2F) had many more MTX-HNT aggregates in than 1% 
MTX-HNT films (Figure 6-2D).
Chitosan films with no drug and 10% HNTs had sparsely located micron-scale 
chitosan particles throughout the film (Figure 6-2G) and more HNT particles when 
compared to 5% HNT chitosan films (Figure 6-2F), although not as evenly distributed. 
Chitosan films with a 10% MTX-HNTs had aggregates of MTX-HNT throughout the 
image, and many of them seem to be encapsulated with in bubble which may signify 
MTX-HNT encapsulation within the films (Figure 6-2H). Additionally, the MTX-HNT 
aggregates in 10%MTX-HNT are not evenly distributed like other groups, and MTX 







Figure 6-2 :4x Phase contrast images scale bars represent 500pm. A, C, E, and G are 
images of non-drug loaded films at 0% HNT, 1% HNT, 5% HNT and 10% HNT, 
respectively. B, D, F, and H are images of drug loaded films at 0% HNT, 1% HNT, 5% 
HNT and 10% HNT, respectively.
Figure 6-3 shows images of chitosan films at lOx magnification. Images show 
the same trends as imaged at 4x magnification. Chitosan microparticles seen in images 
with no drug are -1-20 microns in diameter (Figure 6-3A, C). Drug encapsulated
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Figure 6-3: lOx Phase contrast images scale bars represent 200pm. A, C, E, and G are 
images of non-drug-loaded films at 0%, 1%, 5% and 10% HNT, respectively. B, D, F, 
and H are images of drug loaded films at 0%, 1%, 5% and 10% HNT, respectively.
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6.3.1.3 FE-SEM Imaging
FE-SEM imaging was done to compare of the surface morphologies of chitosan 
films, HNT chitosan films, and MTX-HNT chitosan films. The comparison helped to 
assess the surface properties and identify micro and nano scale features of different film 
composites. Figure 6-4 shows FE-SEM images of chitosan film composites with no 
methotrexate, while Figure 6-5 shows FE-SEM images of chitosan film composites with 
methotrexate.
Figure 6-4 shows FE-SEM images of chitosan film composites at different 
magnifications. Chitosan films alone show few features except the rare appearance of 
non-uniform 500 nm size particles (Figure 6-4 A-C). The 1% HNT chitosan film images 
show a somewhat uniform distribution of HNTs and small sized aggregates (Figure 6-4 
D-F). The 5% HNT chitosan films images show many different sized HNTs aggregates 
and a few single HNTs (Figure 6-4 G-I). The 10% HNT chitosan film images show 
many single HNTs but the majority of HNTs have aggregated into large clusters within 
the film (Figure 6-4 J-L).
Figure 6-4: FE-SEM images of chitosan film composites without drug. A-C Chitosan 
films with 0% HNTs and without MTX. D-F Chitosan films with 1% HNTs and 
without MTX. G-I Chitosan films with 5% HNTs and without MTX. J-L Chitosan 
films with 10% HNTs and without MTX.
Figure 6-5 shows FE-SEM images of chitosan film composites at different 
magnifications. 1% MTX-HNT chitosan film images show sparsely distributed HNTs 
(Figure 6-5 D-F). The surface of the tubes has MTX coatings, and at higher 
magnifications, MTX crystals can be seen on the surface of the HNTs. The 5% HNT
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chitosan films images show many small HNTs aggregates and a few single HNTs 
(Figure 6-5 G-I). Figure 6-5 H shows a pore resulting from MTX-HNTs protruding 
through the surface of the film. Figure 6 -51 shows MTX-HNT completely immersed 
within the film. The 10% HNT chitosan film images show very few singular HNTs and 
most of the HNTs have aggregated into large clusters greater than 50 pm in diameter 
(Figure 6-5 J-L). In all MTX-HNT (Figure 6-5 D-L) groups, HNTs appear to be 
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Figure 6-5: FE-SEM images of chitosan film composites with methotrexate. A-C 
Chitosan films with 0% HNTs and without MTX. D-F Chitosan films with 1% MTX- 
HNTs. G-I Chitosan films with 5% MTX-HNTs the circle indicates a pore, arrow 
points to pores. J-L Chitosan films with 10% MTX-HNTs.
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6.3.2 Release Study
The release profile of MTX from MTX and MTX-HNT-doped chitosan films was 
determined to estimate the amount of drug eluted from the HNTs over a period of 24 
hours and over 7 days (Figure 6-6). This study was carried out to determine if MTX and 
MTX-HNT-doped chitosan films elute enough to inhibit cell proliferation in vitro.
Figure 6-6 shows the trend of the MTX release over a 24-hour time period for 1 
mg/ml MTX chitosan films, 1% MTX-HNT chitosan films, 5% MTX-HNT chitosan 
films and 10% MTX-HNT chitosan films. The amount of MTX release was calculated 
from Eq. 6-1, which was derived from a standard curve for MTX concentrations 
absorbance values obtained at 300 nm wavelength via a NANODROP 2000 
spectrophotometer.
y  =  0.047* + 0.015, Eq. 6-1
where y  is the absorbance value and * is the MTX concentration in pg.
The experiment was carried out in triplicate to reduce error and to check for 
reproducibility of results. The values are the mean of reading of MTX release from 
chitosan film composites at the respective time points from the three repetitions of the 
experiment. The error bars reflect the standard deviation.
Figure 6-6 shows the cumulative release of the MTX for 24 hours in the 
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Figure 6-6: Mean Cumulative Release profile for Chitosan Composite Films at 24 
hours mean of n = 9 for each concentration +/- standard deviation.
The graph of the release profile study for MTX from chitosan composite films for 
7 days is given in Figure 6-7. The experiment was repeated three times to reduce error 
and to check for reproducibility of the results. The values are the means of the readings of 
MTX from chitosan composite films at the respective time points recorded from the 
repetitions of the experiments. The error bars reflect the standard deviation.
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Figure 6-7: Mean Cumulative Release profile for chitosan film composites for Seven 
Days mean of n = 9 for each concentration +/- standard deviation.
The release of MTX from MTX-HNT chitosan films was extended and sustained 
for 7 days. In the first 24 hours, from the three different samples, an average of 54.5%± 
6% of loaded MTX was released and after 7 days an average 56.4%±6% of loaded MTX 
was released. The film chitosan film alone on released 29.3%±2% within the first 24 
hours and 42.6%±2.3% after 7 days. The release for 24 hours and 7 days were in the 
microgram and nanogram range for all samples and well within the range of MTX 
concentrations required for commonly in vitro assays.
The release profile of MTX from chitosan composite films suggest that the 









release. Even with the -80% of the drug being localized in the films, the release is in 
nano and micrograms, which is well within the range of MTX concentrations required for 
a cellular response in in vitro assays. Results obtained from the seven-day release 
profiles are promising, as HNTs release MTX continuously, even with the majority 
released in the first 24 hrs, as opposed to free drug which may be metabolized by the cells 
within the first 2-3 days. A sustained release of MTX is beneficial because film 
composite can be implanted, used to coat tumors and surrounding areas, stents and other 
fiducials once, yet sustain a release in the cancerous tissues for more than seven days thus 
reducing the need for multiple injections of chemotherapeutic drugs (prostate, breast and 
bone cancer). The approach may also be promising in that MTX-doped chitosan 
composite films could provide a localized and controlled drug release as a biodegradable 
chemotherapeutic patch for epithelial cell, mouth, and skin cancers for example. Films 
could be additionally doped with HNTs bearing DNA and/or p-GP blockers as a part of a 
sequential delivery and synergistic drug gene combination.
The release of MTX was not extended beyond seven days because in vitro 
experiments would only focus on the first 7 days and primarily on the first 3- 5 days. The 
comparison of the four composite films, 1 mg/ml MTX chitosan films, 1% MTX-HNT 
chitosan films, 5% MTX-HNT chitosan films and 10% MTX-HNT chitosan films, 
demonstrated films could sustain a release of low and high concentration for more than 7 
days, and the release profile did not differ significantly when using different 
concentrations of HNTs.
Figure 6-8 compares the percentage of drug release between MTX-loaded HNTs, 
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Figure 6-8: Seven Day Mean Release Comparison MTX-HNTs, MTX-HNT-CHT 
films and MTX-CHT films +/- standard deviation.
Initial studies of MTX release from HNTs (Chapter 5) showed that the majority of 
the drug loaded was released within the first 24 hours. The initial burst release was more 
than 70% of the drug loaded. The subsequent embedding of drug-loaded HNTs into 
chitosan films reduced the burst release by more than half. At 24 hours the MTX-HNT 
chitosan films only released 54% of the drug loaded while free MTX HNTs released 85% 
of the drug loaded. At 7 days free MTX-HNTs released more than 90 % of the drug 
loaded and MTX-HNT chitosan films only released 56%. Chitosan films controlled the 
release of MTX from HNTS effectively and reduced the release at 7 days by 34 %, thus, 
extending the release beyond 7 days.
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6.3.3 Cell Culture and Seeding
6.3.3.1 XTT Cell Proliferation Assay
A cell proliferation assay was performed to ascertain whether chitosan film 
composites could inhibit osteosarcoma cells proliferation. The cell proliferation of 
osteosarcoma cells incubated with MTX chitosan film composites were compared to 
proliferation of osteosarcoma cells treated with chitosan film composites with no drug. 
The negative control for this experiment was untreated cells. Following seeding and 
incubation, the plates were analyzed at 24, 72, 120 and 168 hours via XTT cell 
proliferation assay. The media in all plates was changed at 72 and 120 hours because 
cells in the control well were becoming confluent and the cells had used the majority of 
nutrients in the media.
After the absorbance was measured, the data were exported to Excel files. The 
data were subsequently processed and normalized by the absorbance at each time point of 
the untreated cells. IBM SPSS software and a paired t-test were used for statistical 
analysis (Appendix A Table A-5). Figure 6-9 through Figure 6-12 show graphs of the 
cell proliferation from 24-168 hours.
Figure 6-9 shows the proliferation at 24 hours. At 24 hours the drug had yet to 
affect cellular proliferation in the groups treated with 1 mg/ml MTX chitosan films, 1% 
MTX-HNT chitosan films, 5% MTX-HNT chitosan films and 10% MTX-HNT chitosan 
films. The 100 pg (1 mg/ml) MTX chitosan film group proliverated more than any other 
group, and this activity may indicate that osteosarcoma cells proliferate more in the 
presence chitosan films; the chitosan film alone showed a similar level of proliferation. 
The methotrexate is not likely to have affected proliferation because at 24 hours it is not
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completely metabolized and typically takes 1 -3 days to elicit a response. This trend was 
also noticed in 5% and 10 % HNT groups as MTX groups showed more proliferation at 
24 hours than their drug free counterparts. The presence of 5% and 10% concentrations 
of HNTs did seem to reduce the proliferation of cells to almost half when compared to 
untreated cells. The 1% HNT-MTX group was the only group at 24 hours that reduced 
proliferation when compared to the 1% HNT drug free group.
Figure 6-9: Mean Cell Proliferation at 24 hours of n = 9 samples ± standard deviation. 
Statistical analysis was applied with IBM SPSS 22.0 at a = .05, and the black stars 
indicate significant difference exists when encircled groups are compared.
Figure 6-10 shows the proliferation at 72 hours. At 72 hours the drug began to 
affect cellular proliferation in the groups treated in all groups. The chitosan film group 
showed a higher level of proliferation than any other group, suggesting that osteosarcoma 
cells proliferate more in the presence chitosan films. The 1% MTX-HNT group showed 
the most proliferation reduction when compared to 1%HNT, reducing proliferation by
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nearly half. The 1% MTX-HNT was as effective as the 100 pg MTX chitosan films at 
inhibiting proliferation.
The presence of 5% and 10% concentrations of HNTs continued to stifle the 
proliferation of cells by more than half when compared to untreated cells. The 5% MTX- 
HNT reduced proliferation by nearly 60%, but 5 mg plain HNT reduced proliferation by 
-50%, and it became difficult to determine if the effect was brought on by MTX or the 
HNTs. The 10% MTX-HNT and 10% HNT sets behaved similarly, and even though the 
10% MTX-HNT showed the highest reduction in proliferation, the presence of MTX in 
this group had little effect by comparison to the 10% groups. At 72 hours the media was 
changed as it had begun to change colors, indicating that cells had absorbed the majority 
of the nutrients.
Figure 6-10: Mean Cell Proliferation at 72 hours of n = 9 samples ± standard 
deviation. Statistical analysis was applied with IBM SPSS 22.0 at a  = .05, and the 
black stars indicate significant difference exists when encircled groups are compared.
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Figure 6-11 shows the proliferation at 120 hours. At 120 hours, the drug 
continued to affect cellular proliferation in all groups treated with MTX. The chitosan 
film group showed a higher level of proliferation (almost twice the proliferation of 
untreated group). This increased proliferation may be caused by increased surface area in 
chitosan films for cell to proliferate and grow to. 1% HNT films showed a comparable 
amount of growth and proliferation. The 1% MTX-HNT group showed the most 
proliferation reduction when compared to 1% HNT reducing proliferation by nearly two 
thirds. The 1% MTX-HNT was more effective than 100 pg MTX chitosan films at 
inhibiting proliferation while the drug dosage was the same.
The presence of 5% and 10% concentrations of HNTs continued to stifle the 
proliferation of cells by more than half when compared to untreated cells. The 5% MTX- 
HNT reduced proliferation by more than 50%, but 5% HNT reduced proliferation by 
-30%. The 10% HNT-MTX only reduced proliferation 5% more than the 10% HNT set 
even though the 10% HNT-MTX showed the highest reduction in proliferation. The 
presence of MTX in the 10% HNT group apparently had little effect by comparison of 
the 10% groups. At 120 hours the media was changed as it had begun to change colors, 
indicating cells had absorbed the majority of the nutrients.
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Figure 6-11: Mean Cell Proliferation at 120 hours of n = 9 samples ±  standard 
deviation. Statistical analysis was applied with IBM SPSS 22.0 at a  = .05, and the 
black stars indicate significant difference exists when encircled groups are compared.
Figure 6-12 shows the proliferation at 168 hours. At 168 hours, the drug 
continued to affect cellular proliferation in the in all groups treated with MTX. The 
chitosan film group continued to show a higher level of proliferation than any other 
group, although at this point it was comparable to untreated cells, possibly because cells 
finally proliferated throughout the entire chitosan film. The 1 % MTX-HNT and 5% 
MTX-HNT groups showed the most proliferation reduction when compared to 1% HNT 
and 5% HNT, respectively. Proliferation was reduced by more than half by comparison to 
drug free groups. The 1% MTX-HNT was more effective than the 100 pg MTX chitosan 
films at inhibiting proliferation, even though the drug concentration was the same.
The presence of 5% and 10% concentrations of HNTs continued to stifle the 
proliferation of cells by more than half when compared to untreated cells. The 5% MTX- 
HNT reduced proliferation by 80% but 5% HNT reduced proliferation by -58%. The
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10% HNT-MTX only reduced proliferation 10% more than 10% HNT, even though the 
10% HNT-MTX showed the highest reduction in proliferation.
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Figure 6-12: Mean Cell Proliferation at 168 hours of n = 9 samples ±  standard 
deviation. Statistical analysis was applied with IBM SPSS 22.0 at a  = .05, and the 
black stars indicate significant difference exists when encircled groups are compared.
Figure 6-13 compares cell proliferation over the 7 day period (168 Hours). Even 
though 5%MTX-HNT and 10%MTX-HNT chitosan films showed the largest reductions 
in proliferation over the 7 day period, 5 and 10% HNT films significantly reduced the 
cellular proliferation and limited the response shown from the drug released from the 
MTX-HNT groups. All groups were more effective than 100 pg MTX chitosan films at 
every time point after 24 hours, which may indicate that HNTs can localize the drug at 













Figure 6-13: Seven Day Mean Proliferation Comparison normalized by untreated cells 
proliferation.
The 1% MTX-HNT chitosan film showed the highest reduction in proliferation 
when compared to 1% HNT chitosan films, by reducing proliferation by more than 60% 
by Day 7. The 1 % HNT chitosan films and 0% HNT chitosan stimulated cell growth 
until the cells became confluent, and at confluency, chitosan films showed the highest 
rate of proliferation while 1% HNT chitosan films show the lowest reduction in 
proliferation of all chitosan films embedded with HNTs. The 1% HNT chitosan films 
affected cell proliferation the least when administered alone and yielded the most anti­
proliferative effect when loaded with methotrexate.
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Cell proliferation seemed to return at 120 hours, but this return can be an effect of 
changing the media at 72 hours as it reduced the concentration of drug present. This 
effect was not noticed at 168 hours as cells did not recover from drug administration.
6.3.3.2 Live/Dead Assay
A live/dead cell viability assay was performed to determine whether MTX-loaded 
chitosan composite films induced cell death in osteosarcoma cells. The live/dead assay 
images of osteosarcoma cells incubated with MTX-loaded chitosan composite films were 
compared with live/dead images of osteosarcoma cells treated with drug free loaded 
chitosan composite films. The negative control for this experiment was untreated cells. 
Following seeding and incubation, the plates were treated with the live/dead cell viability 
assay kit and imaged at 24, 72, 120 and 168 hours via the Olympus BX51 fluorescent 
microscope with FITC and TRITC filters. The media in all plates was changed at 72 and 
120 hours as cells in the control well were becoming confluent and the cells had used the 
majority of nutrients in the media.
The images were saved and processed with ImageJ software. Figure 6-14 to 
Figure 6-25 show live/dead results from 24-168 Hours.
Osteosarcoma cells in monolayer culture proliferated and became nearly 
confluent after 24 hours with little cell death observed (see Figure 6-14 A-C).
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Figure 6-14: Untreated cells at 24 Hours scale bar indicate 500pm. A= Phase contrast; 
B= Live Dead assay showing live cells (green); C= Dead assay showing dead cells (red).
Osteosarcoma cells were also unaffected by the drug-free chitosan film 
composites (Figure 6-15 A-L). Cells proliferated and achieved confluence comparable to 
normal, untreated cells (compare Figure 6-14 B and C with Figure 6-15 B, E, H, K and
C, F, I, L).
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Figure 6-15: Cytotoxic response to Chitosan Film Composites at 24 Hours scale bar 
indicates 500pm. (A-C) Group 1: Osteosarcoma cell cultures with chitosan films. (D-F) 
Group 2: Osteosarcoma cells exposed to 1% HNT chitosan films. (G-I) Group 3: 
Osteosarcoma cells exposed to 5% HNT chitosan films (J-L) Group 4: Osteosarcoma 
cells exposed to % HNT chitosan films. A, D, G and J = Phase contrast; B, E, H and K = 
Live Dead assay showing live cells (green); C, F, I and L = Dead assay showing dead 
cells (red). The brown coloration in D, G and J is caused by the high concentration of 
HNTs.
179
HNTs could be seen clearly as particulate material (Figure 6-16 D, G and J). At 
24 hours, in MTX (100 pg) chitosan films groups, the cellular response was different 
from untreated cells and cell growth decreased (Figure 6-16 A-C). At 24 hours, in Group 
2, osteosarcoma cells exposed to 1% MTX-HNT chitosan films showed a similar 
reduction in cell growth as MTX (100 pg) chitosan films compared with untreated cells 
(Figure 6-16 D-F). At 24 hours, in Group 3, osteosarcoma cells exposed to 5% MTX- 
HNT chitosan films showed a greater reduction in cell growth as compared to MTX 
group and 1% MTX-HNT chitosan films group (Figure 6-16 G-I). At 24 hours, in Group 
4, osteosarcoma cells exposed to 10% MTX-HNT chitosan films showed the greatest 
reduction in cell growth as compared to MTX group, 5% MTX-HNT chitosan films and 
1% MTX-HNT chitosan film group (Figure 6-16 J-l). However, only a few dead cells 
were observed in all groups (Figure 6-16 C, F, I and L).
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Figure 6-16: Cellular response to MTX-loaded chitosan film composites HNTs at 24 
Hours. Scale bar represents 500pm (A-C) Group 1: Osteosarcoma cell cultures with 
MTX (100 pg) chitosan films addition. (D-F) Group 2: Osteosarcoma cells exposed to 
1% MTX-HNT chitosan films. (G-I) Group 3: Osteosarcoma cells exposed to 5% 
MTX-HNT chitosan films. (J-L) Group 4: Osteosarcoma cells exposed to 10% MTX- 
HNT chitosan films. A, D, G and J = Phase contrast; B, E, H and K = Live Dead assay 
showing live cells (green); C, F, I and L = Dead assay showing dead cells (red). The 
brown coloration in D, G and J is caused by the high concentration of HNTs.
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Osteosarcoma cells in monolayer culture proliferated and became confluent 
within 2-3 days with little cell death observed (see Figure 6-17 A-C).
PHASE LIVE DEAD
Figure 6-17: Untreated cells at 72 Hours. Scale bar represents 500pm A= Phase 
contrast; B= Live Dead assay showing live cells (green); C= Dead assay showing dead 
cells (red).
Osteosarcoma cells were also unaffected by chitosan composite films (Figure 
6-18 A-L). Cells proliferated and achieved confluence exceptionally well compared with 
normal, untreated cells (compare Figure 6-17 B and C with Figure 6-18 B, E, H, K and
C, F, I, L).
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Figure 6-18: Cytotoxic response to Chitosan Film Composites at 72 Hours. Scale bar 
represents 500pm (A-C) Group 1: Osteosarcoma cell cultures with chitosan films. (D- 
F) Group 2: Osteosarcoma cells exposed to 1% HNT chitosan films. (G-I) Group 3: 
Osteosarcoma cells exposed to 5% HNT chitosan films (J-L) Group 4: Osteosarcoma 
cells exposed to % HNT chitosan films. A, D, G and J = Phase contrast; B, E, H and K 
= Live Dead assay showing live cells (green); C, F, I and L = Dead assay showing dead 
cells (red). The brown coloration in D, G and J is caused by the high concentration of 
HNTs.
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At 72 hours, in MTX-treated groups, the cellular response was very different from 
untreated cells and the reduction in cell growth was even greater than at 24 hours (Figure 
6-19 A-C). At 72 hours, in Group 2, osteosarcoma cells exposed to 1% MTX-HNT 
chitosan films showed a marked reduction in cell growth compared with untreated cells 
and cells treated with (100 pg) MTX chitosan films (Figure 6-19 D-F). This reduction 
was even greater than the reduction seen at 24 hours. At 72 hours, in Group 3, 
osteosarcoma cells exposed to 5% MTX-HNT chitosan films showed a greater reduction 
in cell growth than the MTX and 1% MTX-HNT chitosan film groups, but was greater 
than the reduction seen at 24 hours (Figure 6-19 G-I). At 72 hours, in Group 4, 
osteosarcoma cells exposed to 10% MTX-HNT chitosan films showed the greatest 
reduction in cell growth as compared to MTX group, 5% MTX-HNT chitosan films and 
1% MTX-HNT chitosan films group and was similar to the cell growth at 24 hours 
(Figure 6-19 J-L). However, only a few dead cells were observed in all groups (Figure 
6-19 C, F, I and L).
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Figure 6-19: Cellular response to MTX-loaded chitosan film composites HNTs at 72 
Hours. Scale bar represents 500pm (A-C) Group 1: Osteosarcoma cell cultures with 
MTX (100 pg) chitosan films addition. (D-F) Group 2: Osteosarcoma cells exposed to 
1% MTX-HNT chitosan films. (G-I) Group 3: Osteosarcoma cells exposed to 5% 
MTX-HNT chitosan films. (J-L) Group 4: Osteosarcoma cells exposed to 10% MTX- 
HNT chitosan films. A, D, G and J = Phase contrast; B, E, H and K = Live Dead assay 
showing live cells (green); C, F, I and L = Dead assay showing dead cells (red). The 
brown coloration in D, G and J is caused by the high concentration of HNTs.
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Osteosarcoma cells in monolayer culture continued to proliferate and maintained 
confluency within at 120 hours with little cell death observed (see Figure 6-20 A-C).
PHASE LIVE DEAD
Figure 6-20: Untreated cells at 120 Hours. Scale bar represents 500pm A= Phase 
contrast; B= Live Dead assay showing live cells (green); C= Dead assay showing dead 
cells (red).
Osteosarcoma cells also began to show the effects of chitosan composite film 
groups (Figure 6-21 A-L). Cells proliferated and achieved confluence comparable to 
normal, untreated cells (compare Figure 6-20 B and C with Figure 6-21 B and C, E, H, 
K and D, F, I, L) but the chitosan film composite groups had many more dead cells.
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Figure 6-21: Cytotoxic response to Chitosan Film Composites at 120 Hours. Scale bar 
represents 500pm (A-C) Group 1: Osteosarcoma cell cultures with chitosan films. (D- 
F) Group 2: Osteosarcoma cells exposed to 1% HNT chitosan films. (G-I) Group 3: 
Osteosarcoma cells exposed to 5% HNT chitosan films (J-L) Group 4: Osteosarcoma 
cells exposed to % HNT chitosan films. A, D, G and J = Phase contrast; B, E, H and K 
= Live Dead assay showing live cells (green); C, F, I and L = Dead assay showing dead 
cells (red). The brown coloration in D, G and J is caused by the high concentration of 
HNTs.
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At 120 hours, in MTX-treated groups, the cellular response was very different 
from untreated cells and the reduction in cell growth was even greater than at 72 hours 
(Figure 6-22 A-C). At 120 hours, Group 2 osteosarcoma cells exposed to 1% MTX-HNT 
chitosan films showed less cell growth than control untreated cells and cells treated with 
(100 pg) MTX chitosan films (Figure 6-22 D-F). This reduction was even greater than 
that seen at 72 hours. At 120 hours, in Group 3, osteosarcoma cells exposed to 5% MTX- 
HNT chitosan films showed a greater reduction in cell growth than the MTX group and 
the 1% MTX-HNT chitosan films group, and reduction was greater than seen at 72 hours 
(Figure 6-22 G-H). At 120 hours, in Group 4, osteosarcoma cells exposed to 10% MTX- 
HNT chitosan films showed the greatest reduction in cell growth as compared to the 
MTX group, the 5% MTX-HNT chitosan film, and the 1% MTX-HNT chitosan film 
group and was greater than the reduction to the cell growth at 72 hours (Figure 6-22 J-L). 
However, only a few dead cells were observed in all groups (Figure 6-22 C, F, I and L).
188
PHASE LIVE DEAD
Figure 6-22: Cellular response to MTX-loaded chitosan film composite HNTs at 120 
Hours. Scale bar represents 500pm (A-C) Group 1: Osteosarcoma cell cultures with 
MTX (100 pg) chitosan film addition. (D-F) Group 2: Osteosarcoma cells exposed to 
1% MTX-HNT chitosan films. (G-I) Group 3: Osteosarcoma cells exposed to 5% 
MTX-HNT chitosan films. (J-L) Group 4: Osteosarcoma cells exposed to 10% MTX- 
HNT chitosan films. A, D, G and J = Phase contrast; B, E, H and K = Live Dead assay 
showing live cells (green); C, F, I and L = Dead assay showing dead cells (red). The 
brown coloration in D, G and J is caused by the high concentration of HNTs.
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Osteosarcoma cells in monolayer culture continued to proliferate and maintained 
confluency at 168 hours with little cell death observed (see Figure 6-23 A-C).
PHASE LIVE DEAD
Figure 6-23: Untreated cells at 168 Hours. Scale bar represents 500pm A= Phase 
contrast; B= Live Dead assay showing live cells (green); C= Dead assay showing dead 
cells (red).
Osteosarcoma cells also began to show the effects of the chitosan composite film 
groups as they had reached full confluency and grown throughout the films (Figure 6-24 
A-L). Cells proliferated and achieved confluence comparable to normal, untreated cells 
(Compare Figure 6-23 B and C with Figure 6-24 B, E, H, K and C, F, I, L), but the 
chitosan composite film groups had many more dead cells. Also, confluency was reduced 
for 5% MTX-HNT chitosan films, and especially for 10% MTX-HNT chitosan film, 
compared to normal untreated cells, which indicates a more cytotoxic response at 7 days.
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Figure 6-24: Cytotoxic response to Chitosan Film Composites at 168 Hours. Scale bar 
represents 500pm (A-C) Group 1: Osteosarcoma cell cultures with chitosan films. (D- 
F) Group 2. Osteosarcoma cells exposed to 1% HNT chitosan films. (G-I) Group 3. 
Osteosarcoma cells exposed to 5% HNT chitosan films (J-L) Group 4: Osteosarcoma 
cells exposed to % HNT chitosan films. A, D, G and J = Phase contrast; B, E, H and K 
= Live Dead assay showing live cells (green); C, F, I and L = Dead assay showing dead 
cells (red). The brown coloration in D, G and J is caused by the high concentration of 
HNTs.
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At 168 hours, in MTX-treated groups, the cellular response was very different 
from untreated cells, and the reduction in cell growth remained constant (Figure 6-25 A- 
L). At 168 hours, Group 2 osteosarcoma cells exposed to 1% MTX-HNT chitosan films 
showed a marked reduction in cell growth as compared to untreated control cells and 
cells treated with MTX (100 pg) chitosan films (Figure 6-25 D-F). At 168 hours, Group 
3 osteosarcoma cells exposed to 5% MTX-HNT chitosan films showed a greater 
reduction in cell growth as compared to the MTX group and the 1% MTX-HNT chitosan 
films group (Figure 6-25 G-H). At 168 hours, Group 4 osteosarcoma cells exposed to 
10% MTX-HNT chitosan films showed the greatest reduction in cell growth as compared 
to MTX group, 5% MTX-HNT chitosan films and the 1% MTX-HNT chitosan films 
group (Figure 6-25 J-L). However, only a few dead cells were observed in all groups and 
cells were more confluent than at the previous time point, which may be attributed to the 
changing of the media, which removed the majority of the drug that had been released 
(Figure 6-25 C, F, I and L).
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Figure 6-25: Cellular response to MTX loaded chitosan film composites HNTs at 168 
Hours. Scale bar represents 500pm (A-C) Group 1: Osteosarcoma cell cultures with 
MTX (lOOpg) chitosan films addition. (D-F) Group 2: Osteosarcoma cells exposed to 
1% MTX-HNT chitosan films. (G-I) Group 3: Osteosarcoma cells exposed to 5% 
MTX-HNT chitosan films. (J-L) Group 4: Osteosarcoma cells exposed to 10% MTX- 
HNT chitosan films. A, D, G and J = Phase contrast; B, E, H and K = Live Dead assay 
showing live cells (green); C, F, I and L = Dead assay showing dead cells (red). The 
brown coloration in D, G and J is caused by the high concentration of HNTs.
CHAPTER 7 
CONCLUSIONS AND FUTURE WORK
Chapters 4, 5 and 6, discussed three projects with interrelated concepts and the 
novel applications of HNT for gene delivery, drug delivery, and enhancing drug delivery 
and material properties of chitosan composite films. The current chapter details the 
findings from recorded observations and integrates the concepts established in Chapters 
4, 5 and 6. A plan for the future direction of this research is also provided.
Chapter 4 included a discussion of the possibility of using HNTs as a delivery 
platform for the transfection of osteosarcoma cells in vitro. The results suggest that HNTs 
alone were incapable of efficiently transfecting cells because the majority of plasmid 
DNA adsorbed to or wrapped around the surface. Surface localization of pDNA may be 
due to supercoiling, which can make plasmids too large to load into the lumen when 
paired with the lipid-based transfection agent Lipofectamine, HNTs enhanced the 
transfection efficiency of the transfection agent. Among the groups 0.5 pg-pDNA-HNTs 
coated with Lipofectamine achieved better results than pDNA with Lipofectamine alone. 
This effect was sustained throughout the six-day testing period, whereas the 
Lipofectamine-pDNA group’s fluorescence was reduced greatly by the sixth day. 
Therefore, HNTs loaded and coated with pDNA could be subsequently coated with 
lipids, and used as an effective delivery system for plasmid DNA. The release of plasmid 
DNA was sustained and extended, suggesting that plasmid DNA can be made available to
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target cancer cells throughout a seven day period, which is crucial for a prolonged 
cellular response. In the future pDNA could be heat denature pror to loading in order due 
reduce super coiling and increase plasmid DNA loading.
Future research for his project would be developed in three stages. First, a 
calibration curve would be developed for a set concentration of Lipofectamine for 
transfecting differing concentrations of DNA based on cell density. Second, scanning and 
transmission electron microscopy imaging of pDNA loaded HNTs would be done to 
understand the level of wrapping/loading of HNTs. In addition, the pDNA-HNT to 
Lipofectamine ratio would be optimized for in vitro testing. After optimization, these 
HNT-pDNA-Lipofectamine complexes would be tested in other cancer cell lines. Still, 
more work could explore coatings for pDNA-HNT complexes for maximizing 
transfections efficiency. This work might involve coating pDNA-HNT complexes with 
DOTAP and comparing the efficiency to Lipofectamine. Chitosan film data presented in 
this work and recent advances in using chitosan nanoparticle for gene 
transfection[105][106] suggest that embedding pDNA-HNT complexes in chitosan films 
may provide a comparable transfection efficiency to Lipofectamine.
Chapter 5 discussed the concept of using HNTs as a drug delivery vector for 
chemotherapeutic drug methotrexate. The primary hypothesis tested if HNTs loaded with 
methotrexate could extend and sustain a release of methotrexate for seven days and 
sustain a localized reduction of cellular proliferation. Release profile data showed that 
HNTs could release methotrexate in microgram and nanogram concentrations for up to 
seven days. Cell proliferation and XTT viability assay results revealed that the cellular 
proliferation and growth were greatly reduced when compared with free drug. Reducing
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prolifereation can shrink solid tumors and limit the growth of mircometastasis in vivo. A 
significant reduction in cancer cell groth and proliferation is vital in achieving remssion. 
Results also demonstrate that additional drug was required after the changing of media 
for free drug sets; however, in methotrexate-loaded HNT sets, further addition of drugs 
was not required, due to the continuous release of drug. SEM images revealed that drug 
was loaded into the HNTs and also adsorbed onto the surface of the HNTs. Results of the 
combined studies demonstrated that the drug was localized at the cells rather than being 
diluted in the media.
In future studies, HNTs can be coated with poly electrolyte films or by embedded 
MTX-HNTs within chitosan films to reduce the burst release seen within the first hour. 
HNT’s lumen could also be etched with an acid to increase loading capacity. Other work 
may include merging the projects discussed in Chapters 4 and 5. This work would 
involve loading HNTs with methotrexate, coating with plasmid DNA that induces 
fluorescence expression and apoptosis, and subsequently coating with polyelectrolyte. 
This synergistic system would tag cancer cells, reduce or stop proliferation, and activate 
programmed cell death in targeted cancer cells.
Chapter 6 described the fabrication HNT enhanced chitosan film composites for 
localized and sustained drug delivery. The primary hypothesis of this project was that 
chitosan-HNT composite films could encapsulate methotrexate-loaded HNTs, reduce the 
burst release of drug from HNTs, sustain drug release for more than seven days, and 
maintain a reduced amount of cell proliferation and growth in vitro. Imaging revealed 
that films could encapsulate drug-loaded HNTs. Chitosan reduced the burst release by 
more than half and extended the release of drugs from HNTs to more than seven days.
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HNT chitosan films released more methotrexate over a seven-day period than films 
complexed with only methotrexate. SEM imaging revealed that this increase was due to 
the presence of pores created by HNTs embedded in the chitosan films.
In vitro cell proliferation and viability assays indicated that films embedded with 
HNTs loaded with methotrexate were more effective at reducing proliferation than films 
complexed with free methotrexate. Reducing proliferation can shrink solid tumors and 
limit the growth of mircometastasis in vivo. A significant reduction in cancer cell growth 
and proliferation is vital in achieving remission. Additonally films sprayed into areas 
where tumors have been removed can eliminate the risk of recurrence in said region and 
composite films can act as a barrier reducing the amount of exposed leaky vasculature 
that feeds tumors.
These studies were carried out in murine osteosarcoma, and future research could 
be conducted on human osteosarcoma cell line. The release profile study could be 
extended to 21 days, as work presented here indicated only about half the drug was 
released over seven days. To understand the material properties of chitosan composite 
films and evaluate the effect of HNTs on film morphology, pore size analysis and TEM 
imaging can be performed on films. Pore size analysis would quantify the number of 
pores and the average pore size in chitosan composite films. Future research could also 
assess the effect of different concentrations of chitosan on film morphology and drug 
release-kinetics. In addition, HNTs can be loaded with different chemotherapeutic agents, 
like paclitaxel, while the film can be loaded with a synergist, like p-glyco-pump blocker 
tariquidar, creating a synergist, sequential drug release platform for combating multidrug 
resistant cancers.
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All of the above-mentioned projects were tested in vitro due to time and resource 
constraints. Future studies can be carried out in 3 dimensional tumor models and 
eventually extend to in vivo animal models. Chapter 4 was limited to a green fluorescence 
plasmid and in the future this plasmid can be replaced with a genetic material that 
induces apoptosis. The scope of all of the projects in this dissertation was limited to 
extending and sustaining a localized drug release to tumors and surrounding tissues. The 
scope could be expanded to include genes (siRNA knockdown of p-GP expression) or 
drugs (tariquidar, miltefosine, etc.) that target these membrane proteins overexpressed in 
cancers and incorporate them into HNT-embedded films.
An investigative study of chitosan composite films, loaded with chemotherapeutic 
agents or genes, on cancer cell growth and proliferation with a comparison between 
murine osteosarcoma cell lines and human osteosarcoma cell lines can be useful in 
predicting the behavior of these constructs as adjuvant and neoadjuvant chemotherapeutic 
implants. Moreover, experiments can be designed for an extended period of 21 days or 
more advanced metrology techniques like BET pore size analysis can be used to quantify 
results discussed in this dissertation. Looking at the three projects, it can be concluded 
that HNTs hold promise as potential nanoparticle-based chemo and gene therapies for 
cancers and that chitosan composite films show potential as neo adjuvant and adjuvant 
implants and coatings for cancer therapy.




APPENDIX A RESULTS OF STATISTICAL ANALYSIS
Table A-l: Results of IBM SPSS two-tailed Paired T-Test for Transfection Assay.















control vs. lipo 0.1 pg .000 .000 .011 .001
control vs. lipo lpg .000 .000 .001 .000
control vs. 0.5pg HNT-lipo .000 .000 .000 .000
control vs. lpg HNT-lipo .000 .000 .001 .004
lipo O.lpg vs. lipo lpg .148 .729 .008 .038
lipo O.lpg vs. 0.5pg HNT- 
lipo .022 .799 .000 .285
lipo O.lpg vs. lpg HNT-lipo .002 .000 .290 .002
lipo lpg vs. 0.5pg HNT-lipo .000 .951 .845 .340
lipo lpg vs. lpg HNT-lipo .000 .000 .007 .001
0.5pg HNT-lipo vs. lpg HNT- 
lipo .000 .000 .000 .000







HNT vs. MTX-HNT .842
HNT vs. pDNA-HNT .000




Table A-3: Results of IBM SPSS two-tailed Paired T-Test for Zeta Potential n = 4 
Samples.
Com parison (Pairs) Significant Difference (P Value)
HNT vs. MTX-HNT .033
HNT vs. pDNA-HNT .000
MTX-HNT vs. pDNA-HNT .000
Table A-4: Results of IBM SPSS two-tailed Paired T-Test for HNT Proliferation Assay.















untreated vs. drug .092 .000 .000 .000
untreated vs. ling HNT .224 .000 .018 .000
untreated vs. lmg HNT-MTX .004 .000 .000 .000
untreated vs. Smg HNT .081 .000 .000 .000
untreated vs. 5mg HNT-MTX .000 .000 .000 .000
untreated vs. lOmg HNT .000 .000 .000 .000
untreated vs. lOmg HNT- 
MTX .000 .000 .000 .000
drug vs. lmg HNT .010 .000 .000 .000
drug vs. lmg HNT-MTX .001 .045 .001 .050
drug vs. 5mg HNT .263 .237 .047 .615
drug vs. 5mg HNT-MTX .000 .004 .000 .000
drug vs. lOmg HNT .000 .010 .000 .001
drug vs. lOmg HNT-MTX .000 .005 .000 .000
lmg HNT vs. lmg HNT- 
MTX .001 .000 .000 .000
5mg HNT vs. 5mg HNT- 
MTX .000 .002 .000 .000
lOmg HNT vs. lOmg HNT- 
MTX .000 .018 .002 .061
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Table A-5: Results of IBM SPSS two-tailed Paired T-Test for Chitosan Film 
Proliferation Assay.















untreated vs. CHT .000 .007 .000 .026
untreated vs. 100mgMTX_CHT .000 .000 .000 .000
untreated vs. 1%HNT_CHT .066 .002 .000 .000
untreated vs. 1%MTX_HNT CHT .851 .000 .000 .000
untreated vs. 5%HNT_CHT .000 .000 .000 .000
untreated vs. 5%MTX_HNT_CHT .004 .000 .000 .000
untreated vs. 10%HNT_CHT .000 .000 .000 .000
untreated vs. 10%MTX_HNT_CHT .000 .000 .000 .000
CHT vs. 1 OOmgMTX CHT .007 .000 .000 .000
CHT vs. 1%HNT_CHT .001 .000 .045 .000
CHT vs. 1%MTX_HNT CHT .000 .000 .000 .000
CHT vs. 5%HNT_CHT .000 .000 .000 .000
CHT vs. 5%MTX_HNT_CHT .000 .000 .000 .000
CHT vs. 10%HNT_CHT .000 .000 .000 .000
CHT vs. 10%MTX_HNT_CHT .000 .000 .000 .000
lOOmgMTX CHT vs. 
1%HNT CHT .000 .000 .000 .000
lOOmgMTX CHT vs. 
1%MTX HNTCHT .000 .079 .002 .001
lOOmgMTX CHT vs. 
5%HNT CHT .000 .442 .000 .581
lOOmgMTX CHT vs. 
5%MTX HNT CHT .000 .002 .000 .000
lOOmgMTX CHT vs. 
10%HNT CHT .000 .000 .000 .001
lOOmgMTX CHT vs.
10%MTX HNT CHT .000 .001 .000 .000
1%HNT CHT vs. 1%MTX HNT 
CHT .005 .000 .000 .000
5%HNT CHT vs. 
5%MTX HNT CHT .010 .000 .000 .000
10%HNT CHT vs. 
10%MTX HNT CHT .003 .023 .026 .000
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